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ABSTRACT 
 
Introduction: 
Among the cancers that afflict females world-wide, neoplastic disease of breast tissue is the most 
frequently diagnosed form and the leading cause of cancer-related death. Conventional treatment 
entails the use of doxorubicin, an anticancer agent belonging to the anthracycline family of 
chemotherapeutic drugs. Cancer cells are becoming increasingly resistant to doxorubicin therapy. 
The existence of hypoxic zones, which is a common feature of solid tumours, has been shown to 
promote the selection of therapy resistant clones in proliferating cancer cells. By modifying cellular 
homeostasis, neoplastic cells are capable of tolerating the hypoxic insult and thriving within the hostile 
microenvironment of the tumour. This adaptation is known as ‘the hypoxic response’ and is mediated 
through the action of the transcriptional regulator, HIF-1. Its expression in cancer tissue has been 
associated with a dismal prognosis as it promotes the degree of malignancy to an advanced stage. 
 
Hypothesis & Aims: 
We hypothesized that the targeting of HIF-1α would circumvent the ‘protective’ hypoxic response 
conferred upon breast cancer and improve the cytotoxicity of doxorubicin treatment. In this study, the 
first aim was to identify the hypoxic conditions at which the MCF-7 breast cancer cell line manifests a 
doxorubicin-resistant phenotype. This was followed by examination of the molecular pathways 
contributing to the hypoxic resistance by elucidating the potential relationship with the hypoxic 
regulator HIF-1α. Once the involvement of HIF-1α was established, the next aim was to evaluate 
whether the attenuation of HIF-1α would terminate the resistant phenotype and sensitize the 
neoplastic MCF-7 cells to doxorubicin treatment. Finally, the reproducibility of the in vitro experiment 
and efficacy of treatments within an animal model was evaluated. 
2-Methoxyestradiol is a naturally occurring metabolite originating from 17β-estradiol. It has recently 
been exploited as an anticancer agent due to its anti-proliferative and anti-angiogenic properties. 
Among its various mechanisms of action, this compound has been shown to inhibit the expression of 
HIF-1α. It is for this reason that this study employed 2-methoxyestradiol in the adjuvant therapeutic 
treatment, along with doxorubicin. 
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Methods: 
The in vitro experimental model employed the use of the breast adenocarcinoma estrogen receptor 
(ER-positive cell line, MCF-7. These neoplastic cells were propagated under standard culture 
conditions until reaching ~70-80% confluency, after which treatment commenced. The treatment 
regime comprised a 12 hour exposure to the doxorubicin (1 µM) chemotherapeutic agent, either alone 
or in combination with HIF-1α inhibitors, 2-methoxyestradiol (10 µM) or siRNA duplex (400 nM), with 
parallel incubations under normoxic (21%) and hypoxic (~0.1%) conditions. To serve as a positive 
control for HIF-1α expression, cells were treated with CoCl2 (100 µM). Molecular techniques 
employed included the Caspase-Glo® 3/7 Assay, western blotting, and the bioreductive MTT Assay. 
Mitochondrial integrity was assessed by live cell imaging/fluorescent microscopy. Cellular viability was 
monitored at all times. The experiment was then translated into a pre-clinical in vivo model where 
C57BL/6 mice bearing E0771 xenografts (4 week growth) were allocated into the following treatment 
groups: (1) control (2) doxorubicin (5 mg.kg
-1
), (3) 2-methoxyestradiol (45 mg.kg
-1
), and (4) the 
combination of the two previously mentioned groups. Body weight and the rate of tumour growth were 
monitored throughout the experiment. 
 
Results: 
Treatment with CoCl2 effectively stabilized HIF-1α under normoxic conditions. 2-Methoxyestradiol was 
capable of attenuating HIF-1α expression under both normoxia and hypoxia as compared with siRNA 
transfection, which was only effective under normoxia. HIF-1α stabilization was accompanied by an 
increase in autophagy along with the morphological transformation of mitochondria from an elongated 
network to shorter disc-like forms. On the other hand, HIF-1α attenuation caused an induction in the 
expression of the apoptotic markers, cleaved caspase 3 and cleaved PARP, as well as the restoration 
of the normoxic morphology. The exposure of MCF-7 cells to 1 µM doxorubicin for 12 hours produced 
a differential effect in the bioreductive MTT assay between normoxic and hypoxic conditions (42.97 ± 
3.095% vs. normoxic dox, p<0.01), while stimulating the apoptotic and autophagic pathways. 
Compared to the control, a significant expression of phospho-AMPK became evident at 21% O2, while 
the levels remained stable at ~0.1% O2 after doxorubicin exposure. Furthermore, chemotherapeutic 
treatment caused the morphology of the mitochondria to appear dot-like. Although the combination of 
the two drugs removed the differential effect witnessed in the MTT assay, there was no significant 
change when compared to doxorubicin. Levels of apoptotic cell death decreased under both oxygen 
conditions. While HIF-1α and autophagy decreased under normoxia, they remained elevated under 
hypoxia. 
In the in vivo component of the study, the administration of doxorubicin and 2-methoxyestradiol, alone 
or in combination, did not affect the rate of tumour growth or induce systematic toxicity in any of the 
experimental mice. When drugs were administered separately, a decrease in apoptosis along with a 
concomitant increase in autophagy and p-AMPK expression became noticeable while neither 
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treatment had any significant effect on the expression of HIF-1α. Adjuvant administration, however, 
was capable of attenuating HIF-1α along with autophagy. 
 
Discussion: 
By inducing (CoCl2) and inhibiting (2-methoxyestradiol; siRNA duplex) HIF-1α, it was established that 
the autophagic pathway in the in vitro experimental setting of this study was dependent on the 
expression of HIF-1α. The bioreductive MTT assay measures the metabolic state of a cell, which is an 
indirect indication of cellular viability. Based on this, hypoxia was shown to confer survival to 
neoplastic MCF-7 cells based on the differential effect witnessed after doxorubicin treatment. 
Apart from the induction of apoptosis and its associated mitochondrial fragmentation, the 
chemotherapeutic drug increased the activation of the metabolic sensor, AMPK, which upregulated 
autophagy during normoxia. While this autophagic process may assist in the killing mechanism, we 
speculate that the autophagy upregulated under hypoxia may be responsible for the survival effect 
and is most likely dependent on HIF-1α. 
In contrast to eliciting a synergistic cytotoxic effect, the combination of doxorubicin with 2-
methoxyestradiol produced an antagonistic effect on cellular viability instead. We propose that under 
normoxia, the combined treatment may stimulate the MCF-7 neoplastic cells to enter a state of growth 
arrest, or senescence, since the results indicate that the decrease in HIF-1α-dependent autophagy 
did not significantly affect cellular viability. Under hypoxia, despite the incorporation of the 
pharmacological HIF-1α inhibitor (2-methoxyestradiol), the expression levels of HIF-1α remained 
unaffected. We speculate that this could be the result of a potentiated stabilization of HIF-1α caused 
by the build-up of ROS and TCA intermediates which may be the outcome of mitochondrial 
dysfunction inflicted upon adjuvant therapy under hypoxia. Furthermore, it is also likely that the slight 
mitogenic effect observed within the MTT assay may be caused by the conversion of 2-
methoxyestradiol to a chemically-reactive estrogen derivative, possibly by the action of doxorubicin, 
and the fact that an ER-positive cancer cell line was employed in this study. 
With regards to the in vivo experimental model, we speculated that the failure of the molecular 
changes to manipulate the growth of the tumour could have been the result of an ineffective time- 
and/or dose regime.  
 
Conclusion: 
We therefore reject our hypothesis based on the fact that an antagonistic rather than synergistic effect 
was witnessed when the tumorigenic MCF-7 cell line was treated with adjuvant therapy. The results 
warrant the need for extensive testing on the pharmacodynamics of 2-methoxyestradiol, and more 
informative techniques to compliment the study.  
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OPSOMMING 
 
Inleiding: 
Borskanker is die mees algemeen gediagnoseerde kanker asook die hoof oorsaak van kanker-
verwante sterftes in vrouens wêreldwyd. Konvensionele behandeling behels die toediening van 
doxorubicin, ‘n anti-kankermiddel wat aan die antrasiklien-familie van chemoterapeutiese middels 
behoort. Kankerselle begin egter toenemend weerstandbiedend raak teen doxorubicin behandeling. 
Daar is al bewys dat die voorkoms van hipoksiese sones, wat ‘n algemene eienskap van soliede 
tumore is, die seleksie vir weerstandbiedende klone van prolifererende kankerselle, veroorsaak.  
Neoplastiese selle kan hierdie hipoksiese toestande weerstaan en in hierdie ongunstige mikro-
omgewing floreer deur sellulêre homeostase te modifiseer. Hierdie aanpassing staan bekend as die 
‘hipoksiese respons’ en word bemiddel deur die aksies van die transkripsiefaktor reguleerder, HIF-1. 
Die verhoogde uitdrukking van HIF-1 in kankerweefsel word oor die algemeen geassosieer met ‘n 
swak prognose omdat dit die maligniteit vehoog. 
 
Hipotese en Doelwitte: 
Die hipotese van hierdie studie behels dus die volgende: Deur HIF-1 te inhibeer, sal die 
‘beskermende’ hipoksiese respons wat in borskankerselle voorkom omseil kan word en sodoende die 
sitotoksisiteit van doxorubicin terapie verhoog. Die eerste doelwit van hierdie studie was dus om die 
hipoksiese kondisies te identifiseer waar MCF-7 selle ‘n doxorubicin-weerstandbiedende fenotipe 
vertoon. Daarna is die molekulêre paaie wat bydrae tot hierdie hipoksiese weerstand ondersoek 
asook hul moontlike verwantskap met die hipoksiese reguleerder, HIF-1. Nadat die rol van HIF-1α 
bevestig is, was die volgende doelwit om te bepaal of die inhibisie van HIF-1α die weerstandbiedende 
fenotipe sal onderdruk en neoplastiese MCF-7 selle sal sensitiseer vir doxorubicin behandeling. 
Laastens is die herhaalbaarheid en effektiwiteit van behandeling in die in vitro eksperimente ook in ‘n 
diermodel getoets. 
2-Methoxyestradiol is ‘n metaboliet van 17β-estradiol wat natuurlik in die liggaam voorkom. Dit is ook 
onlangs as ‘n anti-kanker middel geïdentifiseer as gevolg van die anti-verdelende en anti-
angiogeniese eienskappe. Een van die eienskappe van 2-methoxyestradiol is dat dit ook die 
uitdrukking van HIF-1α kan onderdruk. Dit is dan ook vir hierdie rede dat 2-methoxyestradiol in hierdie 
studie as bykomende terapie saam met doxorubicin gebruik is. 
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Metodes: 
Die in vitro eksperimentele model behels die gebruik van ‘n borsadenokarsinoom, estrogeenreseptor 
(ER)- positiewe sellyn, MCF-7. Hierdie neoplastiese selle is onder standaard weefselkultuur 
omstandighede gekweek totdat konfluensie van 70-80% bereik is, waarna behandeling begin het. 
Die behandelingsprosedure behels ‘n 12 uur blootstelling aan doxorubicin (1 M) chemoterapeutiese 
middel alleen of in kombinasie met die HIF-1α inhibitore, 2-methoxyestradiol (10 M) of siRNA duplex 
(400 nM) in normoksiese (21% O2) en hipoksiese  (0.1% O2) toestande. Die selle is ook met CoCl2 
behandel wat gedien het as ‘n positiewe kontrole vir HIF-1 uitdrukking. Molekulêre tegnieke wat 
tydens hierdie studie gebruik is, sluit die “Caspase-Glo® 3/7” bepaling in, asook die westelike 
kladtegniek en die MTT bepaling. Mitochondriale integriteit is bepaal deur middel van lewende sel 
afbeeldings/fluoresensie mikroskopie. Sellewensvatbaarheid is ten alle tye gemonitor. Hierdie 
eksperment is verder ook in ‘n pre-kliniese in vivo model uitgevoer waar C57BL/6  muise met E0771 
xenografte (4 weke groei) geïnduseer is en in die volgende behandelingsgroepe verdeel is: (1) 
kontrole; (2) doxorubicin (5 mg.kg
-1
); (3) 2-methoxyestradiol (45 mg.kg
-1
); en (4) die kombinasie van 
laasgenoemde twee groepe. Die liggaamsgewig en die tempo van tumorgroei is tydens die hele 
eksperiment gemonitor. 
 
Resultate: 
CoCl2 behandeling het HIF-1 effektief gestabiliseer tydens normoksiese omstandighede. 2-
Methoxyestradiol het HIF-1 uitdrukking tydens normoksiese en hipoksiese toestande onderdruk 
wanneer dit vergelyk is met siRNA transfeksie wat slegs tydens normoksiese toestande effektief was. 
HIF-1 stabilisering het gepaardgegaan met ‘n toename in autofagie asook morfologiese 
veranderinge in die mitochondria vanaf ‘n verlengde netwerk tot korter skyfagtige vorme. Aan die 
ander kant het HIF-1 onderdrukking ‘n toename in die apoptotiese merkers, nl kliewing in caspase-3 
and PARP veroorsaak wat gepaard gegaan het met die herstel van die tubulêre mitochondriale 
netwerk. Die blootstelling van die MCF-7 selle aan 1 M doxorubicin vir 12 ure het ‘n differensiële 
effek in die bioreduktiewe MTT bepaling tot gevolg gehad tussen normoksiese en hipoksiese 
toestande (42.97  3.095%, p<0.1), terwyl die apoptotiese- en autofagiese paaie in beide toestande 
gestimuleer is. ‘n Insiggewende toename in fosfo-AMPK uitdrukking was sigbaar tydens normoksiese 
toestande van 21% O2, terwyl dit onveranderd gebly het tydens hipoksiese toestande van 0.1% O2  
na doxorubicin behandeling. Die morfologie van die mitochondria het ‘n ‘kollerige’ voorkoms tydens 
doxorubicin behandeling gehad.  Alhoewel die behandeling van die selle met beide middels 
gelyktydig, die differensiële effek soos weerspieël in die MTT bepaling ophef, is daar geen 
insiggewende verandering wanneer met doxorubicin behandeling vergelyk word nie. Apoptotiese 
seldood verminder met gelyktydige behandeling van biede middels tydens normoksiese en hipoksiese 
toestande. HIF1- en autofagie het afgeneem tydens normoksiese toestande, maar bly vehoog 
tydens hipoksie. 
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In die in vivo model, het die toediening van doxorubicin en 2-methoxyestradiol alleen en in 
kombinasie nie tumorgroei geaffekteer nie en ook nie sistemiese toksisiteit in enige van die 
eksperimentele muise tot gevolg gehad nie. Die afsonderlike toediening van die middels het ‘n 
afname in apoptose in ‘n toename in autofagie en p-AMPK uitdrukking tot gevolg gehad, terwyl 
afsonderlike toediening van die middels nie ‘n effek op HIF-1 uitdrukking gehad het nie. Die 
gelyktydige toediening van biede middels het egter ‘n onderdrukking van HIF1- teweeggebring. 
 
Bespreking: 
Deur HIF-1 te induseer (CoCl2) en te inhibeer (2-methoxyestradiol en siRNA) in hierdie in vitro 
eksperimentele omstandighede, bevestig hierdie resultate dat autofagie afhanklik is van die 
uitdrukking van HIF-1. Die bioreduktiewe MTT bepaling meet die metaboliese staat van die sel wat 
indirek sellewensvatbaarheid bepaal. Gebasseer op hierdie bepaling is bewys dat hipoksie ‘n 
weerstandbiedende fenotipe veroorsaak teen doxorubicin behandeling in neoplastiese MCF-7 selle.  
Doxorubicin veroorsaak ‘n toename in apoptose met geassosieerde mitochondriale fragmentering 
asook ‘n aktivering van die metaboliese sensor, AMPK, wat autofagie stimuleer in normoksiese 
omstandighede. Alhoewel ‘n toename in autofagie seldood kan stimuleer, spekuleer ons dat ‘n 
toename in autofagie tydens hipoksie verantwoordelik kan wees vir seloorlewing wat heel moontlik 
ook afhanklik van HIF-1 is. 
In kontras met die verwagting dat die kombinasie behandeling ‘n sinergistiese sitotoksiese effek sou 
teweegbring, dui ons resultate dat daar ‘n antagonistiese effek op sellewensvatbaarheid was. Ons stel 
voor dat die gekombineerde behandeling tydens normoksiese toestande MCF-7 neoplastiese selle 
stimuleer om in ‘n toestand van groeistaking in te gaan aangesien die resultate daarop dui dat ‘n 
afname in HIF-1 afhanklike autofagie nie sellulêre lewensvatbaarheid beïnvloed het nie. Tydens 
hipoksie, ten spyte van die bykomdende behandeling met die HIF-1 inhibitor (2-methoxyestradiol), 
het die vlakke van HIF-1 onveranderd gebly. Ons spekuleer dat dat dit die gevolg kan wees van die 
stabilisering van HIF-1 as gevolg van ‘n toename in ROS en TCA intermediate wat die gevolg van 
mitochondriale wanfunksie kan wees tydens bykomende terapie onder hipoksiese toestande. Dit is 
ook moontlik dat die mitogeniese effek wat waargeneem is met die MTT bepaling die gevolg kan 
wees van die omsetting van 2-methoxyestradiol na ‘n chemiese-reaktiewe estrogeen derivaat; 
moontlik as gevolg van die aksie van doxorubicin en die feit dat die sellyn wat in hierdie studie gebruik 
is, ‘n ER-positiewe kankersellyn is.  
Met verwysing na die in vivo eksperimentele model, spekuleer ons dat die molekulêre veranderinge 
wat nie in die tumorgroei weerspieël word nie, die resultaat van oneffektiewe tyds- en dosis 
behandelingswyses is, of foutiewe toediening van die middel kan wees. 
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Gevolgtrekking: 
Ons verwerp dus ons hipotese gebaseer op die feit dat bykomende (adjuvante) behandeling eerder ‘n 
antogonistiese effek as ‘n sinergistiese effek op seldood in MCF-7 selle het. Hierdie resultate 
regverdig die nodigheid van intensiewe toetsing op die farmakodinamika van 2-methoxyestradiol 
asook die gebruik van meer informatiewe tegnieke om hierdie studie te komplimenteer. 
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CHAPTER 1: LITERATURE REVIEW 
1.1 BREAST CANCER 
1.1.1 Incidence 
According to the Globocan population-based registry of 2008, neoplastic disease of the breast is the 
most frequently diagnosed form (22.9%) and principal cause of death (13.7%) among all cancers in 
women (Globocan, 2010). Based on this registry, the mortality rate of women in South Africa was 
predicted to increase by 56.9% in the year 2030. The Human Development Index (HDI) is a 
calculation that ranks countries into ‘high’, ‘medium’ and ‘low’ human development based on the 
quality of life (Morse, 2003). From trends seen in the incidence rate of breast cancer world-wide, it 
was predicted that ‘low’ and ‘medium’ HDI regions are bound to follow the incidence patterns of the 
‘high’ HDI regions where the rates in breast cancer are elevated (Cancer Research UK, 2012). This is 
primarily due to ‘westernized’ risk factors such as lifestyle (diet, alcohol consumption and lack of 
exercise) and hormonal therapy. Among the etiological risk factors, a strong positive correlation exists 
between the threat of breast cancer development and age, familial history, and genetic mutations.  
 
Breast cancer, in terms of incidence and mortality, is considered to increase with age (Surveillance 
Research, 2012). The lifetime risk in the USA is larger in the age groups 40-59 years (1 in every 27 
women) and 60-69 years (1 in every 28 women), than related to the generation younger than 39 years 
(1 in every 203 women). The chances of developing breast cancer are amplified if a patient has a 
family history of the disease, rising with the diagnosis of one-degree relatives (Washbrook, 2006). 
Inheritance of mutations in the susceptibility genes predisposes a patient to the disease. For example, 
individuals possessing genetic mutations in the breast cancer genes, BRCA1 and BRCA2, are 40-
80% more likely to develop breast cancer (Wang et al., 2012). 
 
The clinical detectable forms of a breast neoplasm are heterogeneous, each with a distinct profile 
(Oakman et al., 2011). Despite the use of mammography screening for earlier detection, and 
multimodality treatment (chemotherapy, radiotherapy, and surgical resection) for management, the 
mortality rate is increasing and highlights the requirement for novel therapeutic approaches. 
 
1.1.2 Chemotherapeutic Treatment 
The abrogation of neoplastic cells without affecting normal non-transformed cells is the primary goal 
of chemotherapy. Cancerous breast tissue that possesses estrogen receptors is generally responsive 
to the steroid hormone estrogen (Wang et al., 2011). To counteract the potential stimulation of 
cancerous cell growth and hyperplasia by this ligand, hormonal therapy is beneficial for control. The 
selective estrogen receptor modulator (SERM) termed Tamoxifen has frequently been prescribed as 
part of adjuvant therapy to treat breast cancer patients that are positive for estrogen receptors 
(Yamamoto et al., 2001). This hormone antagonist blocks the action of estrogen by inducing the 
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formation of a co-repressor complex, and thus preventing transcriptional activation of target genes. 
The use of Tamoxifen, however, is frequently limited due to metastatic relapse with the development 
of endometrial carcinoma (Singh et al., 2007). An alternative antineoplastic drug that is used 
conventionally to treat a broad spectrum of cancers including soft tissues sarcomas, breast cancers, 
haematological cancers, and neuroblastoma in children is Doxorubicin, also known as Adriamycin® 
(Sessa et al., 2008; Cheung et al., 2001; Levy et al., 2001; Minotti et al., 2004). Discovered in the 
1960s, it originates as a secondary metabolite which is biosynthesized by the soil bacterium 
Streptomyces peucetious variant caesius. This compound belongs to a family of chemotherapeutic 
agents called the anthracyclines which also include Daunorubicin and Epirubicin (Minotti et al., 2004). 
Doxorubicin is used either as a single treatment agent or, in an attempt to either compliment a 
mechanism or produce a synergistic effect, in various combinations with other drugs such as 
cyclophosphamide, vincristine, 5-fluorouracil, and/or mitomycin C (Koo et al., 2007; Hatam et al., 
2011; Cheung et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The molecular structure of Doxorubicin. The antineoplastic antibiotic is composed of an 
algycone and a sugar moiety. The four-ring quinone structure is shared amongst the anthracyclines 
and is involved in biotransformation reactions (Airley, 2009a). 
 
1.1.3 Pharmacodynamics of Doxorubicin 
This anti-tumour antibiotic exerts its cytotoxic effects by several molecular mechanisms: 
(1) The anthracycline intercalates between adjacent DNA bases of the double helix chain 
consequently inhibiting the replication of nucleic acids (Gewirtz, 1999). 
(2) The tension generated by the unwinding of the parental double helix during DNA replication and 
transcription is typically relieved with the aid of Topoisomerase-II. This enzyme makes transient 
double-stranded cuts which maintain the structure and sequence of the genetic material as its 
form is changed to remove the supercoils (Minotti et al., 2004). Doxorubicin targets this process 
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by stabilizing enzyme-DNA intermediates, thus preventing the religation of the strands and 
forming double-stranded breaks (Airley, 2009a). 
(3) The formation of covalent Doxorubicin-DNA adducts which precede the formation of non-
covalent DNA interstrand cross links (Cutts et al., 2001; Swift et al., 2006).  
(4) The four-ringed quinone structure that is shared among the anthracyclines allows them to accept 
an electron and become reduced to a free radical, termed semiquinone, which acts as an 
alkylating agent (Raschi et al., 2010). This unstable intermediate may further react with molecular 
oxygen to generate other reactive oxygen species including hydroxyl radicals, peroxides, and 
superoxides, all of which induce oxidative damage within DNA as well as lipid peroxidation of 
plasma membranes (Gewirtz, 1999). 
(5) All these upstream events may culminate in the initiation of a cellular death pathway, termed 
apoptosis (Swift et al., 2006; Lüpertz et al., 2010). 
 
1.2 APOPTOSIS 
Apoptosis, or type I cell death, is a self-destructive, energy-consuming process that is genetically 
regulated by the cell (Maiuri et al., 2007; Edinger & Thompson, 2004). In multicellular organisms, 
under normal physiological conditions, apoptosis is important during embryological development of 
the central nervous system and immune system, as well as in general tissue remodelling. It maintains 
homeostasis by controlling the balance between the growth and death rate of cells (Airley, 2009b; 
Clayton & Hardwick, 2008). Furthermore, it serves as a crucial defence mechanism which can be 
triggered in response to numerous extracellular or intracellular stimuli to eradicate potentially 
malignant cells. The importance of apoptosis is evident from the numerous pathological diseases that 
manifest from a dysfunctional/mutated apoptotic pathway which includes neurodegenerative 
diseases, viral infections and cancer (Anlar et al., 2003; Lowe & Lin, 2000). 
 
1.2.1 Morphological Characterization 
Apoptosis (type I cell death) is characterized by distinct morphological changes. The physical process 
begins with the detachment and shrinkage of the apoptotic-competent cell (Lawen, 2003). This is 
followed by the nuclear chromatin condensation (pyknosis) and its degeneration into internucleosomal 
fragments (karyorrhexis) by endonucleases to produce the classic DNA-laddering pattern. 
Subsequently, permeabilization and blebbing of the plasma membrane gives rise to discrete apoptotic 
bodies. A membrane phospholipid termed phosphatidylserine (PS), typically contained within the 
inner plasma membrane, becomes exposed to the outer membrane surface during the morphological 
transformation  (Botto, 2004). The process culminates in the recognition of these apoptotic-competent 
cells by phagocytes which proceed to engulf the apoptotic bodies in a rapid, yet irreversible manner 
(Steinbach & Weller, 2006). The externalized PS lipids aid in the recognition of the apoptotic bodies 
and its subsequent phagocytosis (Hoffmann & Ogden 2001). Clearance occurs without invoking an 
inflammatory response (Edinger & Thompson, 2004). 
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1.2.2 Molecular Regulation 
Central to this mode of programmed cell death are the caspases, a subfamily of cysteine proteases 
responsible for the degradation of vital components within the cell upon execution (Maiuri et al., 
2007). Activation of these catabolic enzymes can occur through either of two pathways, namely the 
intrinsic or extrinsic pathway and culminate in the demise of the cell. 
 
1.2.2.1 The Extrinsic Pathway 
The extrinsic pathway, also known as the death receptor-mediated pathway, is induced by 
extracellular damage signals leading to the recognition and ligation of a ligand to its corresponding 
death receptor (e.g. FasL/CD95L to Fas/CD95 receptor; TRAIL/Apo2L to DR4 and DR5 receptor; 
TNF-α to TNFR1 receptor) (Clayton & Hardwick, 2008). These receptors are transmembrane proteins 
present on the surface of the cell and are responsible for the initiation of the caspase cascade. The 
intracellular portion of these receptors contains a ‘death domain’ (DD) which associates with an 
adapter molecule. This adapter molecule itself contains a ‘death effector domain’ (DED) which recruits 
the pro-caspase-8 zymogen (inactive precursor) forming a complex called the death inducing 
signalling complex (DISC) (Kumar et al., 2005). Oligomerization of zymogen aggregates at this 
complex transactivates the initiator protease (caspase 8) by the process of autocatalysis (Degterev et 
al., 2003). In turn, caspase 8 proteolytically cleaves and activates procaspase-3 and procaspase-7. 
These executioner caspases mediate the apoptotic process in a systematic manner. 
 
1.2.2.2 The Intrinsic Pathway 
The intrinsic pathway, also known as the mitochondrial-mediated pathway, is controlled by the Bcl-2 
family of proteins, all of which share one or more Bcl-2 homology (BH) domains (Levine et al., 2008). 
This family can be divided into the ‘BH3-only’ pro-apoptotic members (Nox; Puma; Bad; Bim) 
containing a single BH domain, the multi-domain pro-apoptotic members (Bax; Bak) containing three 
BH domains, and the multi-domain anti-apoptotic members (Bcl-2; Bcl-xL) containing four BH 
domains. The balance between pro- and anti-apoptotic key members regulates the mitochondrial 
outer membrane permeabilization (MOMP) (Lawen, 2003). The function of the pro-apoptotic members 
is generally inhibited by those belonging to the anti-apoptotic family in the absence of apoptotic 
stimuli. The intrinsic pathway is stimulated by genotoxic stress (radiation and/or chemotherapy), 
hypoxia and growth factor deprivation, causing a shift in the relative levels of these Bcl-2 family 
proteins. Under these stress conditions, there is an excess of pro-apoptotic signals. Typically the 
specific ‘BH3-only’ members of the Bcl-2 family target the hydrophobic groove of their cognate anti-
apoptotic partners, disrupting the inhibitory association of the latter on multi-domain apoptosis-
promoting members and stimulating the oligomerization of the downstream Bax and Bak in the outer 
mitochondrial membrane (Levine et al., 2008). The MOMP which results promotes the mitochondrion-
cytosolic release of apoptogenic factors (cytochrome c, Smac/Diablo, and apoptosis-inducing factor 
(AIF) from the intermembrane space (Steinbach & Weller, 2006). Upon release of cytochrome c from 
Stellenbosch University  http://scholar.sun.ac.za
5 
 
the mitochondria, a complex termed the apoptosome is formed together with the apoptotic protease-
activating factor-1 (Apaf-1) under the utilization of adenosine triphosphate (ATP). This is the caspase-
activating complex which recruits and oligomerizes procaspase-9, followed by its autocatalytic 
activation (Degterev et al., 2003). Caspase-9 subsequently activates the downstream executioner 
caspases-3 and -7 by cleavage of their inactive forms. The anti-caspase activity of the inhibitor of 
apoptosis proteins (IAPs) is neutralized by the release of another apoptogenic factor, called 
Smac/Diablo, upon Bax/Bak homodimerization (Jiang & Wang, 2004).  Executioner caspases then 
target substrates to dismantle the cellular structure.  
 
Poly-ADP-ribose-polymerase (PARP) is a 113 kDa protein which is constitutively expressed in 
multicellular organisms (Alvarez-Gonzalez et al., 1999). It plays a role in sensing the genotoxic 
damage inflicted upon DNA and maintaining the stability of the genome.  If the damage is mild, PARP 
initiates a DNA repair mechanism by base excision. Beyond a critical point when the damage is too 
severe, PARP will instead signal the release and translocation of AIF from the mitochondrial 
intermembrane space to the nucleus (Zhang et al., 2007; Nguewa et al., 2005). AIF is another 
liberated apoptogenic factor that induces DNA fragmentation and thus apoptosis, but in a caspase-
independent manner. PARP contains a caspase-cleavage site in the DNA binding domain which is 
proteolytically cleaved by caspase-3 into two polypeptide fragments, the 89 kDA carboxy terminus 
and the 24 kDa amino terminus (Nguewa et al., 2005). 
 
The extrinsic pathway is linked to the intrinsic pathway by the ‘BH3-only’ protein, Bid (Lowe & Lin, 
2000). The cleavage of Bid by receptor-mediated activation of caspase-8 produces a truncated form 
which transclocates to the mitochondria and encourages cytochrome c release, followed by the 
caspase cascade. The intrinsic pathway may serve as an amplified signalling route which is cross-
activated by the extrinsic pathway (Michalak et al., 2005). 
 
The transcription factor, p53, functions as a critical cell cycle checkpoint (Lowe & Lin, 2000). Cellular 
stress, including DNA damage and hypoxia, stabilizes this tumour suppressor causing it to 
accumulate in the nucleus where it regulates the balance between cellular proliferation and death. 
There is evidence linking p53 to cell cycle arrest and apoptosis (Michalak et al., 2005). Studies have 
revealed that this factor is able to trigger type I cell death by transactivating distinct p53-responsive 
genes which include the ‘BH3-only’ pro-apoptotic members of the Bcl-2 family, namely Bax, Noxa and 
Puma. Similarly, genes that encode for death receptors (Fas/CD95; DR4; DR5) can be also be 
transcribed. In addition, studies show a transcription-independent mechanism where p53 directly 
associates directly with Bcl-xL leading to Bax oligomerization and the activation of the caspase 
cascade (Steinbach & Weller, 2006). 
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Fig. 1.3 The extrinsic and intrinsic molecular regulation of the apoptotic cellular 
death pathway.  The extrinsic ‘death receptor-mediated’ pathway involves the recognition 
and ligation of a ligand to its corresponding death receptor.  The “death-domain” (DD) of 
the receptor associates with the “death-effector-domain” of an adaptor molecule. This is 
followed by the incorporation of the inactive caspase 8 precursor to form the “death-
inducing signalling complex” (DISC). Upon caspase 8 activation, it either directly activates 
the downstream effector caspases, or cleaves the BH3-only protein, BID, which 
translocates to the mitochondrion and initiates mitochondrial outer membrane 
permeabilization (MOMP). For the initiation of the intrinsic ‘mitochondrial-mediated’ 
pathway, a stressor causes the BH3-only proteins to disrupt the inhibitory interaction 
between pro- and anti-apoptotic family members. The released pro-apoptotic members, 
Bax and Bak, translocate to the mitochondria where they form channels in the outer 
membrane and stimulates MOMP. This leads to the release of apoptogenic factors: 
apoptosis inducing factor (AIF), which initiates a caspase-independent form of apoptosis; 
while cytochrome C activates the initiator caspase 9 protease via the formation of the 
apoptosome. Caspase 9 subsequently activates downstream effector caspases. 
Illustration adapted from Maiuri et al. (2007). 
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1.2.3 Apoptotic Resistance 
Although a myriad of chemotherapeutic drugs, including Doxorubicin, act by inducing apoptosis, 
several studies have revealed a link between drug resistance and an inactivated pathway and/or 
mutations in key regulatory proteins. This could arise either from an increased expression of anti-
apoptotic genes or the diminished expression of pro-apoptotic genes (both multi-domain and BH3-
only members) (Mathiasen & Jäättelä, 2002).  
 
Drug-resistant-selected subclones of human leukemia were shown to have a significant 
overexpression of the Bcl-2 death suppressor protein when compared to their drug-susceptible 
cancerous counterpart (Su et al., 2007). This resistance could be antagonized by the use of the Bcl-2 
inhibitor, HA14-I. Another experimental study found lower levels of the BH3-only pro-apoptotic protein, 
Bik, is a common characteristic in renal cell carcinoma tissues and cell lines (Sturm et al., 2006). 
 
Mutations in many other oncogenes/tumour suppressor genes related to this cell death pathway are 
also common including caspase 8, APAF-1, DR4/DR5, and p53 [as reviewed in (Steinbach & Weller, 
2006)]. Genetic mutations of the p53 gene are a frequently encountered disturbance in more than 
50% of manifested cancers (Airley, 2009c).  
 
The appearance of apoptotic-resistance promotes tumorigenesis as chemotherapeutic drugs, 
specifically relying on this tumour suppressing pathways for treatment, become ineffective. Apoptosis 
incompetence is a hallmark of a broad variety of cancers (Hanahan & Weinberg, 2011). 
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1.3 PATHOPHYSIOLOGY OF SOLID TUMOURS 
During tumorigenesis, an unfavourable environment develops due to the rapid proliferation of 
neoplastic cells coupled with the chaotic architecture of the vascular network which is morphologically 
and functionally inept (Rademakers et al., 2008). This impairs the delivery of nutrients and oxygen to 
the tumour and the outcome is an imbalance between supply and utilization. The common attributes 
witnessed in the microenvironment of solid tumours are hypoxia, acidosis, and nutrient deprivation.  
 
The oxygenation status of a tumour is dependent on two factors. Firstly, when the distance between 
the neoplastic cell and the perfusing tumour-associated vessels exceeds the diffusion distance of 
oxygen, a chronic form of hypoxia develops which is termed diffusion-limited hypoxia (Airley, 2009d).  
The second factor, termed ‘acute hypoxia’ is dependent on the tumour-associated microvasculature 
which is stimulated by hypoxic conditions to fuel neoplastic growth (Magagnin et al., 2006; 
Rademakers et al., 2008). The stimulation of new vessel formation, or angiogenesis, gives rise to an 
abnormally structured and unorganized vascular architecture which frequently experiences temporal 
fluctuations in the flow of blood (Fukumura & Jain, 2007). This could lead to the development of 
transient regions of low oxygen tension known as perfusion-limited hypoxia. 
 
The depleted energy sources, as well as the ROS generated during the cyclic pattern of tumour 
hypoxia-reoxygenation, could be detrimental to the cancerous cells by compromising essential 
physiological functions (Gogvadze et al., 2010). If events that restore homeostasis are activated 
before this stress reaches a critical point, survival of the cells may be maintained. 
 
1.3.1 Regulation of the Hypoxic Response through HIF-1α 
To circumvent these disturbances, a myriad of molecular pathways, collectively known as the hypoxic 
response, is initiated in normal and transformed cells when oxygen tension is low (Roudier & Perrin, 
2009). The pathways are mediated by a family of transcriptional factors termed HIF-1. HIF-1 regulates 
the expression of genes that promote the adaptation and survival of transformed cells to the hostile 
microenvironment of a tumour to restore oxygen and nutrient homeostasis. Therefore, in this 
scenario, HIF-1 acts as an oncogene. This master regulator is a heterodimer composed of two 
subunits: the constitutively expressed HIF-1β (80 kDa) subunit, also known as the aryl hydrocarbon 
receptor nuclear translocator (ARNT), and the oxygen-regulated HIF-1α (120 kDa) subunit which is 
ubiquitously expressed in many tissues (Rohwer & Cramer, 2011). These are helix-loop-helix proteins 
belonging to the PER-ARNT-SIM (PAS) family and contain two transactivation domains (N-terminal 
and C-terminal) along with a central oxygen-dependent degradation (ODD) domain (O’Donnell et al., 
2006).  Two other isoforms of the alpha subunit exist, namely HIF-2α and HIF-3α, the expression of 
which is limited to specific cell types (Keith et al., 2011). 
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1.3.1.1 Normoxic Conditions 
Under normoxic conditions, HIF-1α protein becomes hydroxylated by prolyl hydroxylases using O2 
and α-ketoglutarate as co-substrates, and ferrous iron (Fe
2+
) as a cofactor (Hansen et al., 2011). 
Hydroxyl groups are added to proline residues (P402 and P564) within the ODDD (Keith et al., 2011).  
These modified sites are recognized by the von Hippel-Lindau (VHL) tumour suppressor which 
recruits the E3 ubiquitin complex to subsequently polyubiquitinate the protein, directing it to the 
proteasome for degradation (Rohwer & Cramer, 2011). Therefore the presence of oxygen confers a 
very short half-life to this protein. Beyond regulation of HIF-1α stability by the post-translational activity 
of prolyl hydroxylases, this subunit is also regulated at the transcriptional level by an asparaginyl 
hydroxylase called the factor-inhibiting-HIF-1 (FIH) (Hansen et al., 2011). FIH hydroxylation of an 
asparagine residue (803) present in the carboxy-terminal transactivation domain (C-TAD) hinders the 
interaction of HIF-1α with its transcriptional co-activators, CBP and P300, when oxygen is present 
(Magagnin et al., 2006).  
 
1.3.1.2 Hypoxic Conditions 
During hypoxic conditions, when the relative level of oxygenation is inadequate (below ~5%), the 
oxygen-dependent hydroxylases (PHD and FIH) become inactive and hydroxylation of proline and 
asparagine residues ceases (Hansen et al., 2011). Inactivated PHD allows the HIF-1α protein to avoid 
proteasomal degradation and become stabilized. The stabilized HIF-α translocates to the nucleus 
where it dimerizes with HIF-1β to form the activated HIF-1 complex. The inactivated FIH stimulates 
the assembly of a robust HIF-1α-CBP/P300 transcription-initiation complex to the hypoxia responsive 
elements (HRE) in the promoter regions of downstream hypoxia-inducible genes and transactivation 
proceeds (O’Donnell et al., 2006). Adaptation occurs through changes in the physiological 
characteristics of the neoplastic cells and its microenvironment. 
 
 
1.3.2 Oxygen-independent HIF-1α Stabilization 
Despite oxygen-regulation, HIF-1α expression can be triggered due to mutations in signalling 
pathways that switch on oncogenes, turn off tumour suppressors, and/or stimulate the PI3K-Akt-
mTOR pathway when growth factors bind to receptors belonging to the tyrosine kinase family 
(Ferreira, 2010; Yeo et al., 2004). Studies have also implicated complex III-generated ROS in 
upregulated expression of HIF-1α (Klimova & Chandel, 2008; Chandel et al., 2000). HIF-1α may be 
stabilized by hypoxia-mimicking agents such as the iron-chelating desferrioxamine and cobalt chloride 
(O’Donnell et al., 2006; Al Okail, 2010). Cobalt chloride was shown to inhibit prolyl hydroxylases by 
competing with ferrous iron (Fe
2+
), the essential co-factor regulating the activity of these enzymes 
(Epstein et al., 2001). 
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Figure 1.3 Oxygen-dependent regulation of HIF-1 stabilization and degradation. 
The HIF-1 subunits are basic helix-loop-helix (bHLH) proteins of the PER-ARNT-SIM 
(PAS) family. When adequate O
2
 is available, the HIF-1α regulatory subunit is modified 
by the hydroxylation of proline residues (P402; P564), present in the central oxygen 
dependent degradation (ODD) domain, and the hydroxylation of the asparagine reside 
(N803), present in the carboxy-terminal transactivation domain (C-TAD). These reactions 
are catalysed by the ‘prolyl hydroxylase domain’ (PHD) proteins and the factor-inhibiting 
HIF (FIH), respectively. This proline hydroxylation modification is recognized by the von-
Hippel Lindau (VHL) tumour suppressor which ubiquitinates HIF-1α, targeting it for 
degradation via the proteasome. Under hypoxic conditions (<5%), HIF-1α becomes 
stabilized due to the inactivation of prolyl hydroxylases. HIF-1α heterodimerises with the 
constitutively-expressed HIF-1β subunit. In the absence of FIH activity, the co-activator 
CBP-P300 is recruited, stimulating the assembly of a transcription-initiation complex at 
hypoxia-response elements (HRE) of hypoxia-inducible genes, mediating transactivation. 
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1.3.3 Adaptive Pathways  
Adaptation to the hypoxic microenvironment of solid tumours has been shown to stimulate the 
progression of transformed cells to a more aggressive phenotype. It confers resistance in cancers 
response to radiotherapy (Kessler et al., 2010), chemotherapeutic agents such as Adriamycin, 
Cisplatin, Palitaxel, and Etoposide [as reviewed in (Rohwer & Cramer, 2011)], and predisposes the 
neoplastic cells to metastasis (Dai et al., 2011). Hypoxia has therefore been associated negatively 
with clinical outcome and may be used as a biomarker for poor prognosis (Rohwer & Cramer, 2011). 
 
1.3.3.1 The Metabolic Switch 
One of the first compensatory alterations of the hypoxic response is the remodelling of oxidative 
metabolism to anaerobic glycolysis. In non-transformed cells, glucose is completely oxidized to CO2 
and H2O (Ferreira, 2010). The bulk of energy, in the form of ATP, is produced within the mitochondria 
primarily through the Krebs cycle and oxidative phosphorylation. The conversion of pyruvate to lactate 
(anaerobic glycolysis) is inhibited by the presence of oxygen, this phenomenon being termed the 
‘Pasteur’ effect (Solaini et al., 2010). 
 
In contrast, under aerobic conditions, transformed cells adjust their metabolism and preferentially 
produce the majority of their energy via aerobic glycolysis in spite of the presence of oxygen (Ferreira, 
2010). This process is termed the ‘Warburg’ effect. While certain studies have suggested that this 
phenomenon could be accounted for by the impairment or alteration of normal mitochondrial 
respiration (Chandel et al., 2000; Kroemer & Pouyssegur, 2008), others have shown that 
mitochondria of cancer cells have functional oxidative capacity (Gogvadze et al., 2010). In the latter 
case, the selection of aerobic glycolysis over oxidative phosphorylation may possibly be attributed to 
the increased glucose demand in highly proliferating cancer for anabolic reactions (synthesis of 
ribose-5 phosphate, phospholipids and triacylglycerides, and alanine and malate) to sustain the 
growth and proliferation of the cells (Solaini et al., 2011; Weljie & Jirik, 2011; Roudier & Perrin, 2009).  
This may provide a selective proliferation advantage.  
 
When oxygen is not available as the terminal electron acceptor, production of ATP by mitochondrial 
oxidative phosphorylation is compromised and transformed cells become solely dependent on 
glycolysis (Weljie & Jirik, 2011). In anaerobic glycolysis, energy is extracted from glucose by 
substrate-level phosphorylation where the yield of ATP is significantly lower. To compensate, there is 
an increased demand for glucose. The HIF-1α-mediated switch to anaerobic glycolysis involves the 
upregulation of glucose transporters (GLUT-1; GLUT-3), to augment the uptake of glucose, as well as 
hexokinases (I; II), which are responsible for the ‘priming’ step of glycolysis (Kroemer & Pouyssegur 
2008). This facilitates the increased glycolytic rate often witnessed in hypoxic cancer cells to support 
the biomass. 
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HIF-1α was also shown to shunt pyruvate away from mitochondrial oxidative respiration by the 
expression of two key enzymes that enhance its metabolism (Solaini et al., 2010): (1) pyruvate 
dehydrogenase kinase 1 (PDK1); which inhibits the oxidative activity of pyruvate dehydrogenase 
(PDH), preventing the conversion of pyruvate to acetyl CoA, a carbon substrate for the tricarboxylic 
acid cycle and subsequently the electron transport chain during oxidative phosphorylation; and (2) 
lactate dehydrogenase-5 (LDH-5); which stimulates the reduction of pyruvate to lactate.  
 
1.3.3.2 Acidosis and pH Regulation 
The appearance of high acidity within the tumour microenvironment stems from the excessive lactate 
produced by anaerobic glycolysis. Interstitial acidosis has been linked to an increased risk of 
invasiveness (Semenza, 2009). In 2001, Brizel et al. analysed biopsies of head-and-neck cancer 
which revealed a significant correlation between the metastatic potential of the primary tumours and 
their lactate concentration levels (Brizel et al., 2001). Metastatic relapse was significantly higher in 
patients with elevated tumour lactate concentrations.  
 
As indicated by Robey et al., the aggressively metastatic breast cell lines MDA-mb-435 and MDA-mb-
231 had elevated HIF-1α-induced expressions of GLUT-1 and GLUT-2 with a concomitant elevation in 
their glycolytic rates under normoxic oxygen tension compared to the non-metastatic cell line MCF7 
(Robey et al., 2005). Lactate levels were also higher in the metastatic cell lines compared to the non-
metastatic cell line. Upon hypoxic stimulation, HIF-1α became stabilized and lactate levels within 
MCF-7 were raised. 
 
Maintenance of the intracellular and extracellular pH is achieved by transporters/exchangers. 
Carbonic anhydrase IX (CAIX) is the tumour-specific, membrane-associated enzyme that is 
transcriptionally activated by HIF-1 and responsible for the extracellular hydration of CO2 to HCO3
-
 
and H
+
 (Solaini et al., 2010; Rademakers et al., 2008). The carbonate ion is imported into the cell to 
buffer the excess H
+
. The expression of monocarboxylate co-transporter 4 (MCT-4) is also induced in 
glycolytic cells under hypoxia and catalyse the efflux of lactate and H
+
, potentiating interstitial acidosis 
(Kroemer & Pouyssegur, 2008).   
 
1.3.3.3 Angiogenesis 
Among the genes upregulated during the hypoxic response are the pro-angiogenic factors. The 
expression of vascular endothelial growth factor (VEGF) is necessary to initiate the formation of a new 
micro-vascular network, a process known as angiogenesis (Rademakers et al., 2008). This 
angiogenic switch aims to re-establish a local supply of nutrients and oxygen to the demanding 
tumour, allowing it to maintain growth and expand. Other angiogenesis-stimulating factors include 
erythropoietin (EPO), which stimulates the production and differentiation of endothelial progenitor 
cells into mature red blood cells, and matrix metalloproteases 2 (MMP-2), which degrades the 
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extracellular matrix and may contribute to metastasis (Dome et al., 2009; Rapisarda & Melillo, 2009; 
Fujita et al., 2002).  
 
1.3.3.4 Resistance to Radio- & Chemotherapy 
Evidence exists where hypoxia promotes the selection of therapy-resistant clones in proliferating 
cancer cells. Graeber et al. (1996) found that the in vitro selection of transformed cells, which are 
apoptosis-incompetent due to a mutation in the p53 tumour suppressor gene, is encouraged in the 
presence of hypoxia which thus confers a survival advantage (Graeber et al., 1996). Furthermore, a 
human colon carcinoma clone that harbours a deficiency in the DNA mismatch repair system (MMR) 
was selectively expanded when subjected to anaerobic conditions as compared to the MMR-proficient 
clones (Kondo et al., 2001). The expanded population of MMR-deficient clones showed resistance to 
cisplatin- and 6-thioguanine-therapeautic treatments. 
 
In 2006, Kim et al. showed that the ROS produced under hypoxic conditions stabilized the HIF-1α-
induced expression of PDK1, and this rescues cells from ROS-induced apoptosis (Kim et al., 2006).  
 
In addition, it was discovered that, within the promoter region of the multi-drug resistance (MDR) P-
glycoprotein in both normal and cancerous cells, there exists a hypoxic response element which may 
be regulated by HIF-1α (Comerford et al., 2002). To simulate the hypoxic environment of a tumour, 
Doublier et al. grew 3-dimensional MCF-7 spheroid clusters and discovered that HIF-1α-induced 
expression of P-glycoprotein was associated with resistance to doxorubicin as indicated by lower 
caspase 9 activity (Doublier et al., 2012). 
 
All of the above evidence supports the idea that the hypoxic response increases the tolerance of 
cancer cells to the adverse microenvironment of a tumour. Recently, another cellular pathway that 
has been shown to be upregulated under these unfavourable conditions is autophagy. 
 
1.4 AUTOPHAGY 
Autophagy is defined as a cellular process of self-degradation that is evolutionary conserved amongst 
species (Maiuri et al., 2007).  It occurs constitutively at base-line levels within the cell to ensure 
homeostasis by removing aged, damaged or accumulated proteins and/or organelles. Beyond its 
quality control function, the autophagic process can also be massively augmented in response to 
various intracellular and extracellular stress stimuli (Chen & Karantza-Wadsworth, 2009). These 
include nutrient and growth factor deprivation (metabolic stress), radiation and chemotherapy (DNA 
damage), endoplasmic reticulum (ERt) stress, hypoxia, and viral invasion. During starvation 
conditions, cellular metabolism and biosynthesis can be sustained from the recycled pool of cytosolic 
biomolecules generated during autophagy (Morselli et al., 2009). Elimination of excessive reactive 
oxygen species produced by mitochondria under hypoxia, as well as unfolded or aggregated proteins 
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may prevent these forms of ‘cellular garbage’ from potentially inducing carcinogenesis. While short-
lived proteins are degraded by the ubiquitin proteasome pathway, long-lived proteins are mitigated by 
autophagy (Mathew & White, 2011). 
 
Depending on the mechanism by which the cytosolic cargo is delivered to lysosomes for degradation, 
three different types of autophagy exist. Chaperone-mediated autophagy mediates the direct 
translocation of a single cytosolic protein, possessing a specific sequence motif, to the lysosome for 
degradation (Majeski & Dice, 2004). This form of autophagy lacks the characteristic vesicular 
formation and rather employs the use of cytosolic chaperones which selectively recognize and 
translocate proteins. Micro-autophagy and macro-autophagy (referred to generally as autophagy) are 
the other two forms of autophagy characterized by the formation of vesicles which allow for the 
degradation of cystol, proteins, and/or organelles (Todde et al., 2009). While the former entails the 
direct sequestration and degradation of cargo by lysosomal membrane invaginations, the latter 
necessitates the vacuolization of cargo within double-membraned structures, termed the 
autophagosomes, prior to fusion with the lysosome.  
 
 
1.4.1 Morphological Characterization 
The execution process of autophagy begins within the cytoplasm with the formation of crescent-like 
membranous structures termed phagophores, or isolation membranes (Eskelinen & Saftig, 2009). 
This is the initiation stage of the autophagic process. During the elongation stage that follows, these 
specialized structures expand into double- or multi-membraned autophagosomes, also known as 
early autophagic vesicles, which sequester cytosol or cellular components for ‘bulk’ degradation. The 
cargo may be targeted selectively or non-selectively (Mathew & White, 2011).  
 
The outer autophagosomal membrane first fuses with an endosomal vesicle to form an amphisome 
(Eskelinen & Saftig, 2009). This is followed by fusion with a lysosome to form an autophagolysosome, 
also known as a late autophagic vesicle. Acid hydrolases within the lysosome digest the inner 
membrane of the autophagosome along with its encapsulated luminal cargo. These hydrolases 
include nucleases, proteases, glycosidases, and lipases, enabling a broad range of macromolecules 
to be degraded simultaneously (Maiuri et al., 2007; Kuma & Mizushima, 2010). 
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1.4.2 Molecular Mechanism 
The autophagic signalling pathways are strictly regulated by a group of autophagy-related genes 
(Atgs) that were first identified and characterized in the yeast genome (Chen & Debnath, 2010). The 
entire complement of mammalian homologues has yet to be fully identified, but the mechanisms that 
exist have remained highly conserved. 
 
The induction of the autophagic process involves the activation of the ULK1 (the mammalian 
homologue of Atg1) kinase (Jung et al., 2010). This activation depends on the phosphorylation status 
of Atg 13 (mammalian homolog yet to be identified), a substrate of mTOR.   
 
Once mTOR kinase activity becomes inactivated, the Atg13 protein is dephosphorylated and 
subsequently becomes associated with the scaffold protein, Atg17 (Mizushima, 2010). This promotes 
the formation of a complex with ULK1, stimulating its kinase activity. The complex then localizes to 
the isolation membrane where nucleation proceeds (Levy & Thorburn, 2011). 
 
Vesicle nucleation begins when Beclin 1 (the mammalian homolog of the yeast Atg6) associates with 
the cofactor UV irradiation resistance-associated gene (UVRAG) (Morselli et al., 2009). This 
stimulates the activity of the lipid kinase class III phosphatidylinositol 3-kinase (PI3-K) named Vps34 
to promote the activation of the elongation process and autophagosome biogenesis (Levy & 
Thorburn, 2011; Chen & Debnath, 2010). 
 
Elongation entails the use of two conjugation systems, namely the Atg12-Atg5 and the 
phosphatidylethanolamine-Atg8 systems (Meijer & Codogno, 2004). Both systems resemble the 
ubiquitin-proteasomal pathways. The first system entails the conjugation of Atg12 to Atg5 which is 
catalysed by E1-like Atg7 and E2-like Atg10 enzymes (Notte et al., 2011). This conjugate localizes 
onto an isolation membrane where it becomes associated with Atg16L (mammalian homolog). The 
second conjugation system involves the mammalian homologue of the yeast Atg8, called the 
microtubule-associated protein 1 light chain 3 (LC3) (Levy & Thorburn, 2011). The nascent 
unprocessed form is cleaved by the Atg4 protease, producing soluble cytosolic LC3-I with an exposed 
glycine terminal. A phosphatidylethanolamine (PE) moiety is then conjugated to this terminal with the 
aid of the E1-like Atg7 enzyme and the E2-like Atg3 enzyme, producing the lipidated form, LC3-II, 
which is incorporated into the pre-autophagosomal membrane. The site of LC3-II anchorage is 
dependent on Atg16L which recruits the soluble LC3-I polypeptide to the vicinity of PE in the 
membrane (Fujita et al., 2008). Modification and localization of cytosolic LC3-I to autophagosomal 
LC3-II is used as a marker for autophagosome formation (Zakeri et al., 2008).  
 
Upon closure of the phagophore, maturation proceeds by fusion with the endosomal or lysosomal 
vesicles.  Sequestosome (P62/SQSTM1) is a cargo receptor protein that recognizes polyubiquitinated 
targets via their C terminal domains and delivers them to autophagosomes, thus playing a role in 
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cargo selectivity (Levy & Thorburn, 2011). The P62 protein is cleared along with the cargo and is 
been used as a biomarker of the autophagic process (Mathew & White, 2011; Mathew et al., 2009). 
 
1.4.3 Signalling Pathways Regulating Autophagy 
1.4.3.1 The PI3K-Akt-mTOR axis 
A serine/threonine kinase termed the mammalian target of rapamycin (mTOR) has been implicated as 
holding the central position in multiple signalling cascades regulating transcription, translation and 
metabolism (Jung et al., 2010). It balances cell growth and proliferation with the autophagic pathway. 
The mTOR kinase operates as a negative regulator of autophagy and is controlled by the signalling of 
the upstream class I PI3K-Akt pathway which senses nutrient availability, particularly amino acids and 
glucose (Meijer & Codogno, 2004). An ample supply of nutrients activates the PI3K-Akt-mTOR axis 
inducing cell growth and proliferation while simultaneously inhibiting autophagy (Chen & Karantza-
Wadsworth, 2009). 
 
1.4.3.2 LKB1-AMPK –Autophagy-Axis 
Under bioenergetic stress conditions, the depletion in cellular ATP causes an elevation in the AMP: 
ATP ratio (Hardie, 2004). This parameter is sensed by the AMP-activated protein kinase (AMPK), a 
heterotrimeric complex (catalytic α-subunit; regulatory β- and γ- subunits) responsible for monitoring 
intracellular energy status and controlling glucose, lipid and protein metabolism (Xiao et al., 2011). 
The activity of mTOR is inversely correlated with activated AMPK (Chen et al., 2010). AMP has been 
shown to allosterically activate AMPK (Sanders et al., 2007).  However, major AMPK activation is 
dependent on an upstream tumour suppressor, termed LKB1, which phosphorylates AMPK-α at the 
Thr172 residue. This occurs by binding of AMP to the γ-regulatory subunit, which prevents the 
dephosphorylation at the Thr172 site. Activated AMPK responds by promoting catabolic, energy-
producing pathways while limiting anabolic, energy-consuming pathways.  
 
Since autophagy is an energy-producing pathway, AMPK has been shown to induce this lysosomal 
process by phosphorylation of the tuberous sclerosis complexes -1 (TSC-1) and -2 (TSC-2) which is a 
negative mTOR regulator (Maiuri et al., 2010). Activation of TSC-1 and -2 suppresses mTOR activity. 
An alternative pathway is by the direct phosphorylation and activation of ULK1, the kinase involved in 
autophagosome formation (Egan et al., 2011). 
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1) INDUCTION 2) NUCLEATION 3) ELONGATION 4) COMPLETION 5) MATURATION 6) DEGRADATION 
Phagophore 
Autophagosome 
Autophagolysosome 
Figure 1.4 Schematic representation of the morphological and 
molecular mechanisms involved in autophagic biogenesis. The 
inactivation of mTOR promotes the formation of the ULK1-Atg13-Atg17 
complex, which subsequently associates with the isolation 
membrane/phagophore (1). The successive association of Beclin 1 and 
UVRAG in a complex stimulates Vps34 activity to initiate the formation of 
autophagosomes (“nucleation”) (2). Two ubiquitin-like conjugation 
systems lead to the formation of the Atg12-Atg5 conjugate and the  
Lipidated 
 LC3-II 
Autophagic cargo 
lipidated phosphatidylethanolamine (PE)-associated LC3-II conjugate, both of which promote elongation (3). The LC3-II conjugate becomes 
incorporated into the membranes of the developing autophagosome. Upon completion (4), the maturation phase follows with the fusion of the 
autophagosome with a lysosome to form an autophagolysosome (5). The encapsulated cargo, as well as the inner limiting membrane, becomes 
degraded by acid lysosomal hydrolyases (6). 
Fusion 
Lysosome 
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1.4.4 Relationship between Autophagy & Apoptosis 
A link between the molecular mechanisms controlling autophagy and apoptosis was suggested when 
the conserved tumour suppressor factor, Beclin 1, was identified as a Bcl-2-interacting protein (Levine 
et al., 2008). In 2007, a study entailing the use of in vitro pull down assay demonstrated that Beclin 1 
directly interacts with several anti-apoptotic proteins, each through different binding efficiencies (Erlich 
et al., 2007). Furthermore they showed that, although multidomain pro-apoptotic proteins are unable 
to interact with Beclin 1, the BH3-only proteins indirectly interfere by disrupting its inhibitory 
association with anti-apoptotic Bcl-2 members. Using sequence alignment and molecular modelling, 
they elucidated that Beclin 1 possessed a putative BH3-like domain which interacts with the 
hydrophobic BH3 receptor domains present on anti-apoptotic members of the Bcl-2 family. This was 
supported by studies carried out by Oberstein et al. identifying Beclin 1 as a novel BH3-only member 
(Oberstein et al., 2007). Therefore autophagy is capable of being modulated by the family of Bcl-2 
apoptotic regulators, suggesting a mechanism of cross-talk between the two pathways (Levine et al., 
2008). The physical interaction between Beclin 1 and Bcl-2 or Bcl-xL forms an inhibitory complex that 
prevents the autophagic tumour suppressor from allosterically activating Vps34, the lipid kinase 
responsible for autophagosome formation (Levy & Thorburn, 2011). Competitive disruption by BH3 
only proteins liberates the Beclin 1 allowing it to activate autophagy.  
 
Since similar stimuli can initiate apoptosis and autophagy, the relationship between the two is 
puzzling in terms of the pathway that is preferentially selected (Maiuri et al., 2007). González-Polo et 
al. (2005) performed a study on HeLa cells and mouse embryonic fibroblasts where they showed that 
the protective mechanism of autophagy, which is upregulated under starvation conditions, eventually 
succumbs to apoptosis when autophagy is inhibited. RNA interference was used to deplete two 
lysosome proteins, LAMP1 and LAMP2, thus blocking the fusion of autophagosomes with lysosomes 
during autophagy (Maiuri et al., 2007; González-Polo et al., 2005). Vice versa, the survival of 
apoptotic-deficient bone marrow cells, with a double-knockout of pro-apoptotic Bak and Bax proteins, 
was sustained using autophagy as an alternative source of ATP upon withdrawal of the IL-3 growth 
factor (Lum et al., 2005).  
 
While autophagy may contribute to the survival of cells, in other scenarios it constitutes as an 
alternative form of demise (type II cell death), particularly in apoptotic-incompetent cells (Eskelinen & 
Saftig, 2009).  A study by Shimizu et al. (2004) revealed that the loss of cell viability in Bax
-
/Bak
-
 
apoptosis-deficient mouse embryonic fibroblasts was mediated by the generation of 
autophagosomes/autolysosomes in response to treatment with the topoisomerase inhibitor, Etoposide 
(Shimizu et al., 2004). Another study showed that the selective elimination of mitochondria from 
neurons and HeLa cells occurred through autophagy when the caspases were inhibited (Xue et al., 
2001). The decision of whether BH3-only proteins target pro-apoptotic proteins to induce apoptosis or 
anti-apoptotic proteins to induce autophagy is yet to be elucidated. Certain studies hypothesize that 
the BH3-only members may have variable sensitivities to stimuli (Levine et al., 2008). 
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1.4.5 Autophagy in Tumorigenesis 
The abnormal regulation of the autophagy signalling cascade has been implicated in numerous 
pathological diseases including myopathy, neurodegeneration and cancer (Meijer & Codogno, 2004). 
In the context of tumorigenesis, autophagy has been documented as having both a cellular death as 
well as a pro-survival function (Chen & Karantza-Wadsworth, 2009). 
  
1.4.5.1 Suppression of Tumorigenesis 
The frequent mutations of several genes in the autophagic pathway have suggested a cytoprotective 
role against tumorigenesis. This is either due to the activation/deregulation of oncogenes or 
inactivation of tumour suppressor genes. For instance, Beclin 1 is considered a tumour suppressor 
and is frequently expressed at lower levels in prostate, ovarian, and breast cancers due to its 
monoallelic deletion (Liang et al., 1999). 
 
An in vivo study involving the transgenic expression of GFP-LC3 in mice that harboured a 
heterozygous disruption in Beclin 1 revealed a more diffuse pattern of LC3 as compared to transgenic 
GFP-LC3 Beclin 1 
+
/
+
 which produced punctuate regions under starvation conditions (Qu et al., 2003). 
This disruption in autophagy was shown to correlate with the generation of spontaneous tumours in 
various organs of the Beclin 
+
/
-
 mice. 
 
Multiple lines of evidence support the notion that mutations in other regulators, including the 
monoallelic deletion of UVRAG, the over-expression of Bcl-2 and Bcl-xL autophagy repressors, and 
the diminished expression of BH3-only Bcl-2 family (as reviewed in (Morselli et al., 2009)), can act as 
the driving force for cancer development. 
 
1.4.5.2 Promotion of Tumorigenesis 
Conversely, autophagy may also be upregulated in response to radiation or anticancer drugs to 
eradicate the resulting genotoxic damage imposed, thus contributing to survival (Chen & Karantza-
Wadsworth, 2009). Treatment of malignant U251 glioma cells with the DNA-damaging agent, 
Temozolomide, was shown induce autophagy allowing these cancerous cells to evade cell death by 
micro-nucleation (Katayama et al., 2007).  
 
Carew & Medina provided insight into the survival mechanism of autophagy when they inhibited the 
pathway in HT29 and HCT8 colon tumour cells using a pharmacological inhibitor of lysosomal fusion, 
termed Chloroquine (Carew & Medina, 2010). In this autophagy-deficient setting, cell death via 
apoptosis was augmented during treatment of these cells with the histone deacetylase inhibitor, 
Vorinostat. Cell death was attributed to the increased accumulation of protein aggregates that are 
typically removed by autophagy. 
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The process of autophagy represents a survival response during metabolic stress by the catabolic 
breakdown of macromolecules for nutrient supply under energy limiting conditions (Maiuri et al., 
2007). The development of a solid tumour is typically accompanied by the deprivation of nutrients 
(glucose; amino acids) due to the abnormal vascular network that is associated with the tumour 
(Trédan et al., 2007). The dependency of cancer cells on autophagy during metabolic insult is 
supported by Degenhardt et al., whose research revealed that apoptotic-defective HeLa cells (forced 
Bcl-2 or Bcl-xL expression) thrived under ischaemic conditions (incubation in glucose-free medium 
under 1% oxygen) (Degenhardt et al., 2010). This survival was attributed to the autophagic 
mechanism as the pattern of EGFP-LC3 was converted from diffuse to punctuate when subjected to 
the metabolically stressful conditions. HeLa cells exhibited necrotic cell death upon the knock-down of 
Beclin-1 by RNA interference.  
 
1.5 RELATIONSHIP BETWEEN AUTOPHAGY AND HYPOXIA 
Besides damage by chemo- and radiotherapy, a limited supply of nutrients and oxygen in the 
microenvironment of the tumour can also constitute a stressful insult. As mentioned previously, 
autophagy serves as a protective mechanism in nutrient-limiting conditions and would therefore be 
expected to generate the necessary supplies that fuel the metabolism for neoplastic proliferation (Nan 
Chen & Debnath, 2010). Therefore, disruption of this pathway would lead to a metabolic catastrophe 
and cell death, limiting the growth of the tumour (González-Polo et al., 2005). 
 
A recent in vitro study on human cervical (HeLa) and ovarian (OVCAR-8) cancer cell lines revealed 
that the apoptosis that arises under normoxic conditions in response to treatment with Fenretinide, an 
anticancer agent known to induce apoptosis by generation of reactive oxygen species, is replaced by 
autophagy when oxygen is depleted (Liu et al., 2010). Disruption of the autophagic process with 3-
Methyladenine or Chloroquine sensitized the cells to Fenretinide treatment indicating that autophagy 
upregulated under hypoxia is protective.  Furthermore, HIF-1α knockdown with short hairpin RNA 
(shRNA) abrogated the autophagic response indicating that this process acts downstream of the 
transcription factor. 
 
The hypoxic-inducible gene, BNIP3, has been implicated as the factor responsible for autophagy 
upregulation (Rohwer & Cramer, 2011). Zhang et al. showed that the potential cytotoxicity due to the 
reactive oxygen species generated during hypoxic stress was mitigated by mitochondrial autophagy, 
or mitophagy, in mouse embryo fibroblasts (Zhang et al., 2008). This autophagy was shown to be 
dependent on BNIP3 expression, which was induced by HIF-1α stabilization during hypoxia. BNIP3 is 
a BH3-only member of the Bcl-2 family which is also responsible for antagonizing the pro-survival 
effects of Bcl-2 and Bcl-xL, further providing evidence for potential cross-talk between autophagy and 
apoptosis (Levine et al., 2008). 
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1.6 TARGETING THE HYPOXIC ENVIRONMENT OF TUMOURS 
2-Methoxyestradiol is an endogenous metabolite derived from 17β-estradiol by an oxidative 
biotransformation process occurring naturally under physiological conditions in both males and 
females (Sutherland et al., 2007). Under normal physiological conditions, plasma concentrations of 2-
methoxyestradiol are relatively low (within the pico-molar range) (Mueck & Seeger, 2010). Recent 
interest in the exploitation of 2-methoxyestradiol as an anticancer agent has arisen as it has been 
shown to possess anti-carcinogenic properties. This compound possesses a weak estrogenic activity 
and its mode of action is believed to be independent of the estrogen receptor status of cells 
(Sutherland et al., 2007; LaVallee et al., 2002). 
 
1.6.1 Mechanism of Action of 2-Methoxyestradiol 
The universal mode of action exhibited by 2-methoxyestradiol has yet to be elucidated, but a variety 
of possible mechanisms have been suggested. Its anti-proliferative properties have been 
demonstrated on both endothelial cells and several cancer cell lines [as reviewed in (Mooberry, 2003; 
Dubey & Jackson, 2009)]. These properties may arise from interference of the estradiol metabolite 
with the progression of the cell cycle leading to accumulation of cells in the G2/M phase (Stander et 
al., 2010; Kumar et al., 2001). An alternative mechanism is the induction of the extrinsic and intrinsic 
apoptotic pathways, where studies have shown 2-ME to upregulate the death receptor 5 (LaVallee et 
al., 2003), generate a surge in the production of free radicals due to inhibition of superoxide 
dismutase (Huang et al., 2000), and/or the activation of the stress c-Jun N-terminal kinase (JNK), 
which subsequently inactivates the anti-apoptotic Bcl-2 proteins by phosphorylation (Bu et al., 2002). 
The mechanism of action chosen appears to be dependent on the cell line. Apart from this direct 
effect on endothelial cells, this compound has also been demonstrated to indirectly inhibit neo-
angiogenesis via HIF-1α-dependent down-regulation of VEGF (Stander et al., 2010). Mabjeesh et al. 
noted that the decrease of HIF-1α protein expression in human breast (MDA-MB-231) and prostate 
(PC-3) cancer cell lines upon 2-methoxyestradiol treatment occurred through a translational-
dependent mechanism (Mabjeesh et al., 2003). Not only was VEGF mRNA attenuated, but the 
decreased HIF-1α expression correlated with the depolymerisation of microtubules. Furthermore, 
these researchers proceeded with an in vivo approach where the microvascular density of tumours, 
obtained from an orthotopic breast cancer model, was quantified. A significant decrease in 
vascularization was seen in response to 2-methoxyestradiol exposure. 
Its appeal as an anticancer drug was further emphasized by its ability to selectively target proliferating 
tumorigenic and endothelial cells, while its effect on normal epithelial cells appears to be negligible 
(Parks et al., 2011; Kato et al., 2008). This selective toxicity was observed by Van Zijl et al. (2008) 
who showed that the capability of 2-methoxyestradiol to induce apoptosis, multipolar spindles and 
mitotic blockage, thereby inhibiting cellular proliferation, was weaker in the epithelial non-tumorigenic 
MCF-12A cell line compared to tumorigenic MCF-7 cells (Van Zijl et al., 2008). 
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1.6.2 Adjuvant Therapy & Clinical Trials of 2-Methoxyestradiol 
Previous studies using xenograft murine models have revealed 2-methoxyestradiol to be proficient at 
synergistically enhancing the cytotoxic effects of anticancer agents while maintaining a low systemic 
toxicity profile.  For example, Han et al. (2005) showed that by combining 2-methoxestradiol with the 
anticancer drugs, paclitaxel or vinorelbine, a more pronounced growth inhibitory effect on the MDA-
MB-231 xenografts compared to either drug treatment alone (Han et al., 2005).  
These preclinical results have transcended the 2-methoxyestradiol compound to Phase I and II 
clinical trials where evaluation of its efficacy have been carried out on patients inflicted with epithelial 
ovarian cancer (Matei et al., 2009), metastatic breast cancer (James et al., 2006) and solid tumours 
(Dahut & Lakhani, 2006). Different formulations of this drug, currently registered as Panzem® by 
EntreMed (Rockville, USA), have evolved in order to improve its delivery and stability, including the 
NanoCrystal® Dispersion (NCD) delivery system (Harrison et al., 2011). 
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1.7 PROBLEM STATEMENT 
Despite the manifestation of the pathology of cancer throughout different tissues of the body, that of 
the breast seems to be the prime site of occurrence and the most fatalistic form in women.  
Although breast cancer exhibits a heterogeneous phenotype, the most effective antineoplastic drug 
used for treatment is doxorubicin, belonging to the anthracycline class of antibiotics.  This anticancer 
drug debilitates cancer cells by multiple mechanisms, most of which culminate in the apoptotic cell 
death pathway. The responsiveness to chemotherapeutic treatment is frequently hindered within solid 
tumours. This has been attributed to the adverse microenvironment existing within the tumour, often 
featuring regions of hypoxia. An endogenous biomarker of hypoxia is the HIF-1α transcription factor, 
with its expression in hypoxic environments capable of inducing survival advantages that 
simultaneously select for a more aggressive phenotype in terms of malignancy and chemo-resistance. 
Autophagy is an evolutionary conserved process that is active at basal levels within almost all cells to 
maintain homeostasis of a cell by eliminating potentially hazardous proteins and organelles. Studies 
have indicated that the autophagic process is capable of promoting tumorigenesis and survival 
despite multi-modality treatment. Furthermore, hypoxia is also a potent stimulus for autophagy. 
Therefore, to counteract the chemotherapeutic resistance that impedes the success of doxorubicin, a 
strategy that manipulates autophagy in the context of a hypoxic environment represents an appealing 
approach. To target the hypoxic response, which has been shown to include the autophagic pathway, 
would be by inhibiting the master regulator, HIF-1. Through the posttranslational disruption of the HIF-
1α protein (pharmacological intervention; 2-methoxyestradiol), or alternatively, the silencing of the 
HIF-1α mRNA transcript (transcriptional intervention; siRNA duplex), the cytotoxic pharmacodynamic 
profile of doxorubicin on breast cancer (MCF-7; E0771) may be improved by antagonizing the 
chemotherapeutic-resistant response. The combination of therapies exhibiting different modes of 
action not only allow for the maximum mitigation of tumorigenic cells, but simultaneously enable the 
therapies to be used at sub-toxic doses that would otherwise target and potentially destroy non-
malignant cells. In the context of this study, the full potential of the antineoplastic drug, doxorubicin, 
could thus be exploited by inhibition of the hypoxic response. 
 
1.7.1 Hypothesis 
Abrogation of the ‘protective’ hypoxic response by pharmacological (2-methoxyestradiol) or genetic 
(siRNA transfection) disruption of the HIF-1α master regulator will sensitize MCF-7 neoplastic cells to 
the chemotherapeutic drug, doxorubicin. 
  
1.7.2 Aims 
1. To determine the conditions at which hypoxia confers a survival advantage to the MCF-7 
tumorigenic cells in response to doxorubicin treatment. 
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2. To characterize the molecular events responsible for this selective advantage under hypoxia. 
3. To link these molecular events to the expression levels of the HIF-1 master regulator. 
4. To assess whether the disruption of the ‘protective’ hypoxic response by HIF-1 inhibition can 
sensitize the tumorigenic cell line to doxorubicin treatment, therefore producing a synergistic 
effect. 
5. To show reproducibility of the in vitro experiment in a pre-clinical animal model. 
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CHAPTER 2 - MATERIALS & METHODS 
IN VITRO 
2.1 STUDY DESIGN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 In vitro study design. Human breast cancer epithelial cells (MCF-7) were treated with 
doxorubicin, either alone or in combination with HIF-1α disruption, and incubated in parallel under 
either normoxic (21% O2) or hypoxic (~0.1% O2) conditions for 12 hours. Experiments were assessed 
based on bioreductive capacity (MTT Assay), metabolic pathways (Western blotting), and cellular 
death pathways (Caspase-Glo Assay, Western Blotting, and Live Cell Imaging). 
MTT ASSAY 
Fluorescent MitoTracker® Red CMXRos 
Mitochondrial spatial distribution & morphology 
Measurement of bioreductive capacity 
Indirect indication of cellular viability 
Measurement of caspase-3/-7 activity 
Monitor apoptotic (type-I) cell death 
Apoptosis: Cleaved caspase-3; Cleaved PARP 
Autophagy: LC3; p62 
Hypoxia: HIF-1α 
Metabolic Signalling: p-mTOR; p-AMPK 
Tumorigenic ER-positive human breast cell line [MCF-7]  
Incubation at 37 °C; humidified atmosphere; 5% CO
2
 
Subculture at ~70-80 % confluency 
CELL CULTURE/ROUTINE MAINTENANCE 
 Chemotherapeutic drug: Doxorubicin; 1 µM  
 Stabilizing HIF-1α:  Cobalt Chloride, CoCl
2
; 100 µM 
 Targeting HIF-1α: 2-Methoxyestradiol; 10 µM 
  siRNA transfection; 400  nM 
Parallel incubation NORMOXIA (21 % O
2
) 
 HYPOXIA (~0.1 % O
2
) 
EXPERIMENTAL TREATMENT 
 12 hours 
CASPASE GLO ASSAY 
WESTERN BLOTTING 
FLUORESENCE MICROSCOPY 
 
 
 
 
EXPERIMENTAL ASSESSMENT 
1. 
2. 
3. 
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2.2 CHEMICALS & REAGENTS 
The growth medium constituents: Dulbecco’s Modified Eagle Medium (DMEM; #10564-037), heat-
inactivated Fetal Bovine Serum (FBS; #10082), and Penicillin-Streptomycin-Glutamine (100X liquid, 
#10378-016) were all obtained from Invitrogen, Life Technologies (Johannesburg, South Africa). 
Doxorubicin Hydrochloride (#D1515) was purchased from Sigma-Aldrich (Johannesburg, South 
Africa), 2-Methoxyestradiol (#13021) from Cayman Chemical (Michigan, USA), and Cobalt (II) 
Chloride Hexahydrate (#102539) from Merck (Darmstadt, Germany). The HIF-1α siRNA transfection 
kit (#35561) was obtained from Santa Cruz Biotechnology (California, USA). The MTT reagent, 
Thiazolyl Blue Tetrazolium Bromide (#M2128), was acquired from Sigma-Aldrich (Johannesburg, 
South Africa). Promega (Madison, USA) provided the Caspase-Glo® 3/7 Assay (#G809) kit. For 
western blotting, following primary antibodies: rabbit anti-Cleaved Caspase-3 (Asp175), #9661; rabbit 
anti-Cleaved PARP (Asp214), #9541; rabbit anti-LC3B, #2775; rabbit anti-SQSTM1/p62, #5114; 
rabbit anti-HIF-1α, #3716; rabbit anti-Phospho-mTOR (Ser2448), #2971; rabbit anti-Phospho-AMPK 
(Thr172), #2531; and the secondary antibody: HRP-linked goat anti-rabbit, #7074; were all purchased 
from Cell Signaling (MA, USA). Invitrogen, Life Technologies (Johannesburg, South Africa) supplied 
the MitoTracker® Red CMXRos required for live cell imaging/fluorescent microscopy. 
 
2.3 CELL LINES 
The MCF-7 tumorigenic cell line is an adherent, estrogen-receptor positive cell line where the primary 
culture originated from the pleural effusion obtained from a woman with malignant adenocarcinoma of 
the mammary gland. The MCF-7 cell line was utilized in this study and obtained from the American 
Type Culture Collection (catalogue no# HTB-22; Rockville, MD, USA).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Images of the MCF-7 cell line obtained with an inverted microscope. (A) 100x and (B) 
400x magnification.  
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2.4 CELL CULTURE 
For routine maintenance, the MCF-7 cell line was propagated in tissue culture flasks at a seeding 
density of 5000 cells/cm
2
. Cells were incubated under a humidified atmosphere containing 5% 
CO2/95% O2 at 37°C. The growth medium employed was Dulbecco’s Modification of Eagle’s Medium 
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin. Growth 
of the cultures was monitored using an inverted phase microscope (Olympus CKX4SF; Tokyo, 
Japan). Once a confluency of approximately 70-80% was reached, new cultures were established by 
subculture/passage. Cells were never passaged more than 10 times. Strict aseptic control was 
applied at all times.  
 
2.5 EXPERIMENTAL PROTOCOL 
2.5.1 Seeding Densities for Experimental Purposes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.2 Reverse Transfection 
Knock-down of HIF-1α gene expression was performed using a reverse transfection approach. The 
HIF-1α siRNA duplex was combined with 6 µL transfection reagent, FuGENE®6 (Fugent, L.L.C, 
USA), and diluted in siRNA transfection medium (excluding serum and antibiotics) such that the final 
concentration of the siRNA duplex was 400 nM. The siRNA-FuGENE®6 mixture was added to the 
culture dishes and incubated for a minimum of 45 minutes. MCF-7 cells that had been resuspended in 
growth medium (containing serum for cell growth, but excluding antibiotics) were then seeded at the 
appropriate density into the culture dishes containing the siRNA-FuGENE®6 preparation. Cells were 
Table 2.1 Guide for recommended seeding densities of MCF-7 cells based on the surface 
area of culture vessels. The recommended seeding densities are based on both the doubling 
time of tumorigenic MCF-7 cell line (~29 hours) and the requirement of at least ~24 hours for 
reverse transfection in HIF siRNA groups. The treatment regime commenced once a confluency of 
~70-80% is reached. 
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then incubated at 37°C until reaching a confluency of 80% (~24 hours) after which the drug treatment 
proceeded. 
 
2.5.3 Drug Treatments 
The following stocks were made: 3.4 mM doxorubicin solution using growth medium as the solvent, 
33 mM 2-methoxyestradiol solution using DMSO, and 25 mM CoCl2 solution using dH2O. Aliquots of 
both doxorubicin and 2-methoxyestradiol were prepared so as to avoid freeze-thaw cycles and stored 
at -20°C while the CoCl2 solution was stored at room temperature. Immediately prior to each 
experimental treatment, these chemicals were diluted in growth medium to a final concentration of 1 
µM, 10 µM, and 100 µM for doxorubicin, 2-methoxyestradiol and CoCl2, respectively. 
2.5.4 Treatment Conditions 
Following the treatment regime, cells were then subjected to either normoxic (21% O2) or hypoxic 
(~0.1% O2) conditions for a period of 12 hours in parallel. Cultures were incubated in Perspex sub-
chambers within an incubator and conditions were rendered hypoxic with the aid of the ProOx C21 
(BioSpherix, New York, USA) oxygen controller unit by infusion with Nitrogen gas (Afro, South Africa). 
 
2.6 THE MTT BIOREDUCTIVE ASSAY 
The MTT bioreductive assay is a method used to quantify the metabolically active cells in a 
population, thus giving an indication of cellular viability. This colorimetric assay is based on the 
bioreductive capacity of cells. Metabolically active cells are able to reduce the water-soluble yellow 
tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to water-insoluble 
purple formazan crystals of which the absorbance can be detected spectrophotometrically. The 
amount of the formazan product generated is directly proportional to the number of metabolically 
viable cells. This rapid test is widely used to evaluate and compare the in vitro responses to the 
cytotoxic effects of anti-tumour candidates.  
 
Cells in their exponential growth phase were seeded in 12-well tissue culture plates at a density of 2.0 
X 10
4
 MCF-7 cells/1000 µL/well and allowed to adhere under standard culture conditions (37°C; 5% 
CO2). The groups that required transfection were simultaneously reverse transfected during plating. 
Once a confluency of ~80% was reached, treatment was initiated as described previously in the 
experimental protocol. On completion of the treatment, the medium was aspirated from the adherent 
cells and a prewarmed PBS/1% MTT (0.01 g MTT/1 mL PBS) reagent mixture was gently added to 
each well in a 3:1 ratio. Culture plates were maintained in the dark at 37°C in a humidified 5% CO2 
atmosphere for 60 minutes. Solubilisation of the purple formazan product was achieved using an 
acidified isopropanol:triton-x mixture (50:1). The absorbance values were monitored on a 
spectrophotometer at 540 nm using the acidified isopropanol: triton-x mixture as a blank. Experiments 
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were performed in quadruplicate and repeated a minimum of three times. Data was expressed as a 
percentage compared to untreated control samples (100%). 
 
2.7 THE CASPASE-GLO® 3/7 ASSAY 
Caspase 3- and 7- are the executioners of the apoptotic cellular death pathway and their activities can 
be measured by the addition of a luminogenic reagent that, in combination with the enzyme 
luciferase, produce a light signal proportional to the amount of caspase activity present. Cells in their 
exponential growth phase were seeded in 96-well tissue culture plates at a density of 2000 MCF-7 
cells/100 µL/well and allowed to adhere under standard culture conditions (37°C; 5% CO2). A reverse 
transfection approach was simultaneously followed during plating in the necessary groups. Once a 
confluency of ~80% was reached, treatment was initiated as described previously in the experimental 
protocol. At the end of treatment, 50 µL of the treatment medium was transferred to the wells of a 
white-walled 96-well plate and an equal volume of the Caspase-Glo® Reagent was added. The 
contents were mixed gently and incubated in the dark for 60 minutes. The luminescence was 
measured in a luminometer (GloMax™ 96 Microplate Luminometer, Promega). Data was expressed 
as a percentage (relative light units, RLU) compared to untreated control samples. 
 
2.8. WESTERN BLOTTING 
2.8.1 Protein Extraction 
All the procedures involved in the extraction of total protein from cells were performed on ice (4°C) or 
in a walk-in fridge. Upon completion of treatment, cells were harvested as follows: The medium 
containing the detached cells was transferred directly to conical tubes. After the addition of ice-cold 
PBS to each well, the adherent cells were mechanically harvested by gentle scraping with the aid of a 
rubber cell scraper. The cell suspension was then transferred to its respective conical tube containing 
the medium. MCF-7 cells were pelleted by centrifugation (1500 rpm; 3 minutes; 4°C) and 
resuspended in ~200 uL of RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.25% Na 
Deoxycholate, 1mM PMSF, 1 mM Benzamidine, 1 mM EDTA, 1 µg/1 mL Leupeptin, 2 µg/1 mL 
Aprotonin, 1 µg/1 mL Pepstatin, 4 µg/1 mL SBTI-1, 1 mM Na3VO4, 1 mM NaF) per 9.5 cm
2
 and 
maintained for a duration of 10 minutes. Cells were disrupted by multiple short bursts (~3 seconds) of 
sonication using the ultrasonic liquid processor (Misonix Sonicator 4000, Connecticut, USA). Lysates 
were clarified by centrifugation (8000 rpm for 10 minutes; 4°C) which removed the insoluble cellular 
debris, and final supernatants collected. 
 
2.8.2 Determination of Protein Concentration 
All the procedures involved in the determination of protein content in lysates, as well as sample 
preparation were performed on ice (4°C). Protein quantification was performed using the Bradford 
colorimetric assay (Bradford, 1976) from a bovine serum albumin (BSA) standard curve. The 
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absorbance values were measured with a spectrophotometer (Cecil 2000, type CE 2021 UV/VIS, 
Cambridge, England) at a wavelength of 595 nm.  
 
2.8.3 SDS-PAGE & Electrotransfer 
For high molecular weight proteins (phospho-mTOR, 298 kDa; HIF-1α, 120 kDa; Cleaved PARP, 
89kDa; phospho-AMPK, 62 kDa; p62, 62 kDa), lysates were separated on a 6% polyacrylamide gel, 
whereas for low molecular weight proteins (β-actin, 42 kDa; LC3, 14 kDa, 16 kDa; Cleaved Caspase 
3, 17 kDa, 19 kDa), a 12% polyacrylamide gel was used. Equivalent amounts of protein (50 µg) were 
loaded per lane with a molecular marker being loaded in the first lane to assist with orientation and 
sizing of separated proteins. Proteins were fractionated by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE; Mini-PROTEAN® Tetra cell, Biorad) at a constant voltage of 100 V 
and current of 200 mA (Biorad Power Pac 1000) until the migration front reached the bottom of the 
gel. 
 
Resolved proteins were then electro-transferred onto polyvinylidene fluoride membrane (PVDF; 
Immobilon, Millipore, USA) using a horizontal semi-dry electrotransfer system (Biorad Trans-blot® 
SD, USA) at voltage of 15 V and constant current of 0.5 A (Biorad Power Pac 1000). Alternatively, a 
vertical wet transfer system (Mini- Trans blot cell, Italy) was used when electrotransfer was performed 
using a voltage of 200 V and constant current of 200 mA (Biorad Power Pac™ HC). 
 
2.8.4 Immuno-detection 
Non-specific hydrophobic binding sites were blocked with incubation in 5% non-fat milk. For the 
phosphorylated proteins, 3% bovine albumin serum was used as a blocking solution as non-fat milk 
contains the phosphorylated protein casein which would bind antibody and therefore nonspecific 
proteins. Blots were then incubated overnight at 4°C in primary antibody. The protein of interest was 
detected using recommended dilutions of the primary antibodies: LC3-II and p62 (autophagy), 
cleaved caspase 3 and cleaved PARP (apoptosis), HIF-1α (hypoxia), and p-mTOR and p-AMPK 
(metabolism). The blots were then incubated in anti-rabbit horseradish peroxidase-conjugated 
secondary antibody. Membranes were then exposed to ECL Western Blotting Substrate (BioVision, 
USA, San Francisco) and the light emission produced was detected by exposure to photographic film 
in a dark room. Alternatively, chemiluminescent signals were captured with the Chemidoc MP Imager 
System (Biorad). To control for protein loading, all blots were probed for the representative protein β-
actin. The images were refined in terms of their display using the Image Lab™ Software (version 4.0 
build 17). Densitometric analysis was performed using the Quantity One 1-D Analysis Software 
(Biorad) and normalized against its respective loading control. Three independent experiments were 
performed. 
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2.9 LIVE CELL IMAGING 
2.9.1 Staining the Mitochondria 
To assess the spatial distribution and morphology of intracellular mitochondria, a qualitative approach 
using a mitochondrion-selective dye, MitoTracker® Red CMXRos, was employed. This cell-permeable 
probe becomes oxidized on entry into an actively respiring cell and concentrates in the mitochondria, 
which then fluoresce.  
 
Cells were seeded into an 8-chamber slide (Nunc) at a density of 4.0 x 10
3
 MCF-7 cells/300 µL/well 
and allowed to adhere under standard culture conditions (37°C; 5% CO2). Reverse transfection was 
simultaneously carried out on the necessary groups. Treatment commenced once cells reached 80% 
confluency. At the end of the desired treatment period, cells were loaded with a 1 mM working 
solution of MitoTracker® Red. This specific fluorescent probe has an excitation/emission maximum of 
579 nm/599 nm. Nuclei were counter-stained using Hoechst 33342 (1:200). The cells were observed 
using an Olympus IX81 inverted fluorescent microscope equipped with a 100x oil immersion objective 
and a Xenon-Arc burner (Olympus Biosystems GMBH) as the light source. To minimize 
photobleaching of the mitochondrion-specific dyes, the focal plane was set using the Hoechst-
excitation parameter. Samples were excited with the 360 nm (DAPI) and 572 nm (TxRed) excitation 
filter. The emission was acquired using a UBG triple-bandpass emission filter cube (Chroma). For the 
z-stack image frame acquisition, an Olympus Plan Apo N 60x/1.4 Oil objective and the Cell^
R
 imaging 
software have been used. Increments between the separate image frames in z were 0.4 µm. 
 
2.9.2 Processing the Fluorescent Images 
The raw fluorescent images were processed and non-specific background subtracted using the Cell^
R
 
imaging software. Finally, the image stacks were projected as a maximum intensity projection. 
 
2.10 STATISTICAL ANALYSIS 
Data from at least three independent experiments (each conducted in three replicates) were 
analysed. Significant differences were assessed by one-way analysis of variance (ANOVA) using the 
Bonferroni post-hoc test. The GraphPad Prism version 5 software was employed to conduct all 
statistical analysis. 
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IN VIVO 
2.11 STUDY DESIGN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 In vivo study design. C57BL/6 mice were inoculated with murine adenocarcinoma mammary cells (E0771). Treatment began at 28 days post-
inoculation once the tumours became palpable and the mice were then randomly sorted into 5 different treatment groups. Mice received treatment every 3 
days for 2 weeks. On day 42, they were sacrificed and resected tumours were analysed for biomarkers using western blotting.
DAY 
Tumorigenic murine breast cell line [E0771]  
Incubation at 37°C; humidified atmosphere; 5% CO
2
 
Subculture at ~70-80% confluency 
CELL CULTURE/ROUTINE MAINTENANCE 
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5
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-1
] 
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2.12 ANIMALS 
The in vivo study employed the use of the C57BL/6 mouse strain. Mice were maintained in the animal 
facility at the University of Stellenbosch and provided with standard chow feed and tap water ad 
libitum. Mice were housed in sterilized cages with filtered air. Animal research was ethically approved 
(clearance no# 2009B02004) and experiments were performed under conditions that complied with 
the requirements of the institution. 
 
2.13 CELL LINES 
The cell line used in this study was the tumorigenic E0771 cell line which originated from a tumour 
that developed by spontaneous mutation in a C57BL/6 mouse. This cell line was generously provided 
by Fengshi Li (Roswell Park Cancer Institure, Buffalo, New York, USA). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Images of the E0771 cell line obtained with an inverted microscope. (A) 100X and (B) 
400X magnifications.  
 
2.14 EXPERIMENTAL PROTOCOL 
2.14.1 Cell Culture 
For routine maintenance, the E0771 cell line was propagated in tissue culture flasks under a 
humidified atmosphere containing 5% CO2/95% O2 at 37°C. The growth medium employed was 
DMEM supplemented with 10% Fetal Bovine Serum and 1% Penicillin-Streptomycin. Growth of the 
cultures was monitored using an inverted phase microscope (Olympus CKX4SF; Tokyo, Japan). 
Cultures were established once the confluency reached approximately 70-80%. Cells were examined 
on a daily basis for changes in cell morphology and growth. Cells were not passaged more than 10 
times. Strict aseptic control was applied at all times. A master stock of the cell line at a specific 
passage was made.  
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2.14.2 Inoculation of Cancer 
Female 8-week old C57BL/6 mice with an average weight of ~22.5 g were inoculated subcutaneously 
into the left fourth mammary fat pad with 2.5 x 10
5
 E0771 cells/200 µL Hanks Balanced Salt Solution 
(HBSS; Sigma H8264, St Louis, USA). The day of inoculation was designated as day 0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Modified illustration indicating site of tumour implantation and drug administration.  
Mammary glands of the experimental mouse indicating (A) the site of E0771 cancer cell inoculation 
and (B) the site of drug administration. Illustration was adapted from (Murphy, 1966). 
  
Site of tumour 
implantation 
Site of drug administration 
A 
B 
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2.14.3 Drug Administration, Tumour Excision, and Experimental Evaluation 
The following stocks were made: 10 mg/3 mL doxorubicin solution using growth medium as the 
solvent and a 50 mg/1 mL 2-Methoxyestradiol solution using 0.5% carboxymethylcellulose (CMS) as 
the solvent. Immediately prior to each drug injection, these chemicals were diluted in HBSS (Sigma 
H8264, St Louis, USA) such that the final volume of each treatment administered was 100 µL. When 
the tumours became palpable on day 28, tumour-bearing mice were randomly sorted into 5 different 
treatment groups: (1) control (HBSS), (2) doxorubicin-treated (5 mg.kg
-1
), (3) 2-methoxyestradiol-
treated (45 mg.kg
-1
), (4) mice treated with the combination of doxorubicin and 2-methoxyestradiol, and 
(5) vehicle (0.5% CMS). Mice were restrained and drugs administered intraperitoneally every 3 days 
for a duration of two weeks. 
 
Each mouse was tagged in the ear and monitored individually. The body mass of control and treated 
animals was measured every three days. Simultaneously, tumour volume was monitored by recording 
the perpendicular length and width of the tumours using a slide calliper. The volume of tumours was 
calculated using the following formula: 0.52 x (shortest diameter)
2
 x (longest diameter). 
 
Experimental mice were sacrificed at the end of the treatment period (day 42) and tumours were 
excised as rapidly as possible and placed on ice. Tumour tissue was dissected into pieces and placed 
in ~1 mL of RIPA buffer per 1 mm
3
. Tissue was then disrupted with the aid of a homogeniser. Lysates 
were centrifuged (8000 rpm for 10 minutes; 4°C), which removed the insoluble cellular debris, and 
final supernatants collected. Western blot sample preparation and analysis of tumours was 
approached in the same manner as the in vitro component of this study. 
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CHAPTER 3: RESULTS 
IN VITRO 
3.1 CONCENTRATION-RESPONSE CURVES 
The MTT bioreductive assay was employed to assess the sensitivity of the tumorigenic MCF-7 cell 
line exposed to various concentrations of the chemotherapeutic drug, doxorubicin, and the 
pharmacological HIF-1α-inhibitor, 2-methoxyestradiol, for a duration of 24 hours. This allowed us to 
establish the concentration of the drugs required for the study. 
 
3.1.1 Doxorubicin 
The capacity of MCF-7 cells to reduce the MTT tetrazolium salt under normoxic conditions became 
significantly reduced with increasing concentrations of doxorubicin, from 0.5 – 5 µM (Fig. 3.1.1A). At 
concentrations more potent than 5 µM, this inhibitory effect appeared to plateau. Although a similar 
inhibitory pattern was witnessed under hypoxic conditions, a significant effect only became noticeable 
from a concentration of 0.75 µM and higher. A half-maximal response (IC50) was elicited at ~1 µM and 
was therefore chosen as the concentration of doxorubicin to be used throughout this study. 
 
3.1.2 2-Methoxyestradiol 
The 24 hour exposure of MCF-7 cells to 2-methoxyestradiol exhibited a similar concentration-
dependent inhibitory effect under both normoxia and hypoxia as was seen with the doxorubicin drug 
(Fig. 3.1.1B). Although the capacity of MTT salt reduction decreases with increasing concentrations, 
the effect is much weaker when compared to that of doxorubicin. The IC50 was calculated as ~10 µM. 
 
3.1.3 Cobalt Chloride 
Of the serial CoCl2 concentrations, those higher than 300 µM produced a significant decrease in the 
bioreductive capacity of MCF-7 cells (Fig. 3.1.2). 
 
3.2 TIME-RESPONSE CURVES  
Our next aim was to elucidate the duration of MCF-7 exposure to doxorubicin which would be capable 
of inducing a differential response between normoxic and hypoxic conditions.  
A differential effect was evident in all experimental groups after 6 hours of exposure, where MCF-7 
neoplastic cells under hypoxia possessed a greater bioreductive capacity compared to their normoxic 
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counterparts (Fig. 3.2.1). This effect became statistically significant within the control (117.6 ± 3.479% 
vs normoxic control, p<0.001) and doxorubicin-treated (40.39 ± 2.810% vs normoxic dox, p<0.01) 
groups after a treatment duration of 12 hours. After a 24 hour of exposure, this distinct effect had 
disappeared. Beyond this time point (Fig. 3.2.2, 48 hours; Fig 3.2.3, 72 hours), a reversal of the 
differential effect was observed in the control group where MCF-7 cells under hypoxia presented a 
significant decrease in their capacity to reduce the tetrazolium salt compared to those under 
normoxia. Therefore, 12 hours was selected as the time point for the study based on the prominent 
differential effect that manifested within the doxorubicin treated group.  
 
3.3  THE EFFECT OF THE TREATMENT REGIME ON APOPTOSIS IN MCF-7 CELLS 
DURING NORMOXIA AND HYPOXIA 
3.3.1 The Caspase-Glo® 3/7 Assay 
An increase in the luminescent signal was observed in all the doxorubicin-treated groups (Fig. 3.3). 
Within these groups, the activities of the executioner caspases-3 and -7 were significantly greater 
when HIF-1α was silenced by transfection in MCF-7 cells under both normoxia (16.94 ± 2.749 RLU 
vs. normoxic dox, p<0.05) and hypoxia (17.85 ± 3.059 RLU vs. hypoxic dox, p<0.05). There was no 
noticeable effect when doxorubicin was combined with 2-methoxyestradiol.  
 
3.3.2 Western Blotting 
To further validate the results obtained from the Caspase-Glo® 3/7 Assay, the expressions of two 
biomarkers playing a role in the apoptotic pathway were assessed by immunoblotting.   
Similar to the pattern witnessed in the Caspase-Glo® 3/7 Assay experiment (section 3.3.1), the 
cleavage of caspase 3 became more pronounced in the groups treated with doxorubicin compared to 
the control. Under normoxic conditions, there was a statistical increase of caspase 3 cleavage in the 
doxorubicin-HIF-1α siRNA group (16.81 ± 2.602 AU vs. normoxic dox, p<0.05) compared to 
doxorubicin alone (Fig. 3.4.1). In contrast, cleavage was significantly diminished when doxorubicin 
was combined with 2-methoxyestradiol (3.802 ± 0.06586 AU vs. normoxic dox, p<0.05). Under 
hypoxic conditions, the combination of the doxorubicin and 2-methoxyestradiol produced a similar 
statistical difference (3.239 ± 0.2156 AU vs. hypoxic dox, p<0.05) as evident from Fig. 3.4.2. 
However, no significance was detected when HIF-1α was silenced. 
The apoptotic trend seen with caspase 3 cleavage was mimicked when another biomarker was 
employed, namely the cleavage of PARP, which occurs downstream of caspase 3 activation. Under 
normoxia (Fig. 3.5.1) and hypoxia (Fig. 3.5.2), doxorubicin combined with 2-methoxyestradiol 
reduced PARP cleavage significantly (3.824 ± 0.1078 AU vs. normoxic dox, p<0.05 for normoxia and 
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19.15 ± 4.377 AU vs. hypoxic dox, p<0.0001 for hypoxia), whereas the treatment of HIF-1α silenced 
neoplastic cells with doxorubicin did not alter the expression profile significantly. 
 
3.4 THE EFFECT OF THE TREATMENT REGIME ON AUTOPHAGY IN MCF-7 CELLS 
DURING NORMOXIA AND HYPOXIA 
3.4.1 Western Blotting 
To evaluate the autophagic intensity under baseline conditions and possible changes induced in 
response to experimental treatment conditions, two biomarkers specific for the autophagic pathway 
were employed. 
The conversion of the cytosolic form of the microtubule-associated protein light chain (LC3-I) to the 
lipidated, autophagosome-associated form (LC3-II) is a marker used to assess the formation of 
autophagosomes. Under normal oxygen tension, in comparison to the control, the LC3-I to LC3-II 
conversion detected was considerably higher in groups treated with CoCl2, doxorubicin alone, 
doxorubicin in the presence of 2-methoxyestradiol, HIF-1α siRNA alone, and the siRNA transfection in 
combination with doxorubicin (Fig. 3.6.1). The accumulation of LC3-II was significantly augmented 
(2.076 ± 0.05859 AU vs. normoxic dox, p<0.05) when doxorubicin was used in combination with 2-
methoxyestradiol compared to doxorubicin alone. In relation to the hypoxic control, the treatment of 
cells with CoCl2, doxorubicin, and the doxorubicin-2-methoxyestradiol combination under hypoxic 
conditions caused a significant degree of LC3-II expression (Fig 3.6.2). In contrast to the doxorubicin 
treatment of MCF-7 cells expressing functional HIF-1α, the transfection of these cells with HIF-1α 
siRNA demonstrated a significant decrease in LC3-II accumulation (1.160 ± 0.07788 AU vs. hypoxic 
dox, p<0.05) when 1 µM of doxorubicin was administered for 12 hours. 
Another established marker of autophagy is termed sequestosome (p62) which is digested by 
autophagolysosomes along with the selected cargo. In the normoxic setting, examination of p62 
levels revealed significant differences in three treatment groups compared to the control (Fig. 3.7.1). 
While MCF-7 displayed lower p62 expression in the doxorubicin-only group, it was induced when HIF-
1α was silenced alone and in combination with doxorubicin treatment. Combination of doxorubicin 
with either 2-methoxyestradiol (1.044 ± 0.08184 AU vs. normoxic dox, p<0.05) or HIF-1α siRNA 
transfection (1.434 ± 0.1543 AU vs. normoxic dox, p<0.05) exhibited elevated p62 protein levels as 
compared to when doxorubicin was used as a single agent. Compared to the levels present in the 
control group at ~0.1% O2, p62 was elevated in those groups transfected with HIF-1α siRNA alone 
and in conjugation with doxorubicin when MCF-7 cells were incubated under hypoxic conditions (Fig. 
3.7.2). 
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3.5 THE EFFECT OF THE TREATMENT REGIME ON HIF-1 STABILIZATION IN MCF-7 
CELLS DURING NORMOXIA AND HYPOXIA 
3.5.1 Western Blotting 
The potential of CoCl2 to serve as a positive control for this study was tested. Upon CoCl2 treatment, 
there was an increase in the expression of HIF-α compared to the baseline control levels present 
under normoxia (Fig. 3.8.1). The inhibition of HIF-1α by 2-methoxyestradiol and RNA transfection was 
shown to significantly decrease HIF-1α levels compared to the normoxic control. Furthermore, 
doxorubicin alone and its combination with 2-methoxyestrediol both decreased the levels of HIF-1α 
compared to baseline levels. When related to the expression of non-transfected MCF-7 cells that 
received doxorubicin, a significant expression of HIF-1α became apparent when HIF-1α siRNA 
transfection was integrated with the chemotherapeutic treatment (1.513 ± 0.1222 AU vs. normoxic 
dox, p<0.01). During hypoxia, HIF-1α expression levels were reduced upon CoCl2 treatment with 
respect to the hypoxic control (Fig. 3.8.2). 2-Methoxyestradiol was significantly effective at mitigating 
the expression of HIF-1α under these conditions, whereas no change in HIF-1α levels occurred with 
transfection. As with normoxia, HIF-1α siRNA-transfected MCF-7 cells that were subjected to 12 
hours of doxorubicin treatment upregulated HIF-1α levels by a statistically significant degree (1.621 ± 
0.007219 AU vs. hypoxic dox, p<0.01) compared to un-transfected doxorubicin-treated MCF-7 cells. 
 
3.6 THE EFFECT OF THE TREATMENT REGIME ON THE OXYGEN (AMPK) AND 
NUTRIENT (mTOR) SENSORS IN MCF-7 CELLS DURING NORMOXIA AND 
HYPOXIA 
3.6.1 Western Blotting 
The incubation of MCF-7 cells under the standard atmospheric oxygen concentration (21%) permitted 
the activated form of the mammalian target or Rapamycin, designated as p-mTOR, to become more 
pronounced in two treatment groups compared to the control: the HIF-1α silenced groups, alone and 
upon treatment with 1 µM doxorubicin for a duration of 12 hours (Fig. 3.9.1). The vehicle group which 
contained dimethyl sulfoxide displayed a reduced level of activated mTOR. When oxygen was flushed 
out of the chamber, the phosphorylation status of mTOR became significantly reduced compared to 
the control when MCF-7 cells were treated with CoCl2 or the combination of doxorubicin with 2-
methoxyestradiol (Fig. 3.9.2). Phospho-mTOR expression within the latter group was shown to be 
significantly lower (0.3914 ± 0.01285 AU vs. hypoxic dox, p<0.05) compared to those within the group 
treated with doxorubicin alone. 
With respect to the AMPK oxygen sensor, besides the groups treated with doxorubicin alone, which 
led to an increase in AMPK activation (1.307 ± 0.1053 AU vs. normoxic control, p<0.01), and 2-
methoxyestradiol alone, where p-AMPK expression was attenuated (0.4567 ± 0.07481 AU vs. 
normoxic control, p<0.01), none of the other groups displayed any statistically significant difference 
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with respect to the control when exposed under normal oxygen tension (Fig. 3.10.1). The CoCl2-
treated group was able to significantly decrease p-AMPK (0.9356 ± 0.01247 AU vs. hypoxic control, 
p<0.01) in comparison with control when conditions were rendered hypoxic (Fig. 3.10.2). 
 
3.7 THE EFFECT OF THE TREATMENT REGIME ON THE MITOCHONDRIAL 
INTEGRITY OF MCF-7 CELLS DURING NORMOXIA AND HYPOXIA 
3.7.1 Live Cell Imaging/Fluorescent Microscopy 
With the aid of the mitochondrion-specific dye, MitoTracker® Red CMXRos, imaging by fluorescence 
microscopy allowed for the qualitative characterization of mitochondrial integrity, in terms of structure 
and distribution. Exposure of tumorigenic MCF-7 cells to the low oxygen tension (~0.1%) displayed 
alterations in the structure of their mitochondria. The tubular-network of elongated mitochondria which 
are usually present under normoxic conditions transformed into compact disc-like forms, yet remained 
distributed throughout the cytoplasm (Fig. 3.11.1A). This morphological change was reproduced 
when cells were treated with CoCl2 under both normoxia and hypoxia (Fig. 3.11.1B). 
Under normoxia and hypoxia, the treatment with doxorubicin caused the structure of the mitochondria 
to be completely disrupted and assume a peri-nuclear distribution within the cell, regardless of 
whether it was applied alone (Fig. 3.11.1C), or in combination with 2-methoxyestradiol (Fig 3.11.2E) 
or HIF-1α siRNA transfection (Fig. 3.11.3G). Furthermore, the nuclei which were counter-stained with 
Hoechst 33342 displayed condensation of chromatin. The focal plane of the cells shifted suggesting 
detachment from the growth surface. 
2-methoxyestradiol alone also seemed to give rise to detached cells presenting nuclear chromatin 
condensation, or pyknosis (Fig. 3.11.2D). 
 
3.7  THE EFFECT OF THE TREATMENT REGIME ON THE BIOREDUCTIVE CAPACITY 
OF MCF-7 CELLS DURING NORMOXIA AND HYPOXIA 
3.7.1 The Bioreductive MTT Assay 
The formation of formazan crystals by the reduction of tetrazolium salt became significantly lower 
when MCF-7 cells were exposed to doxorubicin, 2-methoxyestradiol, and the combination of these 
two drugs (Fig. 3.12). Furthermore, the silencing of HIF-1α by transfection produced a similar decline 
when treated with doxorubicin. These effects were noticeable under both normoxia and hypoxic 
conditions. While there was a prominent difference between the normoxic and hypoxic doxorubicin-
treated cells (42.97 ± 3.095%, p<0.01), no other oxygen-dependent differential effects were observed 
in any of the other treatment groups. 
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IN VIVO 
3.8 THE EFFECT OF THE TREATMENT REGIME ON THE RATE OF TUMOUR GROWTH 
The size of the tumours present within all the treatment groups increased over the 42 day period 
(Figure 3.13). However, variance in the size between tumours within groups was large and no 
significance difference in the rate of tumour growth was evident between groups. Despite this, we 
were able to demonstrate changes within groups on a molecular level from tumour tissue lysates with 
the aid of the western blotting technique. 
 
3.9 THE EFFECT OF THE TREATMENT REGIME ON APOPTOSIS WITHIN TUMOUR 
TISSUE 
3.9.1  Western Blotting 
Relative to the group treated with doxorubicin, a significantly larger amount of PARP became cleaved 
when mice were treated with both doxorubicin and 2-methoxyestradiol (1.217 ± 0.1854 AU vs. dox, 
p<0.05) (Fig. 3.14). No significant changes in cleaved caspase 3 became evident. 
 
3.10 THE EFFECT OF THE TREATMENT REGIME ON AUTOPHAGY WITHIN TUMOUR 
TISSUE 
3.10.1  Western Blotting 
The expression of LC3-II became less detectable in tumour tissue when simultaneously treated with 
doxorubicin and 2-methoxyestradiol (0.6163 ± 0.1251 AU vs. dox, p<0.05) compared to doxorubicin 
treatment alone (Fig. 3.15). No significant changes in p62 became evident. 
 
3.11 THE EFFECT OF THE TREATMENT REGIME ON HIF-1α STABILIZATION WITHIN 
TUMOUR TISSUE 
3.11.1  Western Blotting 
HIF-1α within tumour tissue excised from the mice that were simultaneously treated with both 
doxorubicin and 2-methoxyestradiol produced a significantly diminished amount of expression 
compared to the amounts existing in the doxorubicin treated group (0.6514 ± 0.1168 AU vs. dox, p< 
0.05) (Fig. 3.16). 
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3.12  THE EFFECT OF THE TREATMENT REGIME ON THE NUTRIENT (mTOR) and 
OXYGEN (AMPK) SENSORS WITHIN TUMOUR TISSUE 
3.12.1 Western Blotting 
Compared to the levels present in the doxorubicin group, significantly lower p-mTOR (0.1887 ± 
0.02781 AU vs. dox, p<0.01) and p-AMPK (1.045 ± 0.1018 AU vs. dox, p<0.05) levels were evident 
when this drug was used in conjunction with 2-methoxyestradiol (Fig. 3.17). 
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Figure 3.1.1 The inhibitory effect on MCF-7 cells exposed to varying concentrations 
of doxorubicin and 2-methoxyestradiol under normoxic and hypoxic conditions for 
12 hours. The MTT assay was employed to measure bioreductive capacity which 
indirectly indicates cellular viability. The IC
50
 values for (A) doxorubicin and (B) 2-
methoxyestradiol were 1 µM and 10 µM, respectively. Values expressed as a percentage 
of the control (100%). Columns, mean survival fractions; Bars, ± SEM. The results are a 
representative of four independent experiments. * p<0.05 vs. normoxic control; ** p<0.01 
vs. normoxic control; ***, p<0.0001 vs. normoxic control. 
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Figure 3.1.2 The inhibitory effect on MCF-7 cells exposed to varying concentrations 
of cobalt chloride under normoxic and hypoxic conditions for 12 hours. The MTT 
assay was employed to measure bioreductive capacity which indirectly indicates cellular 
viability. Values expressed as a percentage of the normoxic control (100%). Columns, 
mean survival fractions; Bars, ± SEM. The results are a representative of four independent 
experiments. * p<0.05 vs. normoxic control; ** p<0.01 vs. normoxic control; *** p<0.0001 
vs. normoxic control. 
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Figure 3.2.1 The inhibitory effect on MCF-7 cells exposed to doxorubicin (1 µM) and 
2-methoxyestradiol (10 µM) under normoxic and hypoxic conditions at different time 
points. (A) 6, and (B) 12 hours. The MTT assay was employed to measure bioreductive 
capacity which indirectly indicates cellular viability. Values expressed as a percentage of 
the control (100%). Columns, mean survival fractions; Bars, ± SEM. The results are a 
representative of six independent experiments. ** p<0.01 vs. normoxic  2-ME (6 hours)/ 
normoxic doxorubicin (12 hours); *** p<0.001 vs. normoxic control. 
** 
*** 
** 
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Figure 3.2.2 The inhibitory effect on MCF-7 cells exposed to doxorubicin (1 µM) and 
2-methoxyestradiol (10 µM) under normoxic and hypoxic conditions at different time 
points. (C) 24, and (D) 48 hours. The MTT assay was employed to measure bioreductive 
capacity which indirectly indicates cellular viability. Values expressed as a percentage of 
the control (100%). Columns, mean survival fractions; Bars, ± SEM. The results are a 
representative of six independent experiments. *** p<0.001 vs. normoxic control. 
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Figure 3.2.3 The inhibitory effect on MCF-7 cells exposed to doxorubicin (1 µM) and 
2-methoxyestradiol (10 µM) under normoxic and hypoxic conditions at different time 
points. (E) 72 hours. The MTT assay was employed to measure bioreductive capacity 
which indirectly indicates cellular viability. Values expressed as a percentage of the control 
(100%). Columns, mean survival fractions; Bars, ± SEM. The results are a representative 
of six independent experiments. *** p<0.001 vs. normoxic control. 
*** 
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Figure 3.3 The activity of caspase 3/7 in MCF-7 cells in response to the 
experimental regime. Caspase 3/7 activity is directly proportional to the 
luminescent intensity produced. Values are expressed as a percentage of the 
normoxic control (100%). Columns, relative luminescence units (RLU); Bars, ± SEM. 
The results are a representative of six independent experiments. * p<0.05 vs. 
normoxic control; *** p<0.001 vs. normoxic control; # p<0.05 vs. normoxic 
doxorubicin. 
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Figure 3.4.1 The evaluation of the in vitro cleaved caspase 3 expression 
profile in response to the experimental regime under normoxic conditions. 
The (A) densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. * p<0.05 
vs. control; ** p<0.01 vs. control; *** p<0.001 vs. control; # p<0.05 vs. doxorubicin. 
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Figure 3.4.2 The evaluation of the in vitro cleaved caspase 3 expression 
profile in response to the experimental regime under hypoxic conditions. 
The (A) densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. * p<0.05 
vs. control; ** p<0.01 vs. control; *** p<0.001 vs. control; # p<0.05 vs. doxorubicin. 
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Figure 3.5.1 The evaluation of the in vitro cleaved PARP expression profile in 
response to the experimental regime under normoxic conditions. The (A) 
densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. ** 
p<0.01 vs. control; *** p<0.001 vs. control; # p<0.05 vs. doxorubicin. 
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Figure 3.5.2 The evaluation of the in vitro cleaved PARP expression profile in 
response to the experimental regime under hypoxic conditions. The (A) 
densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. * p<0.05 
vs. control; ** p<0.01 vs. control; *** p<0.001 vs. control; ### p<0.001 vs. 
doxorubicin. 
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* 
* 
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Figure 3.6.1 The evaluation of the in vitro LC3-II expression profile in 
response to the experimental regime under normoxic conditions. The (A) 
densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. * p<0.05 
vs. control; ** p<0.01 vs. control; *** p<0.001 vs. control; # p<0.05 vs. doxorubicin. 
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Figure 3.6.2 The evaluation of the in vitro cleaved LC3-II expression profile in 
response to the experimental regime under hypoxic conditions. The (A) 
densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. * p<0.05 
vs. control; ** p<0.01 vs. control; *** p<0.001 vs. control; # p<0.05 vs. doxorubicin. 
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Figure 3.7.1 The evaluation of the in vitro p62 expression profile in response 
to the experimental regime under normoxic conditions. The (A) densitometric 
analysis and (B) immunoblots are represented. A ratio was calculated relative to 
the control (set to 1). Columns, arbitrary units (AU); Bars, ± SEM. The results are a 
representative of three independent experiments. * p<0.05 vs. control; ** p<0.01 
vs. control; *** p<0.001 vs. control; # p<0.05 vs. doxorubicin. 
** 
*** 
* 
# 
# 
 
 
NORMOXIA
Co
nt
ro
l 2
Co
Cl Do
x
2-
M
E
Do
x +
 2
-M
E
 si
RN
A

HI
F-
1
 si
RN
A

Do
x +
 H
IF
-1
Ve
hi
cle
1.0
1.5
2.0
2.5
3.0
TREATMENTS
P6
2
[A
U
]
Stellenbosch University  http://scholar.sun.ac.za
56 
 
  
p62 
β-actin 
[62 kDa] 
[42 kDa] 
Figure 3.7.2 The evaluation of the in vitro p62 expression profile in response 
to the experimental regime under hypoxic conditions. The (A) densitometric 
analysis and (B) immunoblots are represented. A ratio was calculated relative to 
the control (set to 1). Columns, arbitrary units (AU); Bars, ± SEM. The results are a 
representative of three independent experiments. ** p<0.01 vs. control; *** 
p<0.001 vs. control. 
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Figure 3.8.1 The evaluation of the in vitro HIF-1α expression profile in 
response to the experimental regime under normoxic conditions. The (A) 
densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. * p<0.05 
vs. control; ** p<0.01 vs. control; *** p<0.001 vs. control; ## p<0.01 vs. 
doxorubicin. 
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Figure 3.8.2 The evaluation of the in vitro HIF-1α expression profile in 
response to the experimental regime under hypoxic conditions. The (A) 
densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. ** 
p<0.01 vs. control; *** p<0.001 vs. control; ## p<0.01 vs. doxorubicin. 
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Figure 3.9.1 The evaluation of the in vitro p-mTOR expression profile in 
response to the experimental regime under normoxic conditions. The (A) 
densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. * p<0.05 
vs. control; ** p<0.01 vs. control; *** p<0.001 vs. control. 
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Figure 3.9.2 The evaluation of the in vitro p-mTOR expression profile in 
response to the experimental regime under hypoxic conditions. The (A) 
densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. * p<0.05 
vs. control; *** p<0.001 vs. control; # p<0.05 vs. doxorubicin. 
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Figure 3.10.1 The evaluation of the in vitro p-AMPK expression profile in 
response to the experimental regime under normoxia conditions. The (A) 
densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. * p< 
0.05 vs. control; ** p<0.01 vs. control. 
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Figure 3.10.2 The evaluation of the in vitro p-AMPK expression profile in 
response to the experimental regime under hypoxic conditions. The (A) 
densitometric analysis and (B) immunoblots are represented. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± 
SEM. The results are a representative of three independent experiments. ** 
p<0.01 vs. control. 
** 
HYPOXIA
Co
nt
ro
l 2
Co
Cl Do
x
2-
M
E
Do
x +
 2
-M
E
 si
RN
A

HI
F-
1
 si
RN
A

Do
x +
 H
IF
-1
Ve
hi
cle
0.5
1.0
1.5
2.0
TREATMENTS
P
-A
M
P
K
[A
U
]
Stellenbosch University  http://scholar.sun.ac.za
63 
 
  
NORMOXIA HYPOXIA 
Figure 3.11.1 Fluorescent imaging for the characterization of mitochondrial 
integrity of MCF-7 cells in response to the experimental regime. Following the 
treatment regime, mitochondria were labelled with MitoTracker® Red CMXRos (1mM; 
displayed in red), while nuclei were counter-stained with Hoechst 33342 (1:200; 
dispayed in blue). Stained organelles within the MCF-7 cells were viewed with the 
Olympus IX81 inverted fluorescent microscope using a 100X objective and 
representative images captured with an F-view-II cooled CCD camera. The treatment 
groups were as follows: (A) control, (B) CoCl
2
 (100 µM) (C) doxorubicin (1 µM). 
Condensed and fragmented nuclei are pointed by yellow arrows. 
  
  
  
20 µM 
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NORMOXIA HYPOXIA 
Figure 3.11.2 Fluorescent imaging for the characterization of mitochondrial 
integrity of MCF-7 cells in response to the experimental regime. Continued. (D) 2-
methoxyestradiol (10 µM), (E) doxorubicin and 2-methoxyestradiol, (F) HIF-1α siRNA 
(400 nM). Condensed and fragmented nuclei are pointed by yellow arrows. 
  
  
  
20 µM 
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NORMOXIA HYPOXIA 
Figure 3.11.3 Fluorescent imaging for the characterization of mitochondrial 
integrity of MCF-7 cells in response to the experimental regime. Continued. (G) 
doxorubicin and HIF-1α siRNA, and (H) vehicle. Condensed and fragmented nuclei are 
pointed by yellow arrows. 
  
  
20 µM 
Stellenbosch University  http://scholar.sun.ac.za
66 
 
  
Figure 3.12 The bioreductive capacity of MCF-7 cells in response to the 
experimental regime. The MTT assay was employed to measure the capacity of 
MCF-7 cells to reduce the MTT salt to formazan crystals. Values expressed as a 
percentage of the control (100%). Columns, mean survival fractions; Bars, ± SEM. 
The results are a representative of four independent experiments. * p<0.05 vs. 
normoxic control; ** p< 0.01 vs. normoxic control; *** p<0.001 vs. normoxic control; 
# p<0.05 vs. normoxic doxorubicin. 
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Figure 3.13 The effect of the treatment regime on the rate of tumour growth for a 
duration of 14 days. Day of E0771 inoculation was designated as 0. When tumours 
became palpable on day 28, mice were randomly sorted according to tumour size and 
grouped into: untreated control (          ), 5 mg/kg
-1
 of doxorubicin (          ), 45 mg/kg
-1
 of 
2-methoxyestradiol (      ), and doxorubicin & 2-methoxyestradiol combined (      ). 
Treatment commenced from day 28 and was administered every four days, with each 
mouse receiving a total of four treatments. 
 
 
 
 
 
 
   
0
500
1000
1500
2000
2500
3000
3500
0 28 32 36 40
Control
Dox
2-ME
Dox + 2-ME
TU
M
O
U
R
 V
O
LU
M
E 
(m
m
3 )
 
DAYS AFTER E0771 INOCULATION 
Stellenbosch University  http://scholar.sun.ac.za
68 
 
  
CLEAVED CASPASE 3
Co
nt
ro
l
Do
x
2-
M
E
Do
x +
 2
-M
E
0.0
0.5
1.0
1.5
TREATMENTS
C
LE
A
V
ED
 C
A
SP
A
SE
 3
[A
U
]
CLEAVED PARP
Co
nt
ro
l
Do
x
2-
M
E
Do
x +
 2
-M
E
0.0
0.5
1.0
1.5
TREATMENTS
C
LE
A
V
ED
 P
A
R
P
[A
U
]
Figure 3.14 The evaluation of the in vivo cleaved caspase 3 and cleaved PARP 
expression profiles present within tumours in response to the experimental 
regime. The densitometric analysis and immunoblots are represented. (A) Cleaved 
caspase 3; (B) Cleaved PARP. A ratio was calculated relative to the control (set to 1). 
Columns, arbitrary units (AU); Bars, ± SEM. The results are a representative of three 
independent experiments. * p<0.05 vs. control;  ** p<0.01 vs. control; # p<0.05 vs. 
doxorubicin. 
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Figure 3.15 The evaluation of the in vivo LC3-II and p62 expression profiles present 
within tumours in response to the experimental regime. The densitometric analysis 
and immunoblots are represented. (A) LC3-II; (B) p62. A ratio was calculated relative to 
the control (set to 1). Columns, arbitrary units (AU); Bars, ± SEM. The results are a 
representative of three independent experiments. *** p<0.001 vs. control; # p<0.05 vs. 
doxorubicin. 
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Figure 3.16 The evaluation of the in vivo HIF-1α expression profile present within 
tumours in response to the experimental regime. The densitometric analysis and 
immunoblots are represented. A ratio was calculated relative to the control (set to 1). 
Columns, arbitrary units (AU); Bars, ± SEM. The results are a representative of three 
independent experiments. ** p<0.01 vs. control; # p< 0.05 vs. doxorubicin 
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Figure 3.17 The evaluation of the in vivo p-mTOR and p-AMPK expression profiles 
present within tumours in response to the experimental regime. The densitometric 
analysis and immunoblots are represented. (A) p-mTOR; (B) p-AMPK. A ratio was 
calculated relative to the control (set to 1). Columns, arbitrary units (AU); Bars, ± SEM. 
The results are a representative of three independent experiments. **, P < 0.01 vs. 
control; *** p<0.001 vs. control; # p<0.05 vs. doxorubicin; ## p<0.01 vs. doxorubicin. 
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Table 3.2 A summary of significant changes in markers of hypoxia, apoptosis, autophagy, 
and metabolism upon induction and disruption of HIF-1α (in vitro). Hypoxia, HIF-α (hypoxia-
inducible factor α); apoptosis, CC3 (cleaved caspase 3) and CP (cleaved PARP); autophagy, LC3-
II (lipidated autophagosome-associated LC3) and p62 (sequestosome); metabolism, p-mTOR 
(phosphorylated-mammalian target of Rapamycin) and p-AMPK (phosphorylated-AMP-activated 
protein kinase); ↑, significant up-regulation of pathway; ↓, significant down-regulation of pathway 
Table 3.1 A summary of significant changes in markers of hypoxia, apoptosis, autophagy, 
and metabolism upon doxorubicin treatment (in vitro). Hypoxia, HIF-α (hypoxia-inducible factor 
α); apoptosis, CC3 (cleaved caspase 3) and CP (cleaved PARP); autophagy, LC3-II (lipidated 
autophagosome-associated LC3) and p62 (sequestosome); metabolism, p-mTOR 
(phosphorylated-mammalian target of Rapamycin) and p-AMPK (phosphorylated-AMP-activated 
protein kinase); ↑, significant up-regulation of pathway; ↓, significant down-regulation of pathway 
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  Table 3.3 A summary of significant changes in markers of hypoxia, apoptosis, autophagy, 
and metabolism upon adjuvant treatment (in vitro). Hypoxia, HIF-α (hypoxia-inducible factor α); 
apoptosis, CC3 (cleaved caspase 3) and CP (cleaved PARP); autophagy, LC3-II (lipidated 
autophagosome-associated LC3) and p62 (sequestosome); metabolism, p-mTOR 
(phosphorylated-mammalian target of Rapamycin) and p-AMPK (phosphorylated-AMP-activated 
protein kinase); ↑, significant up-regulation of pathway; ↓, significant down-regulation of pathway 
Table 3.4 A summary of significant changes in markers of hypoxia, apoptosis, autophagy, 
and metabolism (in vivo). Hypoxia, HIF-α (hypoxia-inducible factor α); apoptosis, CC3 (cleaved 
caspase 3) and CP (cleaved PARP); autophagy, LC3-II (lipidated autophagosome-associated LC3) 
and p62 (sequestosome); metabolism, p-mTOR (phosphorylated-mammalian target of Rapamycin) 
and p-AMPK (phosphorylated-AMP-activated protein kinase); ↑, significant up-regulation of 
pathway; ↓, significant down-regulation of pathway 
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CHAPTER 4 – DISCUSSION 
4.1 INTRODUCTION 
The deprivation of a sufficient oxygen supply is a hallmark of solid tumours that contributes to the 
pathophysiology of solid breast tumours (Lee, 2009). Within this oxygen-deprived environment, 
neoplastic cells respond by activating a variety of genes that promote their survival. These genes 
typically harbour a hypoxic-responsive element (HRE) and are regulated by the HIF-1 transcription 
factor. Upon binding to this core promoter, the activated HIF-1 heterodimeric complex mediates 
adaptive cellular responses which include anaerobic glycolysis, angiogenesis, apoptotic resistance 
and autophagy, all of which contribute to the malignancy of the cancer (Roudier & Perrin, 2009; Liu et 
al., 2010). The over-expression of HIF-1 in malignant breast tissue has served as a negative 
prognostic indicator as survival of patients is dismal (Zhong et al., 1999). As a result of an increased 
neoplastic viability induced by hypoxic conditions, the efficient treatment of solid tumours has become 
a challenging task. In addition to its prognostic value, the existence of HIF-1 has emerged as a 
relevant target for therapeutic intervention. By eradicating HIF-1, the hypoxia-related protective 
response which it confers upon tumour cells may potentially be eliminated and improve the efficacy of 
chemotherapeutic treatment. 
Therefore this study was designed to provide insight into the molecular events that are responsible for 
the resistance of neoplastic cells to chemotherapeutic treatment under low oxygen tension, and to 
assess whether manipulation of these events can benefit treatment by sensitizing the neoplastic cells. 
The in vitro experimental model employed doxorubicin, an anthracycline antibiotic that is extensively 
utilized in clinical settings to treat patients diagnosed with breast cancer. This study was performed on 
the MCF-7 cell line, a breast adenocarcinoma which is an estrogen-receptor positive cell model. Prior 
to execution of the in vitro experimental model, a suitable concentration and time regiment of the 
chemotherapeutic drug was selected based on the MTT viability data. Specifically, the capacity of 
doxorubicin to elicit a differential viability effect on tumorigenic MCF-7 cells after normoxic and 
hypoxic exposure, and in favour of the latter, was selected as an end point. The concentrations of the 
HIF-1α inducer (CoCl2) and inhibitors (2-methoxyestradiol; siRNA duplex) chosen for this study were 
based on the successful induction and inhibition of this protein in previously reported studies. Using 
molecular (Caspase-Glo® 3/7 Assay; Western Blotting; MTT) and visual techniques (Live Cell 
Imaging/Fluorescent Microscopy), the study proceeded to investigate the putative link between cell 
death, oxygen availability and metabolic sensors, bioreductive capacity, mitochondrial morphology 
and hypoxia. The following aims were formulated: 
1. To determine whether hypoxic conditions confer a survival advantage to the MCF-7 tumorigenic cells 
in response to doxorubicin treatment. 
2. To characterize the molecular events responsible for the selective resistance under hypoxia. 
3. To link these molecular events to the expression levels of the HIF-1 master regulator. 
4. To assess whether the abrogation of the hypoxic response by HIF-1α inhibition can sensitize the 
tumorigenic cell line to doxorubicin treatment, therefore producing a synergistic effect. 
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The impact of treatments on the viability of cells was monitored at all times. The experiment was 
repeated in an in vivo model to assess the level of reproducibility of the in vitro experiment model and 
efficacy of treatments in animal tissue. 
 
The western blotting technique monitored specific biomarkers based on their electrophoretic mobility. 
With respect to apoptosis, two proteins specific to the apoptotic cellular pathway were chosen: (1) the 
cysteine protease, caspase 3, which becomes activated upon cleavage and is the main instigator of 
apoptosis execution, and (2) PARP, a substrate which is subsequently proteolysed by caspase 3 
activity. 
 
Autophagy is generally monitored by western blotting to assess the conversion of the microtubule-
associated light chain 3 (LC3) from LC3-I to LC3-II. During the initiation stage of the autophagic 
process, the formation of autophagosomes requires the lipidation of the cytosolic form LC3-I, followed 
by the incorporation of the product LC3-II into the outer and inner membranes of the early autophagic 
vesicles. It is known that the maturation of autophagosomes entails their fusion with acidic lysosomes 
to degrade the encapsulated cargo. Since LC3-II molecules are present on both outer and the inner 
membranes of the autophagosomes, the degradation of the cargo along with the inner membrane will 
also digest the LC3-II.  
 
The accumulation of LC3-II generally indicates one of two situations and may therefore potentially 
suffer misinterpretation (Mizushima & T Yoshimori, 2007). The detection of LC3-II by western blotting 
may indicate the beginning stages of the autophagic process. Less LC3-II is detected in the later 
stages of autophagy upon fusion with, and digestion by, the lysosomes. Both signify that autophagy is 
occurring. However, many inhibitors of the autophagic process block the fusion of autophagosomes 
with lysosomes. This prevents the turn-over of LC3-II, allowing it to be visualised by immuno-
detection. Therefore, in order to elucidate whether LC3-II detection represents early autophagosome 
genesis of an uninterrupted autophagic flow or the amassing of these vesicles due to a dysfunction in 
their degradation requiring the coupling to p62, an alternative marker of autophagy, the levels of p62 
were evaluated in addition to the LC3 conversion.  
The metabolic state of a cell determines its ability to grow and proliferate. The MTT colorimetric assay 
(Mosmann, 1983) was developed to measure the viability of a cellular population. The reduction of the 
yellow tetrazolium dye to a purple formazan salt, which when solubilized can be quantified 
spectrophotometrically, is mainly attributed to the mitochondrial dehydrogenase enzymes. This 
technique has been used to evaluate the cytotoxicity of drugs (Di et al., 2009; Vengellur & LaPres, 
2004; Van Zijl & Lottering, 2008). 
However, a variety of cancer cell lines have been identified to display the ‘Warburg phenomenon’, a 
pattern of metabolism where cells preferentially utilize glycolysis in spite of a sufficient supply of 
oxygen (Ferreira, 2010). Furthermore, hypoxia has been shown to stimulate the metabolic switch from 
oxidative phosphorylation to anaerobic glycolysis (Kroemer & Pouyssegur, 2008). These alterations 
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have been shown to be beneficial to the growth of the tumour. In these scenarios, the cells remain 
viable regardless of the reduced mitochondrial activity. Therefore, the results from the MTT assay do 
not necessarily indicate viability, but rather the bioreductive potential, or mitochondrial function, of a 
cellular population at that time. A more direct method of measuring the viability of the cellular 
population would be through the vital dye Trypan Blue, where retention of the dye is indicative of a 
damaged plasma membrane. Alternatively, the staining of DNA by intercalation with the red-
fluorescent vital dye Propidium Iodide may also be used to differentiate between living and dead cells 
and is typically analysed via flow cytometry. 
 
4.2 IN VITRO 
4.2.1 Evaluation of the inducers and inhibitors of HIF-1α expression 
This section aimed to address the potential of CoCl2 to stabilize HIF-1α, and 2-methoxyestadiol and 
siRNA transfection to inhibit its expression. 
Results revealed that the exposure of the MCF-7 cell line to 100 µM of CoCl2 for a duration of 12 
hours adequately stabilized HIF-1α under normoxic conditions compared to the baseline levels 
present under normoxia (Fig. 3.8.1). Stabilization of HIF-1α occurred without significantly affecting the 
viability of cells (Fig. 3.1.2). CoCl2 was therefore employed as a positive control for the in vitro study. 
To simulate the reduced oxygen environment that is characteristically witnessed within the 
microenvironment of solid tumours, MCF-7 cells were experimentally rendered hypoxic by subjecting 
them to a hypoxic environment of ~0.1% oxygen (PO2 = 0.8 mm Hg). CoCl2 treatment under hypoxic 
conditions caused a slightly reduced expression of HIF-1α compared to the baseline levels 
established within the hypoxic control group (Fig. 3.8.2). To establish a HIF-1α-knockdown phenotype 
in the in vitro experiment, HIF-1α siRNA transfection was employed at a concentration of 400 nM/1 L. 
This concentration adequately abolished the expression of HIF-1α which is usually present at 
normoxic baseline levels (Fig. 3.8.1). In contrast, the levels of HIF-1α under hypoxia seemed to be 
unaffected (Fig. 3.8.2). This study employed 2-methoxyestradiol at 10 µM for a duration of 12 hours. 
This concentration was capable of significantly attenuating the expression of HIF-1α by 31% and 59% 
in normoxia (Fig. 3.8.1) and hypoxia (Fig. 3.8.2), respectively. 2-Methoxyestradiol treatment caused a 
significant decrease in viability of the MCF-7 cells (Fig. 3.12), although this cytotoxicity was mild 
compared to that inflicted by doxorubicin. 
Cobalt chloride interferes with the activity of prolyl hydroxylases and has previously been used to 
mimic the conditions of hypoxia and stabilize HIF-1α both in vitro (Chan & Sutphin, 2005; Nardinocchi 
et al., 2009) and in vivo (Razeghi et al., 2001). The non-cytotoxic stabilization of HIF-1α under 
normoxic conditions after the addition of 100 µM CoCl2 is supported by a study carried out on the 
human glioblastoma U251 cell line, where concentrations of CoCl2 between 50 µM and 200 µM 
enabled the expression of a 118 kDa-sized HIF-1α protein without adversely affecting cellular viability 
(Al-Okail, 2010). The higher levels of HIF-1α after CoCl2 treatment indicate that the functional prolyl 
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hydroxylases present within the normoxia control group (21% oxygen; PO2 = 160 mm Hg) subject the 
HIF-1α to ubiquitination and proteasomal degradation. In spite of this negative oxygen-dependent, 
post-translational regulation, there is a constitutive expression of HIF-1α under normoxia at low levels. 
This most likely demonstrates an oxygen-independent stabilization of HIF-1α that could result from 
the deregulation of gain-of-function oncogenes or loss-of-function tumour suppressor genes. The 
human epidermal growth factor receptor 2 (HER2), for example, is a proto-oncogene over-expressed 
in ~15% of advanced breast tumours (Dean-Colomb & Esteva, 2008). It is a transmembrane receptor 
possessing tyrosine kinase activity which is capable of stimulating the phosphatidylinositol 3-kinase 
(PI3K-Akt) and mitogen-activated protein kinase (MAPK) signal transducing cascades, both of which 
have been shown to upregulate HIF-1α (Dean-Colomb & Esteva, 2008; Laughner & Taghavi, 2001). 
Moreover, mutations in tumour suppressors that lead to stabilization of HIF-1α include the von Hippel-
Lindau (VHL) protein, such as that in renal cell carcinoma (Razorenova et al., 2011), and 
phosphatase and tensing homolog (PTEN) protein, as seen in glioblastoma (Zundel & Schindler, 
2000). 
Oxygen has been shown to be one of the rate-limiting factors for the function of prolyl hydroxylases, in 
addition to the α-ketoglutarate co-substrate and Fe
2+
 co-factor (Hansen et al., 2011; Bruick & 
McKnight, 2001). The oxygen concentration at which HIF-1α becomes expressed is dependent on cell 
type (Bracken et al., 2006). Experiments carried out by Robey et al. (2005) on the MCF-7 cell line 
showed elevated levels of HIF-1α  increased the expression of its associated transcriptional targets, 
including GLUT-3 and VEGF, when exposed to oxygen concentrations below ≤2% compared to 
normoxia (Robey et al., 2005). Therefore it is presumed that the 12 hour exposure at ~0.1% O2 
utilized in this study is sufficient to prevent proline hydroxylation, and therefore stabilize HIF-1α at 
higher levels under hypoxia (Fig. 3.8.2). 
The weaker HIF-1α expression level observed under hypoxia after CoCl2 treatment was also noticed 
in a 2010 study by Zhang et al. where HeLa cells were treated with 200 µM of CoCl2 which served as 
a positive control (Zhang et al., 2010). It could be speculated that the capacity of CoCl2 to stabilize 
HIF-1α is limited and overrides any further expression. 
The depletion of HIF-1α during normoxia after siRNA transfection is supported by Doublier et al. 
(2012) who demonstrated that at 400 nM/1 L of the siRNA duplex, the expression of the multi-drug 
resistance protein termed P-glycoprotein, which has previously been shown to be upregulated by HIF-
1α under hypoxic conditions (Comerford et al., 2002), was decreased in MCF-7 cells suggesting an 
effective concentration (Doublier et al., 2012).  
Concerning the unaffected HIF-1α protein levels witnessed after siRNA intervention during hypoxia, a 
possible reason could be that the siRNA duplex deactivated the irrelevant isoform of the alpha subunit 
that was upregulated under hypoxia. Various researchers have discovered the presence of both 
isoforms of the alpha subunit, namely HIF-1α and HIF-2α, in MCF-7 cells (Mole et al., 2009; Larsen et 
al., 2008). It has been shown that stability of these isoforms may be regulated differentially (Keith et 
al., 2011). Uchida et al. demonstrated that the duration of exposure of the human lung 
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adenocarcinoma cell line, A549, to hypoxia caused a distinct expression in the HIF-α subunits (Uchida 
et al., 2004). Exposing A549 cells to hypoxia (0.5%) allowed both isoforms to be detected at a 4 hour 
time point, while at 12 hours the HIF-1α expression was diminished with HIF-2α levels remaining 
elevated.  
Since this study employed a siRNA duplex specifically targeting HIF-1α, and a primary antibody of 
polyclonal origin, the detection of the protein in the “HIF-1α siRNA” group could possibly represent 
unaffected HIF-2α. 
Results obtained from a study conducted by Mabjeesh et al. (2003) mirror those acquired in this study 
with respect to the treatment of MCF-7 cells with 2-methoxyestradiol (Mabjeesh et al., 2003). They 
revealed that the exposure of the human breast cancer cell line, MDA-MB-231, and the human 
prostate cancer cell line, PC-3, to 2-methoxyestradiol under both normoxic and hypoxic conditions 
had an inhibitory effect on HIF-1α expression that was dependent on the concentration of the drug. 
Similarly, this inhibitory effect was observed with HIF-2α. In the study, 10 µM of 2-methoxyestradiol 
was sufficient to eradicate the expression of HIF-1α and HIF-2α, albeit for a duration of 16 hours, 
supporting the findings in this study.  
Of the two strategies employed, 2-methoxyestradiol was more effective in reducing normoxic and 
hypoxic HIF-1α protein levels in MCF-7 cells compared to siRNA transfection. Therefore the 
experiment proceeded by assessing the modulation effect of 2-methoxyestradiol alone. 
 
4.2.2 The role of HIF-1α expression on apoptosis and autophagy  
This section explored whether a relationship exists between apoptotic or autophagic induction, and 
the stabilized subunit of the hypoxic responsive transcription factor, HIF-1α. 
While the reduced expression of HIF-1α by 2-methoxyestradiol and siRNA transfection did not affect 
apoptosis in the presence of 21% oxygen (Fig. 3.4.1; Fig. 3.5.1), the activation of caspase 3 followed 
by the cleavage of PARP was significantly induced in the 2-methoxyestradiol group when oxygen 
dropped to 0.1% (Fig. 3.4.2; Fig. 3.5.2). The stabilized HIF-1α after CoCl2 treatment at the low 
oxygen tension did not exhibit signs of apoptosis. These results indicate that under hypoxic 
conditions, an inverse relationship exists between HIF-1α and apoptotic induction. Therefore, the 
stabilization of HIF-1α serves as a negative regulator of apoptosis and could potentially contribute to 
the resistance against the doxorubicin-induced apoptosis. A link between HIF-1α and autophagy was 
suggested based on the results obtained under normoxic conditions where the knock-down of HIF-1α 
expression was effective (Fig. 3.8.1). Transfection with siRNA appeared to disrupt autophagy after 
the formation of autophagosomes, as marked by the higher levels of the autophagic-vesicle 
associated LC3-II (Fig. 3.6.1) accompanied by the concomitant aggregation of p62 (Fig. 3.7.1). In 
contrast, the adequate stabilization of HIF-1α under normoxia by CoCl2 caused an increase in 
autophagy (Fig. 3.6.1). This suggests that autophagy upregulation is dependent on the expression of 
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HIF-1α. The stabilization of HIF-1α by CoCl2 under hypoxia caused a significant increase in cellular 
viability, as evident from the concentration-response curve (Fig. 3.1.2), suggesting that the 
upregulation of autophagy in this group could be responsible for the protective effect. With regards to 
the dissimilar outcomes on the autophagic process by the HIF-1α inhibitors used in this study (Table 
3.1), it is likely that the direct inhibition of HIF-1α seen with siRNA transfection is not imitated by 2-
methoxyestradiol, which may have an alternative target and rather an indirect mode of deactivating 
HIF-1α. 
The ability of 2-methoxyestradiol to induce apoptosis in the MCF-7 cell line has been reported by 
various researchers (Stander et al., 2010; Van Zijl & Lottering, 2008). A study carried out in 2004 by 
Erler et al. on three colon carcinoma cell lines demonstrated that the post-transcriptional suppression 
of HIF-1α with small interfering RNA induced the expression of the pro-apoptotic protein, Bid, under 
hypoxic conditions (Erler et al., 2004). This further supports the relationship between HIF-1α and 
apoptosis that was recognized in this study. 
The suggested relationship between autophagy and HIF-1α is supported by Liu et al. (2010) whose 
research reported a reduced conversion of LC3-I to LC3-II when the cervical HeLa cancer cell line 
was transfected with a plasmid encoding HIF-1α siRNA (Liu et al., 2010). 
According to Mabjeesh et al. (2003), the inhibition of HIF-1α was a consequence of microtubule 
disruption within the human ovarian carcinoma cell line, 1A9 (Mabjeesh et al., 2003). This supports 
the different downstream effects observed when 2-methoxyestadiol and the siRNA duplex were 
utilized to ablate HIF-1α expression. Based on this deviation, it would be possible for the microtubule 
disruptor to cause off-target effects. 
 
4.2.3 Characterization of cellular death pathways and the oxygen sensor, AMPK, upon 
doxorubicin treatment 
This section aimed to assess the molecular changes that the anthracycline anti-tumour agent, 
doxorubicin, confers upon the cellular death pathways, apoptosis and autophagy, and the AMPK 
energy sensor. 
A prominent cleavage of PARP and caspase 3 was revealed after the treatment with doxorubicin. This 
effect is indicative of apoptosis and was seen under both normoxic and hypoxic conditions (Fig. 3.4.1; 
Fig. 3.4.2; Fig. 3.5.1; Fig. 3.5.2). The data obtained from western blotting were strengthened by the 
Caspase-Glo® 3/7 Assay, where the elevated luminescent signal produced by MCF-7 cancer cells in 
response to doxorubicin designated an elevated amount of activity of the two executioner caspases, 3 
and 7 (Fig. 3.3). Under normoxic conditions, the magnitude of autophagy increased as evident from a 
decrease in the levels of p62 (Fig 3.7.1) and a concomitant increase in LC3-II (Fig. 3.6.1), the latter 
possibly representing early autophagosomes. This increased autophagic response is most likely a 
HIF-1α-independent process, as the decline in HIF-1α (Fig. 3.8.1) was not followed by a decline in 
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autophagic activity, an event which was expected based on the link established above (section 4.2.2). 
As doxorubicin increased the activation of the energy sensor, AMPK, under normoxic conditions (Fig. 
3.10.1), this would rather suggest that the autophagic machinery upregulated in this normoxic setting 
to be an AMPK-dependent process. Although LC3-II was present at a greater intensity within 
doxorubicin-treated MCF-7 cells that were exposed to a hypoxic environment, the turnover of p62 
remained constant (Fig. 3.6.2; Fig. 3.7.2). This does not necessarily suggest that the flux of p62 
remained unchanged, but rather that the formation of p62 is balanced out by its removal, whether flux 
is increased or decreased. In this scenario, the increased LC3-II could represent either increased or 
decreased autophagy. Regardless, autophagy is still functional as p62 did not accumulate compared 
to the control. Although a baseline expression of P-AMPK was stimulated in the untreated hypoxic 
MCF-7 cells (Fig. 3.10.2), the addition of 1 µM doxorubicin for 12 hours did not significantly affect P-
AMPK expression. Despite the attenuation in the bioreductive capacity of MCF-7 cells, a significant 
differential effect between normoxic and hypoxic exposure was witnessed in the MTT assay when 
cells were exposed to doxorubicin for the duration of 12 hours (Fig. 3.12). This data it is indicative that 
hypoxic conditions conferred resistance to cytotoxic effects of doxorubicin. This prominent differential 
influence by hypoxia served as the basis for the time point selection of this study. In contrast to 
normoxia, the HIF-1α levels remain elevated (Fig. 3.8.2) and therefore the appearance of 
autophagosomes present at ~0.1% O2 may represent a HIF-1 dependent cytoprotective response, 
promoting the survival of cells in spite of the damaging effects of chemotherapy. 
Along with doxorubicin’s reputation of being a topoisomerase-II poison, it also leads to DNA damage 
via the production of reactive oxygen species, and/or the formation of doxorubicin-DNA adducts 
(Minotti et al., 2004). A general response to the DNA damage is via the type I cellular death pathway, 
apoptosis. The apoptotic effects of doxorubicin witnessed in this study are in agreement with Brantley-
Finley et al. (2003) whose 1 µM drug treatment caused apoptotic cell death in the KB-3 human 
carcinoma cell line, which displayed a molecular profile of significant PARP proteolysis and caspase 3 
activation (Brantley-Finley et al., 2003). Furthermore, the recent research carried out by Chen et al. 
demonstrated a similar activation of the AMPK sensor upon doxorubicin treatment (Chen et al., 2011). 
They verified that AMPK contributed to doxorubicin-induced apoptotic cell death based on the 
increased cellular viability and decreased caspase 3 cleavage when AMPK was deactivated by siRNA 
or compound C. They concluded that ROS generated by mitochondria after doxorubicin treatment 
was the stimulus for AMPK expression. 
While autophagy has been shown to be responsible for the cytotoxic effects of some anticancer 
agents (Kanzawa et al., 2003; Gozuacik & Kimchi, 2004), in other scenarios, the autophagic process 
upregulated by neoplastic cells may contribute to the survival of that population in response to 
adverse treatments (Katayama et al., 2007). In this in vitro experimental model, the autophagic 
process that is stimulated by doxorubicin under normoxic conditions could signify an alternative mode 
of cell death, namely type II, which is activated to augment the killing of MCF-7 cells by this 
antineoplastic drug.  The possibility that AMPK, which becomes increasingly activated under 
normoxia, may be responsible for the autophagic boost (Table 3.2) is supported by Egan et al. who 
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showed that the nutrient sensor was capable of phosphorylating ULK1, a kinase required for the 
induction of autophagy (Egan et al., 2011). The baseline expression of AMPK in the hypoxic control 
group (Fig. 3.10.2) is supported by a study conducted by Mungai et al. (2011) which revealed that the 
augmented ROS produced by mitochondria under hypoxic conditions (1.5% O2) caused an increased 
activation of AMPK, independent of the AMP/ATP ratio (Mungai et al., 2011). As the elevated levels of 
both AMPK and HIF-1α protein were unaffected after doxorubicin treatment, it is challenging to clarify 
whether the autophagy upregulated in this group under hypoxia is dependent on AMPK or HIF-1α 
(Table 3.2). Although hypoxia is capable of upregulating AMPK and HIF-1α, the severity and duration 
of low oxygen tension will most likely determine which protein is preferentially activated (Solaini et al., 
2010).  
The finding that the bioreductive capacity was significantly decreased after 12 hours of doxorubicin 
exposure is indirectly strengthened by a study conducted by Kuznetsov et al. who, with the aid of 
confocal microscopy, measured the mitochondrial oxidative state of MCF-7 cells using the native 
autofluorescence of NADH (Kuznetsov et al., 2011). After the addition of doxorubicin, the 
mitochondrial NADH autofluorescence declined indicating the mitochondrial reduction was decreased. 
The conclusion is in agreement with the results obtained in this study through the MTT assay. The 
suggestion that autophagy may be responsible for this decreased cell death rate under hypoxia is 
supported by Song et al. (2009) whose research revealed that the sensitivity of hepatocellular 
carcinoma cells to the chemotherapeutic agent, cisplatin, under hypoxic conditions became restored 
when autophagy was inhibited by siRNA-mediated knockdown of Beclin 1 (Song et al., 2009). This 
implicates that autophagy activation mediated the resistance under hypoxia in this scenario. 
 
4.2.4 Characterization of cellular death pathways and the oxygen sensor (AMPK) upon 
adjuvant therapy 
The clinical combination of anticancer drugs that possess different molecular targets and/or 
mechanism of action have had a profound impact on the treatment of chemo-resistant tumours. The 
aim of this component of the study was therefore to investigate whether the simultaneous inclusion of 
the HIF-1α inhibitor, 2-methoxyestradiol, could modulate the cytotoxic effects of the antineoplastic 
agent, doxorubicin. 
In the current study, the simultaneous treatment of MCF-7 cells with doxorubicin and 2-
methoxyestradiol, when incubated under normoxia, displayed a significant decrease in the autophagic 
pathway (Fig. 3.6.1; Fig. 3.7.1; Table 3.3) compared to the levels induced by doxorubicin alone. 
While this occurred concurrently with a decrease in the levels of HIF-1α, the depletion of the master 
regulator failed to induce apoptotic cell death.  This was unexpected based on the link establish 
above (section 4.2.2). Instead, the amount of caspase 3 activation and PARP proteolysis became 
significantly reduced, indicating less apoptotic cell death (Fig. 3.4.1; Fig. 3.5.1). Whereas a similar 
effect on the cleavage of caspase 3 and its substrate PARP was witnessed under hypoxia (Fig. 3.4.2; 
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Fig. 3.5.2), indicating an inhibitory effect on doxorubicin-induced apoptosis, the combined treatment 
did not influence autophagy as evident from non-significant changes in LC3-II and p62 protein 
expression (Fig. 3.6.2; Fig. 3.7.2; Table 3.3). The HIF-1α and p-AMPK levels present in this condition 
remained elevated similar to those observed under the hypoxia control conditions (Fig. 3.8.2; Fig. 
3.10.2). This may indicate that 2-methoxyestradiol was incapable of disrupting the HIF-1α. Autophagy 
remained elevated and may therefore have sustained the growth of MCF-7 cells, being stimulated by 
either HIF-1α or p-AMPK. According to the MTT assay, when HIF-1α was silenced by 
pharmacological (2-methoxyestradiol) therapy, the treatment of MCF-7 cells with doxorubicin 
abolished the significant differential bioreductive capacity that was produced when wild-type MCF-7 
cells were treated with doxorubicin alone (Fig. 3.12). However, this was not due to an increase in cell 
death in the hypoxic group as expected. As noticeable from the MTT data, the bioreductive capacity 
of adjuvant doxorubicin-2-methoxyestradiol treatment group (normoxia, 40% viable; hypoxia, 57% 
viable) was less affected than when the neoplastic cells were treated with doxorubicin alone 
(normoxia, 31% viable; hypoxia, 40% viable). This suggests that an antagonistic effect was at play. 
The data indicates that the combined treatment sustained the survival of the neoplastic cells. 
A 2009 study conducted by Di et al. investigated the alternative modes of cell death in the MCF-7 
tumorigenic breast cell line, MCF-7, upon Adriamycin exposure and concluded that, in addition to the 
rise in apoptosis and autophagy, this antineoplastic agent may stimulate an irreversible state of 
growth arrest termed senescence (Di et al., 2009). Similarly, cell-cycle analysis showed that 2-
methoxyestadiol treatment caused growth arrest of human aortic smooth muscle cells in the G0/G1 
and G2/M-phases (Barchiesi et al., 2006). Since there was no significant change in cellular viability in 
this group compared when doxorubicin was used alone (Fig 3.12), it is likely that the combination of 
doxorubicin and 2-methoxyestradiol under normoxic conditions could promote the progression of 
MCF-7 cells to a state of senescence. This form of growth arrest could potentially allow for tumour 
recurrence, as Elmore et al. (2005) showed that following an early senescent arrest, breast cancer 
cells were capable of recovering (Elmore et al., 2005). 
A possible reason for the non-significant change in the elevated hypoxic HIF-1α levels could be 
attributed to the changing cellular metabolism under hypoxia. The likelihood that reactive oxygen 
species (ROS) can act as signalling molecules implicated in the stabilization of HIF-1α has been 
challenged by several researchers [reviewed in (Gogvadze et al., 2010)]. The prime site of ROS 
generation is the mitochondrial electron transport chain (complex I and III) (Solaini et al., 2010). 
However, hypoxic conditions have been shown to amplify the amount of ROS produced, specifically 
at complex III (Chandel et al., 2000). This is supported by findings from Chandel et al. (1998) who 
quantified the intracellular ROS intensity of human hepatoma cell line, Hep3B, by fluorescence 
microscopy where the oxidation of the non-fluorescent dichlorofluorescin (DCFH) diacetate by ROS 
generated a dichlorofluorescin (DCF) fluorescent signal (Chandel, 1998). There it was shown that the 
amount of fluorescence, signifying ROS, increased as experimental oxygen concentrations decreased 
below 8%. Furthermore, this upregulation was supported with the increased expression of VEGF and 
glycolytic enzymes, which are downstream products of HIF-1α transcriptional activity. The ROS was 
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shown to be dependent on the mitochondria as subjection of a respiration-deficient Hep3B cell line to 
the same experimental conditions failed to reproduce these effects. The relationship between 
mitochondrial ROS and HIF-1α was confirmed by follow-up studies (Jung et al., 2008; Chandel et al., 
2000). The generation of ROS by doxorubicin (Lüpertz et al., 2010; Du & Lou, 2008) and 2-
methoxyestradiol (Salama et al., 2011; Stander et al., 2010) has been validated by several studies. 
Therefore, it is possible that the ineffective disruption of HIF-1α by 2-methoxyestradiol could be a 
result of the combined effects of hypoxia, doxorubicin and 2-methoxyestradiol which may lead to the 
augmented stabilization of HIF-1α by ROS production observed in cells exposed to hypoxia. 
The decrease in the tricarboxylic acid cycle rate as a consequence of lower oxygen availability and 
leading to the build-up of intermediates is another metabolic transformation occurring under hypoxia 
(Solaini et al., 2010). These TCA intermediates, specifically succinate and fumarate, were shown by 
means of Electrospray Ionization-Mass Spectrometry (ESI-MS) and co-crystallization experiments to 
compete with the 2-oxoglutarate-biniding site on the prolyl hydroxylases enzymes (Hewitson et al., 
2007). As 2-oxoglutarate, or α-ketoglutarate, is an essential co-substrate required for the 
hydroxylation activity of these enzymes, this competitive binding of TCA intermediates in conjunction 
with oxygen deprivation could intensify the stabilization and transcriptional activity of HIF-1α. 
Research carried out by Koivunen et al. (2007) in an attempt to assess the effect of TCA 
intermediates on HIF-1α disclosed that the interference of two TCA cycle enzymes, fumurate 
hydratase and succinate dehydrogenase, by the inclusion of the dual inhibitor 3-nitropropionic acid, 
stabilized the expression of HIF-1α which was shown to be transcriptionally active as evident from the 
upregulation of VEGF, one of its downstream targets (Koivunen et al., 2007). Therefore, combining 
doxorubicin and 2-methoxyestradiol under hypoxia may potentiate the accumulation of TCA 
intermediates and a concomitant expression of HIF-1α. 
Experiments measuring the production of ROS and concentration of TCA intermediates, along with 
the expression of HIF-1α are suggested for future studies in order to clarify whether they influence the 
stability of the master regulator. 
In an attempt to expose a possible synergistic cytotoxic effect, Han et al. (2005) combined the two 
anti-cancer drugs, doxorubicin and 2-methoxyestradiol, at similar doses (Han et al., 2005). To their 
surprise, the combination treatment displayed antagonism to the expected anti-proliferative effect on 
the growth of breast cancer cell lines. This could possibly be attributed to the residual estrogenic 
activity of 2-methoxyestradiol. 
17β-estradiol is initially oxidized to estrone, which may then be converted to the catechol estrogens, 
4-hydroxyestradiol and 2-hydroxyestradiol, by a cytochrome-P450-catalyzed reaction (Mueck & 
Seeger, 2010). 2-Hydroxyestradiol is subsequently methylated by catechol-ortho-methyltransferase 
(COMT) to produce 2-methoxyestradiol. While this latter metabolite was shown to possess mild 
estrogenic activity, the molecules it is derived from display greater estrogenic activity (Sutherland et 
al., 2007). In addition to enzymatically oxidizing 17β-estradiol to the catechol estrogens, cytochrome 
P450 1A1 (CYP1A1) and cytochrome P450 1B1 (CYP1B1) were revealed to catalyse the 
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demethylation of 2-methyoxyestradiol to 2-hydroxyestradiol in experiments carried out by Dawling et 
al. (Dawling et al., 2003). Normal and tumorigenic breast cancer tissue has revealed the expression of 
the cytochrome P450 enzymes by reverse-transcriptase-PCR (Iscan et al., 2001). By the inclusion of 
gangalin, a flavonoid known to inhibit the CY-P450-enzyme, LaVallee et al. indicated that the 
mitogenic effect on MCF-7 cells after 2-methoxyestradiol became attenuated, and thus proposed that 
the CY-P450-catalyzed conversion of 2-methoxyestradiol to 2-hydroxyestradiol was responsible for 
the stimulation of growth (LaVallee et al., 2002). Moreover, this mitogenic effect was shown to 
disappear when the estrogen receptors were antagonized (Liu & Zhu, 2004).  
Since our study employed the tumorigenic MCF-7 breast cell line which is estrogen-receptor positive 
(American Type Culture Collection, 2009), this metabolic conversion to the active estrogenic 
compounds may be possible. It can therefore be postulated that the doxorubicin component of the 
adjuvant therapy might be capable of reverting 2-methoxyestradiol back to its chemically reactive 
estrogenic derivate, 2-hydroxyestradiol, enabling it to engage with the ER-receptor and induce a 
mitogenic effect. 
 
4.2.5 The effect on mitochondrial integrity upon induction and inhibition of HIF-1α 
The mitochondria are ATP-producing organelles whose existence is crucial to satisfy the bioenergetic 
requirements of eukaryotic cells (Galluzzi et al., 2010). Beyond their role in bioenergetic production 
via aerobic respiration, these ‘power-houses’ are also implicated in buffering intracellular calcium 
levels, and in the apoptotic cellular death pathway. A dynamic relationship between the fission and 
fusion of mitochondria exists (Twig et al., 2008). This constant cycle determines both the functional 
and structural (morphology and spatial distribution) characteristics of these organelles within the cell 
(Chen & Chan, 2005). 
In this study, the treatment of the MCF-7 cell line with CoCl2 stabilized HIF-1α in the normoxic setting 
(Fig. 3.8.1). As seen in the fluorescence micrographs, CoCl2 also stimulated the morphological 
transformation of mitochondria from an elongated network to enlarged disc-like pattern (Fig. 3.11.1B), 
an effect that was noticeable under hypoxia (Fig 3.11.1A). Since CoCl2 is known to mimic hypoxia by 
stabilizing HIF-1α, the data in this experimental setting are suggestive that HIF-1α is responsible for 
this morphological effect. 
It was therefore investigated whether the inhibition of HIF-1α should revert the morphology back to 
that present under normoxia. This was vaguely evident in the fluorescent micrographs of the 2-
methoxyestradiol-treated group (Fig. 3.11.2D). However, morphological features of apoptotic cellular 
death were noticeable by the condensed chromatin suggesting the sensitivity to apoptosis was 
increased. This correlates with immunoblotting data where biomarkers for type I cell death (cleaved 
caspase 3 & cleaved PARP) were increased upon 2-methoxyestradiol treatment (Fig. 3.4.2; Fig. 
3.5.2). 
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Hypoxia has been shown to confer heterogeneity to the structural and functional characteristics of 
mitochondria. The appearance of the enlarged disc-like mitochondria in the hypoxic setting of this 
study mirror the observations made by Chiche et al. whose examination of electron micrographs 
identified the mitochondria of the colon carcinoma cell line, LS174, to assume an enlarged, circular 
morphology upon exposure to hypoxia. When standard atmospheric oxygen was re-established, the 
tubular network that is typically present within these cells became restored (Chiche et al., 2010). They 
attributed this transformation to the hypoxic upregulation of Mfn1, a GTPase that has previously been 
shown to promote the fusion of mitochondria (Koshiba et al., 2004; Chen et al., 2005). These 
enlarged mitochondria were also shown to be less sensitive to apoptotic inducers (Chiche et al., 
2010). Earlier it was suggested that HIF-1α negatively regulates apoptosis based on our 
immunoblotting results (Table 3.1). Furthermore, while HIF-1α stabilization (CoCl2 treatment) 
promoted the formation of these enlarged mitochondria, the ablation of HIF-1α with 2-
methoxyestradiol increased the amount of apoptotic cell death, further implicating the master 
regulator to play a role in this morphological ‘protective’ adaptation. 
 
4.2.7 The effect on mitochondrial integrity upon doxorubicin treatment 
Examination of the fluorescent images revealed that the mitochondria were adversely affected when 
MCF-7 cells were subjected to doxorubicin treatment (Fig. 3.11.1C). In addition to exhibiting the 
distinguishing apoptotic features including cellular shrinkage and detachment (shift in focal plane), 
membrane blebbing and nuclear pyknosis and karyorrhexis, the mitochondria to became fragmented 
and formed dot-like irregular structures.  
Our imaging data is supported by a 2001 study where Frank et al. treated HeLa cervical cancer cells 
with etoposide, a DNA-damaging anticancer agent known to induce apoptosis, and this caused a 
phenotypic change in the mitochondria, from elongated to punctiform (Frank et al., 2001). 
However, the MCF-7 cells appeared to possess a greater mitochondrial functionality under 0.1% 
oxygen after doxorubicin treatment compared to normoxic conditions (Fig. 3.12). In addition to the 
change in mitochondrial redox state, Kuznetsov et al. also demonstrated that doxorubicin treatment 
dissipated the mitochondrial membrane potential (Kuznetsov et al., 2011). The fusion of mitochondria 
has been shown to maintain the membrane potential (∆Ѱ), allowing the cells to evade potential 
cellular dysfunction (Chen et al., 2005). Although it is only mildly noticeable from our micrographs that 
some hypoxic cells retained enlarged mitochondria, the greater mitochondria functionality based on 
our MTT results could be attributed to the fused disc-like mitochondria which manifest under hypoxia, 
an effect which could protect the cells from depolarization induced by doxorubicin. The HIF-1-
inducible autophagic proteins, BNIP3 and BNIP3L, were also linked to a similar protective 
enlargement of the mitochondria (Chiche et al., 2010). Therefore the enlarged disc-like structures that 
manifest after 12 hours of hypoxic treatment could also indicate a survival pathway through the 
autophagic degradation of potentially damaged mitochondria by doxorubicin (Fig. 3.11.1C). This 
process is termed mitophagy. A beneficial role of BNIP3-regulated mitophagy in mouse embryonic 
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fibroblasts was described in 2008 by Zhang et al. where the knock-down of BNIP3 caused an 
increase in mitochondrial mass and hypoxia-induced cellular demise. This effect was reversed when 
BNIP3 expression was forced (Zhang et al., 2008). Therefore, in the scenario of this study, HIF-1 
induced mitophagy may reduce the oxidative damage conferred by doxorubicin. Further studies are 
required to assess the extent of mitophagy and the oxidative phosphorylation status. 
Upon the ablation of HIF-1, this defensive process of mitochondrial fusion or mitophagy should be 
mitigated, and thus augment the fragmentation of mitochondria while decreasing its functionality in the 
presence of the antineoplastic drug, doxorubicin.  
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4.3 IN VIVO 
The efficacy of the adjuvant treatment was investigated in an in vivo setting in order to determine 
whether the effects observed within the in vitro component of this study would be translated into an 
animal model. By exploiting the hypoxic response that would otherwise fuel the growth of a solid 
tumour, the sensitivity to chemotherapeutic intervention could be improved. For the treatment of mice 
bearing an E0771 xenograft (~4 week growth), the dosages of the drugs employed were based on 
those previously reported in the literature that combined effectiveness while simultaneously limiting 
harmful side effects. The aims of the in vivo component of the study were as follows: 
1. To evaluate to effect of doxorubicin treatment, either alone or in combination with 2-methoxyestradiol, 
on the rate of tumour growth. 
2. To assess the degree of systemic toxicity conferred upon mice after treatment with doxorubicin, either 
alone or combination with 2-methoxyestradiol. 
3. To characterize the molecular events within the tumour tissue in response to doxorubicin treatment, 
either alone or in combination with 2-methoxyestradiol. 
 
4.3.1 The effect of treatment on the tumour growth rate and systemic toxicity 
While a non-significant change in body weight of all animals during the two week treatment period 
provided an indication of low systemic toxicity, mice treated with doxorubicin, in absence and 
presence of 2-methoxyestradiol, exhibited slight tissue blistering at the infusion site.  
The intraperitoneal administration of doxorubicin (5 mg.kg
-1
) and 2-methoxyestradiol (45 mg.kg
-1
), 
separately and in combination, had no significant effect on the rate of tumour growth after the two 
week treatment regime (Fig. 3.13). Despite the lack of changes in the size of the tumour, the 
treatment did cause variations on the molecular level.  
 
4.3.2 The effect of treatment on cellular death pathways, the oxygen sensor (AMPK) 
and hypoxia 
In relation to the E0771 tumour xenografts of mice that did not receive any treatment, doxorubicin 
caused a significant decrease in the amount of apoptosis as evident from the reduced cleavage of 
PARP (Fig. 3.14), while the diminishing levels of p62 signified an elevation in autophagy in this group 
(Fig. 3.15). The metabolic sensor, AMPK, became increasingly activated by a significant degree (Fig. 
3.17) in response to chemotherapeutic treatment while the expression of HIF-1α remained unaffected 
(Fig. 3.16). 
2-methoxyestradiol treatment caused a response in tumour-bearing mice that was analogous to the 
doxorubicin treated group in terms of the cellular death pathways (Fig. 3.14; Fig. 3.15). In contrast to 
the in vitro results, rather than increasing the amount of apoptotic cell death, 2-methoxyestradiol 
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induced the opposite effect instead. Likewise, HIF-1α expression was not disrupted after the 
administration of 45 mg.kg
-1
 of this compound (Fig. 3.16).  
The ability of the adjuvant therapy to induce the apoptotic cellular death pathway while simultaneously 
inhibiting the autophagic pathway was unexpected. A primary reason for this dismal expectation was 
firstly due to the fact that 2-methoxyestradiol was incapable of inhibiting the expression of HIF-1α in 
the in vivo setting, an occurrence which would concomitantly induce apoptosis according to the in 
vitro results. Secondly, there was no change in the growth rate of the tumour in this group. Adjuvant 
therapy, however, reduced HIF-1α expression (Fig. 3.16) along with autophagy (Fig. 3.15), while 
yielding a greater amount of type I cell death (Fig 3.14).  
The non-significant change in the growth of the doxorubicin-treated tumours could represent a 
putatively ‘protective’ mechanism instigated by AMPK, allowing the neoplasm to continue proliferating 
regardless of antineoplastic drug administration. This suggestion can be supported by the finding of 
the AMPK-dependent upregulation of autophagy and diminished apoptotic potential in this group. 
These processes were HIF-1α-independent (Fig. 3.16) and incapable of manipulating the growth of 
the tumour. 
Similar to the unaffected rate of tumour growth witnessed in the 2-methoxestradiol treated animals, 
Ireson et al. demonstrated the failure of this metabolite to manipulate the growth of an MDA-MB-435 
xenograft that had been transplanted into mice (Ireson et al., 2004). They attributed this result to the 
half-life of the estrogenic derivate which was estimated to be approximately 14 minutes when 
administered intravenously. There is a possibility that during the in vivo experiment, intraperitoneal 
administration of the drug could accidentally have penetrated other non-specific tissues. The 
ineffective drug administration may be supported by the appearance of the slight tissue loss/blistering 
at the injection site after doxorubicin treatment. If a major blood vessel had been penetrated, the 
direct delivery of 2-methoxyestradiol to the bloodstream would lead to a decreased bioavailability as a 
result of rapid clearance, preventing this compound from exerting its anti-proliferative and anti-
angiogenic functions proficiently. 
The non-significant change in tumour growth rate witnessed upon adjuvant therapeutic administration 
is in disagreement with the outcome of the study carried out by Azab et al. (2008). Their combined 
administration of 5 mg.kg
-1
 doxorubicin and 30 mg.kg
-1
 2-methoxyestadiol produced a synergistic 
effect by significantly reducing the growth of doxorubicin-resistant MCF-7 tumour xenografts 
compared to the untreated tumour-bearing mice (Azab et al., 2008). 
There are many additional reasons that could explain the unexpected differences between groups 
within the animal study.  
Firstly, tumours were allowed to reach a measureable volume before the treatment regime 
commenced. After inoculation of the mice with E0771 cancer the tumours grew at different rates and, 
by the end of the fourth week (day 28), the mice displayed different-sized tumours. In an attempt to 
achieve a representative sample of the entire population, mice were allocated to groups so that each 
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would have a similar-sized tumour. Moreover, the pathophysiological oxygenation status of a tumour 
is dependent both ‘chronic’ and ‘acute’ hypoxia which could lead to an intermittent supply of oxygen to 
the cancerous cells. The outcome of both factors would be a heterogeneous phenotype manifested 
within tumours, both in location and intensity (Magagnin et al., 2006). Therefore, while tumours may 
display a similar size, the oxygenation pattern within is bound to vary between them. It can therefore 
be surmised that, although the mice were allocated to incorporate a representative degree of tumour 
sizes, the unexpected variations may be due to the unique hypoxic phenotype of the individual 
tumours of mice within each group, prior to treatment.  
Secondly, an ineffective concentration for doxorubicin and 2-methoxyestradiol and/or the timing of 
treatment initiation might be responsible for a lack in the expected differences. Furthermore, the two 
week treatment period could have been insufficient to allow these molecular variations to manifest in 
a physical change of the rapidly growing tumour. If this was the case, then the effects in the 
doxorubicin- and/or 2-methoxyestradiol-treated groups would represent the average basal levels of 
the tumours within that group. Judging from the HIF-1α protein levels which become significantly 
reduced during adjuvant therapy (Fig. 3.16), this would ultimately suggest the existence of another 
HIF-1α disrupting mechanism that is independent of 2-methoxyestradiol action.  
 
4.4 DIFFERENCES BETWEEN IN VITRO AND IN VIVO EXPERIMENTAL RESULTS 
The differences in our results between the in vitro and in vivo aspect of our study may be attributed to 
the parameters controlled. 
Although the in vitro normoxic and hypoxic experimental conditions required cells to be subjected to 
controlled conditions of 21% (PO2 = 160 mm Hg) and ~0.1% (PO2 = 0.8 mm Hg), respectively, the 
tissue oxygenation levels within in vivo models are rather different. Physiologically, the concentration 
of oxygen that is normally delivered to tissue is ~5% (PO2 = 40 mm Hg) (Becker & Casabianca, 2009). 
The pathology of solid tumours, as mentioned above, experiences oxygen levels that are constantly 
fluctuating resulting in oxygen gradients. 
Furthermore, the tumour forms a dynamic relationship with its microenvironment, influenced by 
several factors including heterogeneous patterns of oxygenation, nutrient and growth factor 
availability, and neoplastic cellular growth rates. Although these factors may exist simultaneously, it is 
possible that they may occur exclusively of one another.  
While the in vitro study focused on the contribution of oxygenation to the status of chemotherapeutic 
resistance in isolation, it is challenging to control other associated parameters when attempting the 
same experiment in an in vivo setting. The fewer the parameters that are controlled for, the more 
complex it becomes to extrapolate relationships due to potential irrelevant variation. 
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Therefore, the extent to which in vitro monolayer experiments can be reproduced in an in vivo model 
is limited. The in vitro experimental models which elucidate relationships may preclude fundamental 
aspects of tumour biology. 
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CHAPTER 5: CONCLUSION 
To overcome the major obstacle of chemotherapeutic resistance that is frequently manifested by 
breast cancer patients bearing solid tumours, the key mechanisms responsible for the reduced 
sensitivity of tumours to anticancer treatment needs to be identified before they may be exploited for 
therapeutic benefit. Furthermore, the conventional use of doxorubicin, an anti-carcinogenic used to 
treat the pathological state of breast cancer, may potentially cause cardio-toxic effects that could be 
implicated directly after administration, or manifest months or years later due to excessive build-up of 
the drug (Minotti et al., 2004).   
An extensively studied characteristic present within the microenvironment of solid tumours are the 
hypoxic regions. The transcription factor HIF-1α elicits a multi-target response from hypoxia-inducible 
genes that mediate adaptation to this physiologically destructive environment. HIF-1α expression is 
elevated in tumorigenic breast tissue compared to their non-tumorigenic counterparts, with the level of 
this expression increasing as the degree of malignancy advances (Zhong et al., 1999; Bos & Zhong, 
2001; Schindl & Schoppmann, 2002). 
In the pathophysiological context of neoplastic disease, the presence of the autophagic pathway has 
been considered to act as a survival mechanism. Its activity has been recognized to increase under 
hypoxia, nutrient deprivation and/or upon chemotherapeutic administration (Chen et al., 2010). It 
promotes the growth and proliferation of neoplastic cells through the recycling of damaged organelles 
and proteins, while simultaneously providing the required bioenergetic fuel. In the context of hypoxia, 
autophagy upregulation is mediated through the expression of the HIF-1α-inducible protein, BNIP3 
(Sowter et al., 2001; Zhang et al., 2008). Therefore HIF-1α has become recognized as one of the 
main instigators in cancer progression under hypoxic conditions.  
This study was formulated to uncover the extent to which oxygen deprivation, or hypoxia, contributes 
to the development of chemotherapeutic resistance. This study aimed to circumvent the hypoxic 
response by attenuating the HIF-1α master regulator using pharmacological (2-methoxyestradiol) and 
genetic (siRNA transfection) approaches. In this scenario, the resistance of hypoxic neoplastic cells to 
doxorubicin is proposed to become abolished. Moreover, the combination of therapies exhibiting 
different modes of action may allow for the maximum mitigation of tumorigenic cells, while 
simultaneously being used at sub-toxic doses that would otherwise target and potentially destroy non-
malignant cells. While both strategies were capable of mitigating the resistant effect conferred by 
hypoxia upon doxorubicin-treated MCF-7 cells, the mechanism of action differed between the two. 
Although the suppression of the HIF-1α mRNA transcript by transcriptional intervention with siRNA 
was unsuccessful under hypoxic conditions, an alternative approach using the novel HIF-1α-inhibiting 
drug, 2-methoxyestradiol, effectively abrogated the protein expression and was therefore utilized 
throughout the study. Furthermore, CoCl2 was able to stabilize the expression of HIF-1α and served 
as a positive control. 
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To exploit the autophagic machinery for therapeutic benefit, an understanding of its role in the context 
of the tumour microenvironment is necessary. With the aid of an inducer and inhibitor of HIF-1α, this 
aim was satisfied when it was established that the autophagy in the in vitro experimental settings was 
dependent on HIF-1α. This study provided evidence that MCF-7 cells were resistant to doxorubicin 
treatment under hypoxic conditions (~0.1%; 12 hours), displaying an upregulation of the autophagic 
pathway. While the upregulation of autophagy under normoxia was attributed to the induced activation 
of the AMPK energy sensor, we were unable to distinguish the regulator of the lysosomal survival 
pathway under hypoxia as both AMPK and HIF-1α remained active. The qualitative fluorescent data 
suggested that the HIF-1α-induced fusion of mitochondria may aid in the hypoxic defence mechanism 
and protect these organelles from the cytotoxicity of doxorubicin treatment. This hypoxic fusion has 
also been linked to BNIP3/BNIP3L-dependent autophagy (Chiche et al., 2010). 
Rather than eliciting a synergistic cytotoxic effect on the neoplastic MCF-7 growth, the in vitro 
combination of 2-methoxyetradiol with doxorubicin produced an antagonistic effect on cellular viability 
instead. We suspected this phenomenon to be ascribed to different reasons, depending on the 
oxygenation status of the environment. Since the combined treatment under normoxia caused a HIF-
1-dependent attenuation of autophagy, yet no adverse toxicity on the cellular viability, we propose that 
the MCF-7 cells under the experimental conditions of the study would possibly enter a state of growth 
arrest. Senescence may provide a mechanism to avoid anti-proliferative signalling, and allow for 
tumour recurrence (Hanahan & Weinberg, 2011; Elmore et al., 2005). In contrast, when the neoplastic 
cells received adjuvant therapy while being exposed to a ~0.1% oxygen environment, HIF-1α 
remained stabilized. We propose this unaffected protein expression to be the result of a potentiated 
stabilization of HIF-1α caused by mitochondrial dysfunction upon adjuvant therapy under hypoxic 
conditions. This mitochondrial dysfunction would lead to the build-up of ROS and TCA cycle 
intermediates, both of which have been shown to stabilize HIF-1α (Jung et al., 2008; Koivunen et al., 
2007). Furthermore, the slight mitogenic effect observed with the MTT assay in this treatment group 
may be caused by the residual estrogenic activity of 2-methoxyestradiol. We speculate the activity of 
doxorubicin might induce the demethylation of 2-methoxyestradiol to a more active estrogenic 
metabolite that can stimulate the ER-receptors of MCF-7 cells. 
In the context of the in vivo animal model, although the normoxic AMPK-upregulated autophagic 
process was mimicked in response to doxorubicin administration, its effect on tumour growth was 
negligible. Similarly, 2-Methoxyestradiol unexpectedly decreased the amount of type I cell death while 
simultaneously augmenting autophagy, both of which had no prominent consequence on tumour 
growth rate. To the contrary, a synergistic molecular profile after adjuvant therapeutic administration 
decreased the autophagy that was upregulated within the tumours. Despite these findings, the 
adjuvant therapy failed to repress the rate of tumour growth. We conclude that the in vivo model 
requires the treatment regime to be reconsidered in terms of the dosage, the time of initiation, period 
of treatment, and/or the mode of administration. If administration had been successful, our results 
would imply the dynamics of the tumour microenvironment to be multi-faceted and demand future in 
vivo studies to control for more parameters. 
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We therefore reject our hypothesis on the basis that an antagonistic effect, rather than a synergistic 
effect, was witnessed when the neoplastic breast cell line was treated with the adjuvant therapy. 
Furthermore, the significant synergistic effect that becomes noticeable in vivo at a molecular level 
failed to manifest significant changes in tumour growth. 
The results obtained clearly warrant the need for a more practical, yet extensive testing of 2-
methoxyestradiol to reveal its precise pharmacokinetics. Only then can it be optimally employed in 
adjuvant therapy with doxorubicin and possibly identify a possible hypoxia-targeting therapy. 
  
Stellenbosch University  http://scholar.sun.ac.za
94 
 
CHAPTER 6: LIMITATIONS & FUTURE STUDIES 
6.1 IN VITRO 
Although we assessed the expression of HIF-1α, it does not necessarily imply that the stabilized form 
is transcriptionally active. The synthetic YC-1 compound (Chun et al., 2001) and antibiotic derivate 
geldanamycin (Mabjeesh et al., 2002) are examples of HIF-1α inhibitors which mediate their effects 
post-translationally (O’Donnell et al., 2006). The detection of HIF-1α levels may represent expressed 
HIF-1α prior to protein degradation and may therefore be inaccurate. An evaluation of its 
transcriptional activity would therefore provide additional validation. This could be achieved by using a 
HIF-1α responsive reporter assay where the firefly luciferase gene contains an HRE promoter, 
entailing its transcriptional activation by HIF-1α to be captured as bioluminescent light. Alternatively, 
immuno-detection of downstream proteins that are known to be HIF-1α-inducible would not only 
indicate transcriptional activity, but also the specific profile of upregulated proteins. 
Since this study focused primarily on cellular death pathways, the metabolic profile of the cancer cell 
line in the absence or presence of treatments could further be evaluated to compliment the study. The 
functionality or preference of a pathway may be revealed by inhibiting specific steps in metabolism, 
such as glycolysis (2-deoxy-D-glucose) and oxidative phosphorylation (oligomycin), and monitoring 
the changes in ATP availability and the mitochondrial membrane potential. This would enable one to 
delineate the role of aerobic respiration not only under hypoxic exposure, but within the cancer cells 
themselves. A technique used to quantify ATP includes a luciferin-luciferase based ATP 
bioluminescence Assay (Katayama et al., 2007), while mitochondrial membrane potential may be 
measured by fluorescent microscopy using the potentiometric-sensitive dye tetramethylrhodamine 
ethyl ester (TMRE) (Kuznetsov et al., 2011). The rate of respiration/O2 consumption before and after 
anticancer drug-afflicted damage, as well as the possibility of recovery after the damage, may also be 
monitored with the aid of clark-type electrode (e.g. Hansatech Instrument Oxygraph). With regard to 
our study, implicating ROS in the hypoxic stabilization of HIF-1α in MCF-7 cells responding to the 
combined treatment of doxorubicin and 2-methoxyestradiol would entail the measurement of oxygen 
radicals. ROS measurement has been achieved by fluorescent microscopy using the probes, 2,7’-
dichlorofluorescein diacetate (DCFH-DA) (Salama et al., 2011), and MitoSOX™ Red (Kuznetsov et 
al., 2011). 
Aside from the metabolic profile functionally validating our qualitative fluorescent imaging data, the 
role of mitochondria dynamics can further be unravelled by evaluating the mitochondrial fusion (Mfn1, 
Mfn2, and OPA1) and fission (DRP1) proteins (Chiche et al., 2010; Frank et al., 2001). 
To elucidate whether the mitogenic effect identified in this study was due to the 2-methoxyestradiol’s 
residual estrogenic activity, the experiment should be repeated on ER-negative breast cancer cells 
(e.g. MDA-MB-231). As 2-methoxyestradiol has a low affinity for estrogen receptors, its potential 
biotransformation to more reactive estrogen metabolites can mitigated by including inhibitors of 
cytochrome P450 enzymes. The identification of the precise receptors with which 2-methoxyestradiol 
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engages to mediate its anti-proliferative and anti-angiogenic effects would enable researchers to 
successfully exploit its antitumor properties. 
To more accurately simulate the native microenvironment of a tumour, the growth of 3-dimensional in 
vitro spheroids rather than a monolayer culture could provide a more relevant representation of 
tumour structural and functional dynamics. Furthermore, characterisation of the molecular profile 
using the 3-D in vitro analogy testing could then be easily translated into a preclinical in vivo model 
(Doublier et al., 2012).  
Lastly, reproducing the experiment in a non-tumorigenic epithelial cell line (e.g. MCF-12A) would 
allow us to delineate a concentration and time protocol that is selectively cytotoxic to the cancerous 
MCF-7 cell line, while exert a minimal effect on the normal cell line.   
 
6.2 IN VIVO 
The in vivo animal model may be improved by assessing the hypoxic fraction of tumours prior to 
allocation of the mice, therefore enabling a more accurate representative sample of the population to 
be identified. One solution would be to use the in vivo Imaging System (IVIS), a non-invasive 
technique that enables the spatial and temporal distribution of fluorescent or bioluminescent markers 
to be visualized within living animals. By exploiting a reporter gene system where the HIF-1α gene 
was fused to the firefly luciferase gene, Viola et al. (2008) were able to quantify the expression of HIF-
1α by measurement of the luciferase signal (Viola et al., 2008). This imaging system also facilitated 
the changes in the response of HIF-1α to chemotherapy to be monitored. It is therefore an attractive 
technique that may aid future studies that aim to assess the role of HIF-1α as a potential regulator of 
drug resistance in cancer treatment. 
With regards to the results on tumour growth in the in vivo animal model, we suggest this could be 
attributed to either an unsuccessful intraperitoneal administration of the drugs, or the short-half-life of 
2-methoxyestradiol should it have entered the bloodstream of the animal. A solution to this issue 
would be employing a 2-methoxyestradiol analogue with a slower clearance rate so as to enable the 
drug to exert its anti-proliferative and anti-angiogenic functions on the tumour growths in our in vivo 
model. This increased efficacy was noticed by Ireson et al. when they compared the 
pharmacokinetics of 2-methoxyestradiol and its sulphamoylated analogue, 2-methoxyestradiol-bis-
sulphamate (2-MeOE2bisMATE) (Ireson et al., 2004). Compared to the low bioavailability of its 
derivate molecule, oral administration of 2-MeOE2bisMATE (10 mg.kg
-1
) presented a bioavailability of 
~85% in Wistar rats which peaked after 3 hours and remained detectable in plasma after 24 hours. An 
oral dosage of 20 mg.kg
-1
 of the analogue was capable of significantly reducing the growth of MDA-
MB-435 xenografts after 2 weeks, while the same treatment regime with 2-methoxyestradiol had no 
effect.  
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Finally, we recommend that dose- and time-response curves of each individual drug used in the in 
vivo model be implemented prior to confirm effective dosages and time points reported in literature. 
 
Evaluating the precise role of HIF-1α within breast cancer malignancies as well as an efficient means 
of inhibiting the concomitant hypoxic response may entail the full potential of the antineoplastic drug 
to be exploited while simultaneously minimizing the adverse toxic side effects associated with its 
administration.  
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APPENDIX A: PROTOCOLS 
IN VITRO 
SUBCULTURING/PASSAGING 
The following aseptic culture procedures should be carried out in a microbiological safety cabinet 
under sterile conditions. 
1. Remove the growth medium from the adherent cells of the culture flask using an aspirator. 
2. Rinse the culture with Ca
2+
 or Mg
2+
-free PBS to remove any remaining serum that would 
inactivate the dissociating agent, trypsin. 
3. Detach the cells from their anchor by the process of trypsinization. Trypsin is added at an amount 
which is sufficient enough to completely cover the surface of the monolayer. Pre-heating the 
trypsin to 37°C minimizes the exposure time of the cells to this potentially toxic agent. 
4. Incubate the T-75 flask at 37°C for ~ 5 minutes without agitation as to avoid clumping. Frequently 
monitor the cell layer under an inverted microscope to ensure that at least 95% of cells have 
detached. 
5. Terminate the lysis action of trypsin by adding an equal volume of serum-containing growth 
medium.  
6. Transfer the cell suspension to a 15 mL conical Falcon tube. Separate the clumped cells by 
pipetting up and down several times with a serological pipette. 
7. Count the cells using a Hemocytometer. 
8. Spin the cell suspension down at 1500 rpm for 3 minutes at ambient temperature. 
9. Discard supernatant and resuspended the pellet in the appropriate amount of growth medium. 
10. A new culture flask containing the appropriate growth medium is then inoculated with this 
suspension. Cell growth is monitored using an inverted microscope. Microbial infection can be 
monitored by the colour change of the phenol red present in the growth medium.  
 
CELL COUNTING 
1. Clean Hemocytometer and coverslip with 70% ethanol just prior to use. 
2. Place the coverslip over the grooved calibrated grid until the rainbow-like pattern of Newton’s 
rings become apparent. 
3. Using a pipette, transfer ~20 μL of cell suspension to each chamber by touching the tip of the 
pipette at the edge of the coverslip-hemocytometer barrier. 
4. Place the hemocytometer onto the mechanical stage of the inverted microscope and examine. 
5. Using a tally counter, count the cells in four corners of the calibrated grid.  The average is then 
multiplied by 10
4
 to obtain the number of cells per mL. Calculate the total amount of cells in the 
solution my multiplication with the dilution factor. 
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CRYOPRESERVATION 
Label cryogenic vials with the following information: cell line with passage number, date of freezing, 
cryoprotective medium used, and cell density. 
1. Remove the growth medium from the almost confluent (~90%) cells of a T-75 flask using an 
aspirator. 
2. Rinse the culture with Ca
2+
 or Mg
2+
-free PBS to remove any remaining serum that would 
inactivate the trypsin. 
3. Detach the cells from its growth surface by the addition of trypsin, preheated to minimize 
exposure time and an amount sufficient enough to completely cover the surface of the 
monolayer. 
4. Incubate the T-75 flask at 37°C for ~ 5 minutes without agitation as to avoid clumping. Monitor 
under an inverted microscope to ensure that at least 95% of cells have detached. 
5. Terminate the lysis action of trypsin by adding an equal volume of serum-containing growth 
medium. 
6. Transfer the cell suspension to a 15 mL conical Falcon tube. 
7. Determine the concentration of cells in suspension using a Hemocytometer 
8. Spin the cell suspension down at 1500 rpm for 3 minutes at ambient temperature. 
9. Discard the supernatant and resuspend the pellet in appropriate amount of cryoprotective 
medium (FBS + 10% DMSO) so that the cell density is 1 x 10
6
 cells/1 mL. DMSO prevents 
mechanical injury from ice crystal formation during freezing. 
10. Transfer 1ml of cell suspension into each cryogenic vial. 
11. The following freezing rate should be followed: -20°C for an hour, -80°C for 24 hours and finally 
submerged in liquid nitrogen (-196°C) for permanent storage. 
 
MTT ASSAY 
1. Freshly prepare a filtered 1% MTT solution and cover in aluminium foil to protect from light. 
2. Remove the medium from the adherent cells in each well of the multi-well plate using an 
aspirator. 
3. Add a prewarmed mixture of PBS: 1% MTT solution (3:1) to each well gently so as to avoid 
detachment of cells from the surface of the plate. 
4. Maintain the plates in the dark at 37°C in a humidified 5% CO2 atmosphere for ~2 hours to allow 
for colour development. 
5. Remove the PBS: 1% MTT solution mixture from the adherent cells in each well of the multi-well 
plate using an aspirator. 
6. Solubilize the formazan crystals by pipetting 1mL of an acidified isopropanol: triton-x (50:1) to 
each well. Solubilisation is increased by vigorous shaking at 300-500 rpm (~5 minutes). 
7. Read the absorbance on a spectrophotometer at a wavelength of 540 nm using the acidified 
isopropanol: triton-x mixture as a blank.  
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CASPASE-GLO® 3/7 ASSAY 
1. Thaw the Caspase-Glo® Reagent to room temperature 45 minutes prior to start of the assay. 
2. Remove the culture plate from the incubator and equilibrate to room temperature (~10 minutes). 
3. Transfer 100 µL of the medium from the culture plate to the wells of a white-walled 96-well plate. 
4. Add an equivalent amount (100 µL) of Caspase-Glo® Reagent to each well of a white-walled 96-
well plate. Mix the plates at 300-500 rpm (~30 seconds). 
5. Incubate the plates in the dark for 60 minutes at a constant room temperature. 
6. Measure the luminescence in a luminometer. 
 
WESTERN BLOTTING 
HARVESTING CELLS/PREPARATION OF LYSATES 
1. To avoid proteolysis and de-phosphorylation of proteins, the extraction steps are carried out in a 
walk-in freezer at 4°C. 
2. Label conical tubes for each treatment group. 
3. To harvest the detached population of cells that are suspended in the medium, transfer the 
medium of each treatment group to its respective pre-cooled conical tube. 
4. Mechanistically harvest the adherent cells from the growth surface using a rubber spatula after 
the addition of ~1 mL of ice-cold PBS and transfer to its respective conical tube. Ensure 
sterilization of the rubber spatula with 70% ethanol between treatment wells. Pellet the cells by 
centrifuging at 1500 rpm for duration of 3 minutes at 4°C. 
5. Resuspend the pellet in ~200 μL modified RIPA lysis buffer (freshly supplemented with 1 µg/1 
mL PMSF), transfer to a micro-centrifuge tube and maintain for 10 minutes with gentle agitation. 
6. Disrupt the cells using multiple short bursts of a sonicator by immersing the Microtip™ in the cell 
suspension. Rinse the probe with ethanol between samples to prevent cross-contamination. 
7. Remove the insoluble cellular debris by centrifugation in a micro-centrifuge using a force of 8000 
rpm for duration of 10 minutes at 4°C. 
8. Transfer supernatant to fresh pre-cooled micro-centrifuge tube and store the lysates at -80°C 
until use. 
 
BRADFORD ASSAY – COLORIMETRIC ASSAY TO DETERMINE PROTEIN 
CONCENTRATION 
1. Shortly prior to use, prepare a 200 μg/1 mL BSA working solution by diluting the 1 mg/1 mL stock 
in a 1:4 ratio with dH2O as the solvent. 
2. Label micro-centrifuge tubes for each dilution standard, as well as the treatment group samples 
to be tested. 
3. Prepare a standard curve by setting up a series of BSA dilutions as follows: 
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Concentration (μg) BSA (μL) dH2O (μL) 
0 0 100 
2 10 90 
4 20 80 
8 40 60 
12 60 40 
16 80 20 
20 100 0 
 
4. For each sample to be tested, pipette 5 μL of the supernatant to a microcentrifuge tube 
containing 95 μL of dH2O. Vortex briefly. 
5. Pipette 900 μL of Bradford working reagent to each microcentrifuge tube. Vortex briefly. 
6. Incubate the dilution standards and samples for 10 minutes at ambient temperature. 
7. Using a spectrophotometer, measure the absorbencies of the dilution standards and samples at 
a wavelength of 595 nm. 
8. Plot a standard curve using the BSA serial dilution absorbencies and quantify the amount of 
protein in each sample by interpolation.    
 
SAMPLE PREPARATION 
1. Label the desired amount of microcentrifuge tubes for each experimental group. 
2. Fix the aliquoted sample in Laemmli sample buffer equal to a third of the final volume. 
3. Pipette the amount of supernatant previously calculated to obtain desired protein yield for 
immunoblotting. 
4. Boil the samples for five minutes in a heating block at 95°C. Ensure that pin-sized holes have 
been made in the microcentrifuge tubes so as to prevent pressure build-up. 
5. Store at -80°C in a freezer.  
 
IMMUNOBLOTTING 
PREPARATION & LOADING OF MINI POLYACRYLAMIDE GELS 
1. Thoroughly clean short glass plates and spacer plates (1 mm thickness) with 70% ethanol and 
rinse with dH2O. 
2. Assemble the short glass plate to the spacer plate in the green casting frame. Complete the 
assembly by securing the clips and placing the casting frame onto the rubber gasket in the 
casting stand. Ensure a tight seal between the glass plates and rubber gasket so as to prevent 
leakage. 
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3. Make up a 6%/12% resolving polyacrylamide gel (see appendix B). The concentration of 
acrylamide used in the gel will depend on the size range of the proteins to be separated.  
4. Using a plastic Pasteur pipette, immediately transfer the polyacrylamide solution between the 
glass plates in the assembly. Leave enough space for the stacking gel. 
5. Overlay with isobutanol to prevent evaporation and exclude air. Allow resolving gel to polymerise 
for ~45 minutes. A sharp interface between the top of gel and bottom of isobutanol layer 
indicates a complete polymerisation. 
6. Remove the isobutanol and rinse with dH2O. 
7. Make up a 5% stacking polyacrylamide gel (See appendix B). 
8. Using a plastic Pasteur pipette, transfer the polyacrylamide solution between the glass plates in 
the assembly on top of the resolving gel. Gently align the comb (1 mm) in the correct position 
and allow gel to polymerise for ~10 minutes.  
9. Gently remove the comb and rinse the wells out with dH2O. 
 
 
SDS – FRACTIONATION OF PROTEIN EXTRACT 
1. Prepare an amount of migration buffer appropriate to the electrophoretic separation apparatus. 
2. Retrieve prepared samples from -80°C freezer as well as the molecular weight marker from -
20°C and allow to thaw. 
3. Remove the glass plates from the casting stand and frame, and place in a U-shaped adapter 
cassette. 
4. Place the assembled cassette into the electrophoresis tank 
5. Fill the inner compartment with migration buffer so that it fills the wells 
6. Place the yellow sample loading guide onto the top of the U-shaped adapter cassette between 
the glass plates. 
7. The electrophoretic run is monitored by inclusion of 10 µL of molecular weight marker in the well 
of the first lane. 
8. Thereafter, load an equivalent amount of sample protein per well starting from lane 2.  
9. Fill the outer compartment with migration buffer 
10. Attach the lid and connect the leads to the power supply. 
11. An initial run of 100 V (constant) and 200 mA 
12. Thereafter, the gel is run at 200 V (constant) and 200 mA. 
13. Once the migration front reaches the end of gel, the power to the electrophoresis separation 
apparatus is switched off. Migration efficiency may be verified by the Coomassie stain 
(irreversible) 
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ELECTROBLOTTING – TRANSFER EXACT REPLICA OF PROTEIN PATTERN FROM GEL TO 
MEMBRANE 
 
1. Prepare an amount of transfer buffer appropriate to the electrotransfer apparatus. 
2. Cut the membrane/blotting pads/filter paper/foam pads to the correct size. 
3. If using polyvinylidene fluoride (PVDF) membrane, activate by immersion in 100% methanol for ~ 
5 minutes. Thereafter, rinse quickly in dH2O and soak in transfer buffer. Handle using tweezers 
avoiding as much contact as possible.  
4. Submerge blotting pads/filter paper/foam pads briefly in transfer buffer. 
5. Remove the polyacrylamide gel with fractionated protein pattern from the U-shaped cassette and 
equilibrate in transfer buffer with gentle agitation for ~10-15 minutes. 
6. Construct the horizontal semi-dry transfer sandwich orientation: from the bottom electrode 
(anode), (1) a blotting pad, (2) the activated PVDF membrane, (3) the polyacrylamide gel, and 
another (4) blotting pad on top. Air bubbles must be removed using a test-tube as a roller 
otherwise they will reduce the efficiency of the transfer. Close the system and perform the semi-
dry electrotransfer at 500 mA (constant) and 15 V for 1 hour. 
7. Alternatively, the vertical wet transfer sandwich is constructed in the following orientation: open 
the holder cassette and lay flat. Then, from the cathode side (black electrode), place (1) a foam 
pad, (2) 2x filter papers, (3) the polyacrylamide gel, (4) the activated PVDF membrane, (5) 2x 
filter papers, and another (6) foam pad in contact with red surface. Air bubbles must be removed 
using a test-tube as a roller otherwise they will reduce the efficiency of the transfer. Close the 
latches of the cassette and place in the electrotransfer apparatus. A cooling brick unit is 
incorporated to minimize excessive heating. The wet transfer is performed at 200 mA (constant) 
and 200 V for 1 hour. 
8. Upon completion of transfer, the membrane is washed three times in rinse buffer (1x TBS; 0.1% 
Tween-20) for 5 minutes each.  
9. Transfer efficiency may be verified by the reversible Ponceau stain. 
 
IMMUNODETECTION 
1. Prevent non-specific binding to unoccupied sites on the membrane by incubation in 5% (w/v) 
non-fat dry milk blocking solution for 1 hour at room temperature. If the protein of interest is 
phosphorylated, a 3% (w/v) BSA blocking solution is used as milk contains the phosphorylated 
protein casein which will bind the antibody. 
2. Wash the membrane three times in rinse buffer (1x TBS; 0.1% Tween-20) for 5 minutes each. 
3. The blots are then incubated overnight at 4°C in primary antibody with gentle agitation using the 
recommended dilutions, typically 5 µL antibody in 5 mL rinse buffer (1x TBS; 0.1% Tween-20). 
Equal protein loading is confirmed using a primary antibody directed against beta-actin. 
4. Wash the membrane three times in rinse buffer (1x TBS; 0.1% Tween-20) for 5 minutes each. 
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5. Incubate the blots for 1 hour at room temperature in HRP-linked secondary antibody with gentle 
agitation using the recommended dilutions, typically 1.25 µL antibody in 5 mL rinse buffer (1x 
TBS; 0.1% Tween-20). 
6. Wash the membrane three times in rinse buffer (1x TBS; 0.1% Tween-20) for 5 minutes each. 
7. Prepare a 1:1 ECL solution in a conical tube and protect from light by covering with foil.  
8. For exposure, cover the section of the membrane containing the protein of interest with ~500 µL 
ECL and incubate for 1 minute. 
9. The light produced is captured on photographic film in a dark room, or alternatively using the 
Chemidox MP Imager. 
 
LIVE CELL IMAGING 
PREPARATION & IMAGE ACQUISITION 
1. Dilute the stock MitoTracker® Red CMXRos stock solution (1 mM) in serum-free growth medium.  
2. Remove growth medium using an aspirator 
3. Wash the cells 2X with PBS 
4. Add prewarmed medium containing the selected MitoTracker® Red CMXRos probe at a final 
concentration of 100 nM, as well as the Hoechst 33342 (1:200). Staining is performed for at least 
3 minutes prior to visualisation. 
5. Ignite the Xenon burner ~10 minutes prior to visualisation. 
6. Open Cell^R imaging software. 
7. In Illumination Control, switch on main burner. 
8. In the Experiment Manager, set up a new experimental plan using Image Acquisition icons and 
different command frames.  Frames are drawn around the icons in the editor’s display. The Z-
Stack Frame enables multiple images at different focal planes to be recorded. The Multi-Colour 
Frame combines monochrome images each with different excitation wavelengths into a single 
multi-colour image.  
9. Place a drop of oil on the 100x oil-immersion objective. 
10. Select the eyepiece function in Microscope Control. 
11. Select the specific excitation filter (Illumination Control). Begin by using DAPI to locate the focal 
plane. 
12. Open the shutter to illuminate the specimen (Illumination Control). Ensure to start with a low 
intensity setting so as to protect the eyes. 
13. Focus on the specimen using the focus knobs of the microscope. 
14. Once specimen is in focus, switch eyepiece to camera (Microscope Control) and select live mode 
to view image on screen. 
15. For a Z-Stack Frame, the starting (lower) and ending (upper) limits of the focal plane, the number 
of layers and the desired step width between the images needs to be set. 
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16. Other parameters to be adjusted in the Experiment Manager include light intensity (Illumination 
Control) and exposure time (Camera Control). Optimise and save the settings in the Experiment 
Manager. 
17. Close the shutter and turn off the live mode. 
18. The feasibility, storage allocation and execution of the image acquisition is achieved by clicking 
on verify, prepare, start icons in the Control Centre toolbar, respectively. 
 
IMAGE PROCESSING 
1. Open the cell^R imaging software and select the personal database under which the files were 
saved. 
2. Select the Navigate-Z icon and overlay the different layers of the Z-stack by selecting Maximum 
Intensity Projection. 
3. To remove stray light during Z-stack acquisition, go to the menu bar and select Process, 3-D 
Images, and 3-D Deconvolution from the list. Choose the Nearest Neighbour option under Filter 
Selection and 80% Haze Removal Factor under Filter Parameters. Click Execute. 
4. To remove the background, select the Define ROI icon and choose the ellipse tool. Using the left 
mouse button, define the area to subtract and confirm selection by clicking with the right mouse 
button. Subsequently, the Background Subtraction icon is selected. 
5. On the menu bar, select Image, Image Display, and Adjust Display. In the window that appears, 
each colour channel may be selected and the intensity and contract of the image adjusted with 
the aid of histograms. 
 
IN VIVO 
CANCER CELL INOCCULATION 
1. Resuspend approximately 1250 cancer cells per µL of Hank’s Buffered Salt Solution. 
2. The mice that are to be inoculated are restrained by a firm grip of the animal’s scruff. 
3. Draw up the desired volume of the cancer cell suspension (200 µL/25 g mouse) using a syringe. 
4. Inject the 200 µL of the cancer cell suspension into the left fourth mammary pad. 
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TUMOUR PROCESSING/PREPARATION OF LYSATES 
1. Retrieve the harvested tumour samples from the -80°C freezer. 
2. Using a scalpel, slice the tumour into 1 mm
2
 pieces 
3. In a glass test tube, immerse one piece of tumour in 1 mL of RIPA buffer (freshly supplemented 
with 1 µg/1 mL PMSF). 
4. Using a tissue homogeniser, disrupt the tumour until foam develops (~5 seconds). 
5. Place the test-tube on ice for approximately 1 hour so as to allow the foam to settle 
6. Transfer the contents to a micro centrifuge tube and pellet the insoluble debris by centrifugation 
at 8000 rpm for 10 minutes. 
7. Transfer the supernatant to a fresh micro-centrifuge tube. 
8. Store the lysate at -80°C. 
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APPENDIX B: REAGENTS & SOLUTIONS 
IN VITRO 
CELL CULTURE 
GROWTH MEDIUM - Tumorigenic MCF-7/E0771 breast epithelial cell line 
CONSTITUENT FINAL VOLUME (%) FINAL VOLUME (mL) 
DMEM, High Glucose, GlutaMAX™, HEPES 
[Gibco®] 
 500 
Fetal Bovine Serum (FBS), Heat inactivated 
[Gibco®] 
10 50 
Penicillin-Streptomycin, liquid [Gibco®] 1 5.5 
 
Equilibrate the growth medium constituents to 37°C in a waterbath. Remove flocculence from FBS by 
centrifugation at 400 g, followed by filtration through 0.2 µm filters. Combine constituents as specified 
above while working in a microbiological safety cabinet under sterile conditions. Reconstituted growth 
medium is stored between 2-8°C. Protect from light. 
 
PHOSPHATE BUFFERED SALINE [PBS; 1L] 
Materials: 
▪ Sodium Chloride [NaCl; Mr = 58.44 g/1 mol]| Merck Millipore 567440 
▪ Potassium Chloride [KCl; Mr = 74.55 g/1 mol]| Merck Millipore 104936 
▪ di-Sodium Hydrogen Phosphate di-Hydrate [Na2HPO4; Mr = 177.99 g/1 mol]| Merck Millipore 106580 
▪ Potassium Dihydrogen Phosphate [KH2PO4; Mr = 136.08 g/1 mol]| Merck Millipore 104873 
▪ dH2O 
Methods: 
Dissolve the following in 500 mL of the following in 500 mL of dH2O: 8 g NaCL, 0.2 g KCl, 1.44 g 
Na2HPO4, and 0.24 g KH2PO4. Mix thoroughly with the aid of a magnetic stirrer. Adjust the pH of the 
solution to 7.4. Fill up to 1 L with dH2O. Sterilize by autoclaving. Store at room temperature. 
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TREATMENT 
DOXORUBICIN STOCK SOLUTION [3.4 mM] – CHEMOTHERAPEUTIC AGENT 
Materials: 
▪ Doxorubicin Hydrochloride [Mr = 579.98 g/1 mol]| Sigma D1515| St Louis, USA 
▪ Sterile reconstituted growth medium 
Method: 
Under sterile conditions, dissolve 10 mg Doxorubicin Hydrochloride in exactly 5071 µL reconstituted 
growth medium.  Vortex the solution, filter-sterilize and store in aliquots at -20°C. Avoid freeze-thaw 
cycles. Protect from light by covering with foil. 
 
2-METHOXESTRADIOL STOCK SOLUTION [33 mM] - HIF-1α INHIBITOR 
Materials: 
▪ 2-Methoxyestradiol [Mr = 302.4 g/1 mol]| Cayman Chemical 13021| Michigan, USA 
▪ Sterile-filtered Dimethyl Sulfoxide Hybri-Max™ [DMSO]|Sigma D2650 
Methods: 
Under sterile conditions, dissolve 50mg 2-Methoxyestradiol in approximately 5010µL DMSO. Vortex 
the solution, filter-sterilize and store in aliquots at -20°C. Avoid freeze-thaw cycles. 
 
COBALT CHLORIDE STOCK SOLUTION [25 mM] – HIF-1α STABILIZER 
Materials: 
▪ Cobalt (II) Chloride Hexahydrate [Mr = 237.90 g/1 mol]| Merck 102539| Darmstadt, Germany 
▪ Sterilized dH2O 
Methods: 
Under sterile conditions, dissolve approximately 297.375 mg Cobalt (II) Chloride Hexahydrate in 
approximately 50 mL dH2O and mix thoroughly. Autoclave to sterilize and aliquot in practical amounts. 
Storage between 2-8°C. 
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HIF-1α SILENCING STOCK SOLUTION [10 µM] – HIF-1α INHIBITOR 
Materials: 
▪ Lyophilized siRNA duplex | Santa Cruz Biotechnology 35561| California, USA 
▪ RNAse-free H2O 
Methods: 
Under sterile conditions, dilute the 3.3 nmol of lyophilized siRNA duplex in 330 µL RNAse-free water. 
Store at -20°C. Avoid freeze-thaw cycles. 
 
BIOREDUCTIVE CAPACITY 
MTT WORKING SOLUTION [1%]  
Materials: 
▪ MTT tetrazolium dye reagent [Mr = 414.32 g/1 mol]| Sigma M2128| St Louis, USA 
▪ Sterile PBS 
Methods: 
Shortly prior to use, add 0.01 g MTT tetrazolium dye reagent for every 1 mL PBS and dissolve with 
vigorous vortexing.  Pass through single filter. Protect from light. 
 
ACIDIFIED ISOPROPANOL [1% (w/v)] 
Materials: 
▪ 2-Propanol [Mr = 60.1 g/1 mol]| Merck Millipore 109634| Darmstadt, Germany 
▪ Hydrochloric Acid 
Methods: 
For every 1 mL of isopropanol, add 10 µL of hydrochloric acid. Mix thoroughly with aid of a vortex. 
 
TRITON-X [0.1%; 100 mL] 
Materials: 
▪ Triton-X-100| BHD Laboratory Supplies| Midrand, South Africa 
▪ dH2O  
Stellenbosch University  http://scholar.sun.ac.za
121 
 
▪ Methods: 
Triton-X-100 is a viscous liquid so pipette at a slow pace. Dissolve 100 µL Triton-X-100 in dH2O and 
make up to 100 mL. Mix thoroughly and store at 2-8°C. 
 
CASPASE-GLO® 3/7 ASSAY 
CASPASE-GLO® REAGENT 
Materials: 
▪ Caspase-Glo® 3/7 Buffer| Promega G8091| Madison, USA 
▪ Lyophilized Caspase-Glo® 3/7 Substrate| Promega G8091| Madison, USA 
Methods: 
Thaw assay constituents to room temperature. The buffer reagent is added to the lyophilized 
substrate and mixed vigorously by vortexing.  
 
PROTEIN EXTRACTION 
SODIUM DEOXYCHOLATE SOLUTION [10%; 100 mL] 
Materials: 
▪ Sodium Deoxycholate [C24H39O4; Mr = 414.55 g/1 mol]| BDH Laboratories 430353D| Poole, England 
Methods: 
Dissolve 10 g of Sodium Deoxycholate in 80 mL of dH2O. Adjust the pH to 9.0 using HCl. The solution 
is subsequently boiled and cooled and the pH adjusted to 9.0. This step is repeated until there is the 
solution becomes colourless. Fill up to 100 mL with dH2O. Aliquot into practical amounts so as to 
avoid freeze-thaw cycles and store at -20°C. Protect from light. 
 
SODIUM FLUORIDE SOLUTION [200 mM; 500 mL] 
Materials: 
▪ Sodium Fluoride [NaF; Mr = 41.99]| Hopkins & Williams 7859| Essex, England 
▪ Sterile dH2O 
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Methods: 
Weigh out 4.199 g of Sodium Fluoride and dissolve in 500 mL of dH2O. Mix thoroughly with a 
magnetic stirrer. Store at -20°C. Inhibitor of serine and threonine phosphatases. 
 
SODIUM ORTHOVANADATE SOLUTION [200 mM; pH 9; 100 mL] 
Materials: 
▪ Sodium Orthovanadate [Na3VO4; Mr = 183.91 g/1 mol]| Sigma S6508| St Louis, USA 
▪ Sterile dH2O 
Methods: 
Weigh out 3.678g of Sodium Orthovanadate and dissolve in 80 mL dH2O. Boil until the solution is 
colourless. Set the pH to 9 using HCl. Fill up to 1 L with dH2O. Aliquot the solution into practical 
amounts to avoid freeze-thaw cycles. Store at -20°C. Inhibitor of tyrosine phosphatases. 
 
ETHYLENE-DIAMINE-TETRAACETIC-ACID SOLUTION [EDTA; 100 mM; 100 mL] 
Materials: 
▪ EDTA Salt Dihydrate [Mr = 372.24 g/1 mol]| Analar 10093| Lutterworth, UK 
▪ Sterile dH2O 
Methods: 
Weigh out 3.722 g EDTA Salt Dihydrate and dissolve in 80 mL dH2O. Adjust the pH to 8.0. Fill up to 
100 mL with dH2O. Mix thoroughly with magnetic stirrer. Store at room temperature. Inhibitor of 
metalloproteases.  
 
PHENYLMETHYLSULFONYL FLUORIDE [PMSF; 0.2 M; 50 mL] 
Materials: 
▪ Phenylmethylsulfonyl fluoride [C7H7O2SF; Mr = 174.2 g/1mol]| Roche| Mannheim, Germany 
▪ 100% ethanol 
Methods: 
Weigh out 1.742 g PMSF and dissolve in 50 mL of 100% ethanol. Store at room temperature – stable 
for ~9 months. Inhibitor of serine and cysteine proteases. 
Stellenbosch University  http://scholar.sun.ac.za
123 
 
MODIFIED RADIO-IMMUNO-PRECIPITATION-ASSAY BUFFER [RIPA; 100 mL] 
Materials: 
▪ 50 mM Tris-HCl [pH 7.4] 
▪ Sterile dH2O 
▪ NaCl 
▪ 10% NP-40 
▪ 10% Sodium Deoxycholate 
▪ 0.2 M PMSF 
▪ 1M Benzamidine Hydrochloride Hydrate 
▪ 100 mM EDTA [pH 7.4] 
▪ 1 mg/1 mL Leupeptin 
▪ 10 mg/1 mL Aprotonin 
▪ 1 mg/1 mL Pepstatin 
▪ 5 mg/1 mL Soy Bean Trypsin Inhibitor-1 (SBTI-1) 
▪ 200 mM Na3VO4 
▪ 200 mM NaF 
Methods: 
The following procedure should be carried out on ice. Working in a 100 mL beaker, prepare a 50 mM 
Tris solution by dissolving 790 mg Tris 75ml of dH2O. Correct the pH to 7.4 using HCl and add the 
following constituents in the following order: 
CONSTITUENTS FINAL 
CONCENTRATION 
VOLUME/WEIGHT OF 
STOCK 
NaCl 150 mM 876 mg 
NP-40 1% 10 mL 
Sodium Deoxycholate 0.25% 2.5 mL 
Protease Inhibitors   
PMSF 1 mM 500 µL 
Benzamidine 1 mM 100 µL 
EDTA 1 mM 1 mL 
Leupeptin 1 µg/1 mL 100 µL 
Aprotonin 2 µg/1 mL 20 µL 
Pepstatin 1 µg/1 mL 100 µL 
SBTI-1 4 µg/1 mL 80 µL 
Phosphatase Inhibitors   
Na3VO4 1 mM 500 µL 
NaF 1 mM 500 µL 
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Make solution up to 100 mL with dH2O and mix thoroughly with a magnetic stirrer. Unwanted 
proteolysis and de-phosphorylation are slowed down by the addition of protease and phosphatase 
inhibitors. Aliquot the solution into practical amounts so as to avoid freeze-thaw cycles and store at -
20°C. PMSF is unstable in aqueous solutions with a short half-life and thus should be added to RIPA 
buffer just prior to lysate preparation. 
  
PROTEIN CONCENTRATION DETERMINATION 
BRADFORD STOCK REAGENT [5X; 1 L] 
Materials: 
▪ Coomassie Brilliant Blue G [Mr = 854.02 g/1 mol]| Fluka 27815| Switzerland 
▪ 95% ethanol 
▪ Phosphoric acid 
▪ Sterile dH2O 
Method: 
Weigh out 500 mg of Coomassie Brilliant Blue G and dissolve in 95% ethanol (250 mL) and 
phosphoric acid (500 mL). Once the dye has dissolved, make the solution up to one litre with distilled 
water and pass through a single filter. Storage in amber bottle at 4°C. Protect from light.   
 
BRADFORD WORKING SOLUTION 
Materials: 
▪ 5X Bradford Stock Reagent 
▪ Sterile dH2O 
Method: 
Shortly prior to use, prepare a 1:4 Bradford working reagent by diluting the 5x stock in a 1:4 ratio with 
dH2O used as the solvent.  Pass the solution through 2 filters simultaneously. Storage in amber bottle 
at 4°C. Protect from light. 
 
BOVINE SERUM ALBUMIN (BSA) STOCK SOLUTION [1mg/ml] 
Materials: 
▪ Bovine Serum Albumin Fraction V [Mr = 68 kDa]| Roche 10735 
▪ Sterile dH2O 
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Method: 
Dissolve 10 mg of Bovine Serum Albumin Fraction V in 10 mL of dH2O. Aliquot into practical amounts 
and store at -20°C. 
 
WESTERN BLOTTING 
LAEMELLI SAMPLE BUFFER [2X; 10 mL] 
Materials: 
▪ 0.5M Tris-HCl [pH 6.8] 
▪ dH2O 
▪ Glycerol |Saarchem Analytics| Krugersdorp, South Africa 
▪ 10% SDS 
▪ 2-Mercaptoethanol [Mr = 78.13 g/1 mol]| Sigma M7154| St Louis, USA 
▪ Bromophenol Blue [Mr = 669.99 g/1 mol]| Saarchem Analytics | Krugersdorp, South Africa 
Methods: 
Prepare a 125mM Tris solution by dissolving 1.514g Tris in 10mL dH2O. 
CONSTITUENTS 
FINAL CONCENTRATION 
(%) 
AMOUNT OF STOCK 
Glycerol 20% 2 mL 
SDS 4% 4 mL 
Bromophenol blue 0.004% 0.4 mg 
2-mercaptoethanol 10% 1 mL 
 
Bring the volume up to 10 mL with dH2O. 
 
1.5 M TRIS-HCL BUFFER [pH 8.8; 1 L] 
Materials: 
▪ Tris Base, Molecular Biology Grade [Mr = 121.1 g/1 mol]| EMD Millipore 648310 
▪ Sterile dH2O 
Methods: 
Weigh out 181.65 g of Tris Base and dissolve in 800 mL dH2O. Adjust pH to 8.8 using HCl. Fill up to 1 
L with dH2O. 
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50 mM TRIS-HCL BUFFER [pH 7.4; 1 L] 
Materials: 
▪ Tris Base, Molecular Biology Grade [Mr = 121.1 g/1 mol]| EMD Millipore 648310 
▪ Sterile dH2O 
Methods: 
Weigh out 6.055 g of Tris Base and dissolve in 800 mL dH2O. Adjust pH to 7.4 using HCl. Fill up to 1 
L with dH2O. 
 
0.5 M TRIS-HCL BUFFER [pH 6.8; 1 L] 
Materials: 
▪ Tris Base, Molecular Biology Grade [Mr = 121.1 g/1 mol]| EMD Millipore 648310 
▪ Sterile dH2O 
Methods: 
Weigh out 60.55 g of Tris Base and dissolve in 800 mL dH2O. Adjust pH to 6.8 using HCl. Fill up to 1 
L with dH2O. 
 
SODIUM DODECYL SULPHATE (SDS) SOLUTION [10% (w/v); 1 L] 
Materials: 
▪ Sodium n-Dodecyl Sulfate, Molecular Biology Grade [Mr = 288.4 g/1 mol]| Merck Millipore 428023| 
Darmstadt, Germany 
▪ Sterile dH2O 
Methods: 
Weigh out 28.84g of SDS and dissolve in 800mL dH2O. Place in heated waterbath to speed up the 
dissolving process. Fill up to 1 L. 
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AMMONIUM PERSULPHATE (APS) [10% (w/v)] 
Materials: 
▪ Ammonium Persulfate [APS]| Saarchem Analytics| Wadeville, South Africa 
▪ Sterile dH2O 
Methods: 
For every mL of dH2O, dissolve 1 mg of APS by vigorous vortexing. Prepare immediately before use. 
Unstable and storage at -20°C should not exceed 1 week. 
 
TRIS-GLYCINE SDS-POLYACRYLAMIDE GELS 
6% Resolving Gel 
CONSTITUENTS FINAL VOLUME [10 mL/2 gels] 
dH2O 5.3 
40% Acrylamide Bis (37.5 : 1) 2.0 
1.5 M Tris (pH8.8) 2.5 
10% SDS 0.1 
10% Ammonium Persulfate 0.1 
TEMED 0.008 
 
12% Resolving Gel 
CONSTITUENTS FINAL VOLUME [10 mL/2gels] 
dH2O 3.3 
40% Acrylamide Bis (37.5 : 1) 4.0 
1.5 M Tris (pH8.8) 2.5 
10% SDS 0.1 
10% Ammonium Persulfate 0.1 
TEMED 0.004 
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5% Stacking Gel 
CONSTITUENTS FINAL VOLUME [2mL] 
dH2O 1.4 
40% Acrylamide Bis (37.5 : 1) 0.33 
1.5 M Tris (pH6.8) 0.25 
10% SDS 0.02 
10% Ammonium Persulfate 0.02 
TEMED 0.002 
 
As APS acts as a catalyst for the polymerization reaction, it should be added as the last component. 
 
TRIS BUFFERED SALINE BUFFER [TBS; 10x; 5 L] 
Materials: 
▪ Tris Base, Molecular Biology Grade [Mr = 121.1 g/1 mol]| EMD Millipore 648310 
▪ Sodium Chloride [NaCl; Mr = 58.44 g/1 mol]| Merck| Wadeville, South Africa 
▪ dH2O 
Methods: 
Weigh out 302.5 g Tris Base and 438.0 g Sodium Chloride, and dissolve in 5 L of dH2O. 
 
MIGRATION BUFFER [25 mM TRIS, 192 mM GLYCINE, 0.1% (w/v) SDS, pH 8.3; 1 L] 
Materials: 
▪ 10x premixed Tris/Glycine/SDS buffer| Bio-Rad 161-0772| Bio-rad, Johannesburg, South Africa 
▪ Sterile dH2O 
Methods: 
Dispense 100 mL of 10x premixed Tris/Glycine/SDS buffer into a 1 L measuring cylinder and make up 
to 1 L with dH2O. Prepare just before electrophoresis.  
 
TRANSFER (TOWBIN’S) BUFFER [25 mM TRIS, 192 mM GLYCINE, pH 8.3] 
Materials: 
▪ 10x premixed Tris/Glycine buffer | Bio-Rad 161-0771| Bio-rad, Johannesburg, South Africa 
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▪ Methanol| Merck| Darmstadt, Germany 
▪ Sterile dH2O 
Methods: 
Dispense 100 mL of 10x premixed Tris/Glycine buffer into a 1 L measuring cylinder. Add 200 mL 
methanol and make up to 1 L with dH2O. Store at room temperature. 
 
RINSE BUFFER [1x TBS; 0.1% TWEEN-20; 1 L] 
Materials: 
▪ 10x TBS 
▪ Tween®20|Sigma P9416|St Louis, USA 
▪ Sterile dH2O 
Methods: 
Dispense 100 mL of 10x TBS stock solution into a 1 L measuring cylinder and make up to 1 L with 
dH2O. Add 1 mL of Tween®20 and mix thoroughly. Store at room temperature. 
 
SODIUM HYDROXIDE [0.2 M; 1 L] - STRIPPING BUFFER 
Materials: 
▪ Sodium Hydroxide pellets [NaOH; Mr = 40 g/1 mol]| Merck Millipore 106482| Midrand, South Africa 
▪ Sterile dH2O 
Method: 
Weigh out 8 g of NaOH pellets and dissolve in 1 L of dH2O. Mix thoroughly with a magnetic stirrer. 
Store at room temperature. 
 
5% (w/v) NON-FAT DRY MILK BLOCKING SOLUTION 
Materials: 
▪ Fat free instant milk powder 
▪ Rinse Buffer [1x TBS; 0.1% Tween-20] 
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Methods: 
Weigh out 5 g of fat-free instant milk powder and dissolve in 100 mL rinse buffer (1x TBS; 0.1% 
Tween®20). Make up fresh just prior to blocking of membranes. 
 
3% (w/v) BSA BLOCKING SOLUTION 
Materials: 
▪ Bovine Serum Albumin Fraction V [Mr = 68 kDa]| Roche 10735 
▪ Rinse Buffer [1x TBS; 0.1% Tween-20] 
Methods: 
Weigh out 3 g of Bovine Serum Albumin Fraction V and dissolve in 100 mL rinse buffer (1x TBS; 0.1% 
Tween®20). Make up fresh just prior to blocking of membranes. 
 
LIVE CELL IMAGING/FLUORESCENT MICROSCOPY 
HOECHST 33342 STOCK SOLUTION [1 mg/1 mL] 
Materials: 
▪ bisBenzimide H 33342 trihydrochloride [Mr = 561.93 g/1 mol]| Sigma B2261| St Louis, USA 
▪ Sterile-filtered Dimethyl Sulfoxide Hybri-Max™ [DMSO]|Sigma D2650 
Methods: 
For every mL of dH2O, dissolve 1 mg of the yellow solid powder by vigorous vortexing. Protect from 
light by storage in an amber eppendorf tube. Storage at 2-8°C. 
 
MITOTRACKER RED® CMXROS [1 mM] 
Materials: 
▪ Lyophilized MitoTracker Red® CMXRos [50 µg; Mr = 531.5236 g/1 mol]| Invitrogen M7512| 
▪ Sterile-filtered Dimethyl Sulfoxide Hybri-Max™ [DMSO]|Sigma D2650 
Methods: 
Dissolve the 50 µg lyophilized solid in 100 µL DMSO. Protect from light. Storage at -20°C. 
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IN VIVO 
DOXORUBICIN STOCK SOLUTION [3.33 mg/1 mL] 
Materials: 
▪ Doxorubicin Hydrochloride [Mr = 579.98 g/1 mol]| Sigma D1515| St Louis, USA 
▪ Sterile reconstituted growth medium 
Methods: 
Dissolve 10 mg of the powder in 3 mL of reconstituted growth medium. Thorough solubilisation is 
achieved by vigorous vortexing. Store at 4°C. Protect from light. 
 
CARBOXYMETHYLCELLULOSE [0.5%] 
Materials: 
▪ Carboxymethylcellulose sodium salt [CMC; Mr = 90kDa]| Sigma C5678| St Louis, USA 
▪ Sterile dH2O 
Methods: 
Weight out 4 g of carboxymethylcellulose sodium salt and add in portions to 100 mL dH2O. Thorough 
solubilisation is achieved by gently mixing with a magnetic stirrer. Sterilize by autoclaving. Storage at 
room temperature.  
 
2-METHOXESTRADIOL [10 mg/1 mL] 
Materials: 
▪ 2-Methoxyestradiol [2-ME; Mr = 302.4 g/1 mol]| Cayman Chemical 13021| Michigan, USA 
▪ 0.5% Carboxymethylcellulose 
Methods: 
Dissolve 10 mg of 2-ME crystalline solid in 1 mL of 0.5% carboxymethylcellulose. Thorough 
solubilisation is achieved by vigorous vortexing.  Store at 4°C. 
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